

BIOTECH IN BAVARIA – ROLLERCOASTER TO INNOVATION



We have 80,000 R&D centres like this one.

Roche develops and produces highly effective treatments and diagnostic tools for diseases such as cancer, hepatitis, diabetes and rheumatoid arthritis.

Our innovations help millions of people by alleviating their suffering and improving their quality of life. We give them hope.



We Innovate Healthcare

Where the future becomes reality



HOTSPOTS FOR LIFE SCIENCE STARTUPS

- Lab and office space (S1 & S2)
- Competitive leasing rents
- Furnished, flexible rooms
- In-house estate management
- The center of an impressive research campus
(2 excellent universities TU & LMU, Max Planck Institutes for Biochemistry and Neurobiology, Clinic Großhadern, Gene Center, Biomedical Center, Prion Center)
- Close contacts with investment partners
- Home for more than 60 startups
- Joint location marketing
- Attractive, modern conference rooms also for external booking



**Innovations-
und Gründerzentrum
Biotechnologie IZB**
Martinsried · Freising

Am Klopferspitz 19
82152 Planegg/Martinsried
Tel.: +49 (0) 89 - 700 656 70
Fax: +49 (0) 89 - 700 656 77

we are active
participants in the
**CLUSTER
BIOTECHNOLOGY**
BAVARIA

www.izb-online.de

Our tenants in Martinsried: 4SC AG (DD) · AMSilk GmbH (P) · amYmed GmbH (DS) · Bayerische Gewebekbank GmbH (P/S) · Bernina Plus & Hartmann Diagnostic Service (DD/DS) · BioM AG (S) · BioM Cluster Development GmbH (S) · Biontex Laboratories GmbH (P) · Blackfield AG (S) · ChromoTek GmbH (DS) · conoGenetix biosciences GmbH (S) · Coriolis Pharma (S) · CRELUX GmbH (DD/DS) · DoNatur GmbH (DD) · DPC Pharma Consulting (S) · EKFS Herzchirurgie Prof. Dr. Eissner (DD) · Ella Biotech GmbH (DS) · eticur) GmbH (DS) · EuMMCR (European Mouse Mutant Cell Repository) (S) · evotec Munich (DD) · Exosome Diagnostics GmbH (DS) · Fresenius Biotech GmbH (DD) · FROST LIFESCIENCE (DS/S) · GNA Biosolution GmbH (I/P) · Helmholtz Zentrum München (S) · IBB Netzwerk GmbH (S) · ibidi GmbH (DS) · Leukocare AG (P/S) · Max-Delbrück Centrum (T-Abs.) (DD/DS) · MenloSystems GmbH (I) · NanoScape AG (P) · Omegamatrix GmbH (DS) · origenis GmbH (DD/DS) · Patentquadrat Patentanwaltskanzlei (S) · PELOBiotech (S/P) · PhaToCon (S) · quattro research GmbH (DD/DS) · R&D Biopharmaceuticals GmbH (DD/DS) · SiNatur GmbH (DD) · SIRION Biotech GmbH (P/S) · Smart Move GmbH (I) · Smartec Ingenieur Büro GmbH (S) · SpheroTec GmbH (DS) · SuppreMol GmbH (DD) · that's it GmbH (IT-S) · THE WORKING GROUP Unternehmensberatung (S) · TRION Research GmbH (DD/DS) · VELUMETRIX GmbH (S) · Vesalius Biocapital (VC)

Our tenants in Freising: AromaLAB AG (S) · ATRES engineering biogas (S) · GENidee (DS) · gimbio mbH (P/S) · HDBI Hans-Dieter-Belitz-Institut (P/I) · Pieris AG (DD) · UGT Umwelt-Geräte-Technik GmbH (P) · vertis Biotechnologie AG (DD/DS) · XL Protein GmbH (DD/P)

Furthermore in Martinsried: CEM Chemieschule Dr. Elhardt GmbH · Café Freshmaker · Kindertagesstätte BioKids

DD = Drug Discovery · DS = Diagnostic Services · I = Instruments · IT-S = IT-Services · S = Services · VC = Venture Capital · P = Products

status: february 13

Imprint

Editorial staff:

Georg Kääh, Bianca Reuter, Daniela Tonn

Data collection: Daniel Neumeier, Sabine Jordan

Company Profiles: Daniel Neumeier, Monika Bertuleit

We thank the Bavarian companies and the regional organizations of the Bavarian Biotechnology Cluster for their support of this survey.

April, 2013

Contact

Prof. Dr. Horst Domdey, Managing Director

Spokesman of the Bavarian Biotechnology Cluster

Dr. Georg Kääh, Cluster Manager

The Bavarian and the Munich Biotechnology Cluster are managed by:

Bio^M Biotech Cluster Development GmbH

Am Klopferspitz 19 a

D-82152 Martinsried

Phone: +49 (0)89-89 96 79-0

Fax: +49 (0)89-89 96 79-79

E-Mail: info@bio-m.org

Internet: www.biotech-bavaria.de



The layout, graphics and other contents of this brochure of the Bavarian Biotechnology Cluster are protected by copyright law.

Layout-Design: aimcom, Munich, www.aimcom.de

Picture credits: fotolia.com (© Bastos, © christian-colista, © sergey02); istockphoto.com

Supported by the Bavarian State Ministry of Economic Affairs, Infrastructure, Transport and Technology
www.stmwivt.bayern.de/en/foreign-trade

Content

Internationale Anerkennung für Innovationen – Internationally Renowned for Innovation	07
■ Prof. Dr. Horst Domdey – Spokesman Bavarian Biotechnology Cluster	
Schnellüberblick – Executive Summary	08–11
Biotechnology: Regional Profiles in Bavaria	12–13
Interview with Claus Haberda, Roche Penzberg	14–15
The network IBB – Biotechnology is an industry application in Bavaria	16
Biotechnology: Science in Bavaria	18–20
Facts and Figures 2012	22–36
■ Employment 24–25	
Jobs in Biotechnology Companies	
■ Products and Pipeline 26–28	
Drug Development	
■ Deals, Cooperation, Mergers, Financing 29–36	
Deals and Cooperation	
Interview with Richard Paulson, Amgen GmbH	30–31
M&A-Activity	
Milestone Payments	
Financing	
Company Profiles	39–148
in alphabetical order	

About this survey:

For the following report, a biotechnology company has been defined as a company, which develops and/or manufactures products on the basis of state-of-the-art molecular biological methods. But as “conventional” pharmaceutical companies are increasingly also using such methods, it is often difficult to differentiate between biotech and pharma. Traditional phytopharmaceutical companies and manufacturers of homeopathic products are however not included in this compilation. We distinguished the parameters specific to each sector and conducted separate surveys for biotech companies, pharmaceutical companies, (pre)clinical contract research organizations (CROs), contract manufacturing organizations (CMOs), suppliers and others with activities in the biotechnology sector. In the case of the biotech companies, a distinction was once again made between small and medium-sized companies (SMEs) having their headquarters in Bavaria, and branch offices and subsidiaries of national and international biotech companies (biotechnology companies, non-SMEs). The term “non-SME” therefore does not say anything about the actual size of this branch office.

The data forming the basis of this report are based on the evaluation of a written survey carried out by Bio^M Biotech Cluster Development GmbH at the beginning of 2013 of approx. 340 Life Science companies throughout Bavaria. Based on the questionnaires returned and intensive follow-up telephone calls it was possible to achieve a response rate of almost 90 %. Possible deviations from previously published figures are the result of additional data obtained in this survey that also may refer to previous years. The period under review for this report is the year 2012.

Company profiles:

There are about 300 companies listed in the appendix of this brochure (page 39 ff). Not every company being listed is also “counted” in this survey (for example those from the Medtech area), and there are other Bavarian biotech and pharma companies having not activated their listing.

Nanotechnology-based Drugs Patented Drugs and branded Generics Innovative Formulations

„Creating new values for established drugs!“

Concept | Development | Drug Approval | Patents | GMP-Manufacturing



leon-nanodrugs is developing nanotechnology-based reformulations (Generic plus) of successfully marketed brands and generics as well as innovative drug delivery systems for NCEs. Based on our patented superior MJR-Technology we can process all kinds of application forms and a variety of different substance classes like small molecules, peptides, hormones and proteins.

More than half of all marketed therapeutic drugs are poorly soluble in water or display a low grade of membrane permeability, limiting their bioavailability and

oral administration. This vital problem in pharmacotherapy can be solved by using our innovative MJR-Technology: by downsizing particle size to nanoscale, compounds become more soluble and faster dissolving in water. The unique MJR-Technology allows small and large scale GMP-production any size without changing the hardware.

Each of our API-specific and customized „Generic plus“-projects is covered by an API-specific formulation patent. Our technology is superior to all other competitors in terms of cost and efficiency.

Internationale Anerkennung für Innovationen

Die Biotechnologiebranche in Bayern hat ihre Wurzeln in den hervorragenden wissenschaftlichen Einrichtungen des Landes. Hierzu zählen einerseits die heute mit einem nationalen „Exzellenz-Status“ versehenen Universitäten in München (Ludwig-Maximilians-Universität, LMU; Technische Universität München, TUM) mit ihren Kliniken, sowie die biowissenschaftlich ausgerichteten universitären Institute in Regensburg, Würzburg, Nürnberg-Erlangen und Bayreuth. Andererseits tragen die Forschungsinstitute der Max-Planck-Gesellschaft (Max-Planck-Institut für Biochemie sowie für Neurobiologie, beide in Martinsried b. München), das Helmholtz Zentrum München für Umwelt und Gesundheit wie auch die Arbeitsgruppen und Institute der Fraunhofer Gesellschaft zur internationalen hohen Anerkennung für „Science made in Bavaria“ bei.

Eine aus dieser klinischen Forschung (der LMU) stammende Firma – Micromet – sorgte im Jahr 2012 für die größte positive Schlagzeile. Die Technologie- und Produktpipeline hatte bei dem US-Biotech-Giganten AMGEN ein dermaßen großes Interesse gefunden, dass der erst in 2011 geschlossene Kooperationsvertrag in einen Kaufvertrag umgewandelt wurde: Im Frühjahr 2012 wurde so aus der Münchner Micromet die AMGEN Research (Munich) GmbH – für den stolzen Preis von 1,2 Mrd. US\$! (siehe auch S. 30)

Manchmal geht es auch schneller: die erst 6 Jahre alte, aus Würzburg/Tübingen stammende und in München gegründete Corlmmun, wurde (bei einem Einsatz von wenigen Millionen Euro) im Sommer 2012 für einen dreistelligen Millionenbetrag an Johnson & Johnson verkauft.

Die internationale Aufmerksamkeit ist also gegeben – und das aus gutem Grund! Dies lässt uns für die „Achterbahnfahrt“, wie sie für den Technologietransfer von Innovationen auch im vergangenen Jahr 2012 charakteristisch war, auch für die weitere Zukunft hoffen.



PROF. DR.
HORST DOMDEY

Spokesman Bavarian
Biotechnology Cluster

Internationally Renowned for Innovation

The biotechnology sector in Bavaria has its roots in the excellent scientific institutions in the region. On the one hand these are the nationally approved "Excellence" universities in Munich (Ludwig-Maximilian University, LMU, Technical University of Munich, TUM) with their hospitals and the bioscientific orientated university institutes in Regensburg, Würzburg, Nuremberg-Erlangen and Bayreuth. On the other hand the research institutes of the Max Planck Society (Max-Planck-Institute of Biochemistry and of Neurobiology, both in Martinsried/Munich), the Helmholtz Centre Munich for Environment and Health as well as the research groups and institutes of the Fraunhofer Society, which are key for the international high recognition of "Science Made in Bavaria".

One spinoff from Munich Science environment – Micromet – delivered the main success story in 2012. The technology and product pipeline had found such a big interest of the U.S. biotech giant AMGEN that a co-operation agreement only closed in 2011 was converted into a purchase agreement. In spring 2012, the Munich Micromet AMGEN Research (Munich) Ltd. emerged from this acquisition - for the nationwide record price of \$ 1.2 billion! (see page 30)

Sometimes things move even a little faster: the only 6 year old company Corlmmun– originating from Würzburg and then founded in Munich, was sold with a 3-digit million US\$ price tag to Johnson & Johnson in mid 2012. This particularly attracted attention, as only a few million Euros had been invested into Corlmmun thus far.

International attention is thus given – and for good reason! This leaves us hopeful for the "roller coaster ride" that is characteristic for the technology transfer of innovations.

Der Schnellüberblick

Executive Summary

Die Biotechnologiebranche in Bayern – aber auch in ganz Deutschland – hat sich Schritt für Schritt entwickelt und einige der wesentlichen Wegmarken liegen bereits eine ganze Reihe von Jahren hinter uns.

Richtig los ging es - mit der für Deutschland oft üblichen Verzögerung von gut einem Jahrzehnt zu Entwicklungen in Übersee – Anfang der 90er Jahre des letzten Jahrhunderts mit (nun wieder aus bayerischer Sicht) den ersten Firmengründungen, darunter Mikrogen, Medigene, Morphosys und Micromet.

Die Dynamik nahm deutlich zu, als 1996 der nationale BioRegio-Wettbewerb der Bundesregierung erste regionale „Branchen-Cluster-Konzepte“ mit einem Preisgeld würdigte – und München als einer der Gewinner in der Folge ein „Bottom-up“-Entwicklungskonzept zum Aufbau der biopharmazeutischen Biotechnologiebranche angehen und umsetzen konnte. Schnell wuchs die Firmenanzahl von ursprünglich rund 30 Unternehmen auf gut 100 Unternehmen im Jahr 2001. Trotz erster Anzeichen, dass die „Internet- und Finanzkrise“ des Jahrtausendwechsels auch auf die deutsche Biotechnologiebranche durchschlagen könnte, stiegen auch die Mitarbeiterzahlen in zweistelligen jährlichen Wachstumsraten von ursprünglich wenigen Hundert auf knapp 3000 alleine im Großraum München noch bis 2002 steil an. Erst dann verursachte diese erste Finanzkrise des neuen Jahrtausends auch eine erste Restrukturierungswelle, die zu einem Verlust von gut 20% der Beschäftigten bis zum Jahr 2005 führte – ohne jedoch die Gesamtzahl der Unternehmen wesentlich zu reduzieren.

Seither, und obwohl weitere Finanzkrisen über Deutschland und Europa hereingebrochen sind, ist die bayerische Biotechnologie wieder in einem anhaltenden Aufwärtstrend, und stabilisiert sich in diesen für eine junge Branche schwierigsten äußeren Rahmenbedingungen auf einem guten Niveau.

Bereich Biotech-Pharma:

Heute zählen wir in Bayern **über 170** Biotechnologie-Unternehmen, die sich mit großer Mehrheit (ca. **140**) im Bereich „biopharmazeutische Entwicklung und Technologieplattformen“ mit der präklinischen und klinischen Forschung und Entwicklung von Therapeutika und Diagnostika bzw. mit Technologieangeboten zur Prozessopti-

The biotechnology sector in Bavaria – but also in other regions of Germany – has developed step by step, and some very important milestones were already passed a number of years ago.

After the typical delay of such developments in Germany in comparison to the US, things started to happen in the early 1990s, when the first biotech companies were founded, in Bavaria for example Mikrogen, Medigene, Morphosys and Micromet.

This dynamic gained momentum when the national BioRegio competition awarded considerable financial contributions to the first regional “sector-specific cluster concepts” in 1996, with Munich among the winners. This allowed the development of a bottom-up strategic concept to foster the growth of the biopharmaceutical biotechnology sector in the region. The number of companies increased quickly, from initially 30 to more than 100 enterprises in 2001. Employee numbers increased accordingly, with double digit growth figures (per year), from initially a few hundred to around 3000 employees in Greater Munich in 2002. And this despite the first indications that the worldwide “dot-com bubble” and the financial crisis at the turn of the millennium could also affect the German biotechnology sector.

However, this became manifest after 2002, when the first financial crisis of the 21st century also led to the first wave of re-structuring and re-focussing in the industry accompanied by a loss of around 20% of employees until the end of 2005. Nevertheless, the overall number of companies remained more or less stable.

Since then, the Bavarian biotechnology sector has shown continuous growth, even despite further financial crises affecting Germany and Europe, and is establishing itself on a good and stable level, even in the current economic climate, which is still not particularly favourable for such a innovative sector.

Pharmaceutical biotechnology and pharma industry:

*Today there are **more than 170** biotechnology companies in Bavaria, many of which (around **140**) are working in the field of “biopharmaceutical development and technology*

mierung dieser F&E-Arbeiten bzw. während der klinischen Zulassungsphasen befassen.


Weitere kleine und mittlere Biotechnologieunternehmen in Bayern beschäftigen sich mit „neuen Materialien“, neuen „industriell herstellbaren“ Substanzen für unterschiedliche Bereiche des täglichen Lebens, mit Bioinformatik, Umweltbiotechnologie und beispielsweise auch Innovationen für den Nahrungsmittelsektor.

Im Pharmasektor stärken bedeutende Niederlassungen internationaler Unternehmen mit zum Teil sehr erheblichen Mitarbeiterzahlen den Standort Bayern: Roche Diagnostics (Penzberg, über 5000 Beschäftigte in Forschung und Produktion); Merck, Sharp&Dohme (über 1500 Beschäftigte); AMGEN (mit Niederlassungen in Regensburg und München); LifeTechnologies/GeneArt (Regensburg); Novartis (mit mehreren Tausend Beschäftigten bei Novartis Pharma in Nürnberg sowie dem Hauptsitz der Generikasparte Sandoz in Holzkirchen bei München); Daichii Sankyo (mit deutscher und europäischer Zentrale in München, einer großen Produktionsstätte – und der Forschungseinheit für Onkologie, die früher eigenständige U3 Pharma in Martinsried); dazu

platforms.“This includes preclinical and clinical research and development of therapeutics and diagnostics, as well as technologies for supporting these R&D activities and the subsequent clinical development and market approval phases.

Other small and mid-sized enterprises as well as recent start-ups in Bavaria are focusing on “new materials”, new “industrially producible” substances for everyday applications, on bioinformatics, environmental biotechnology and also on innovations for the food sector.

The biotechnology sector in Bavaria is supported and strengthened by large subsidiaries of several multinational pharmaceutical companies, who are significantly contributing to the overall employee head count in the region: Roche Diagnostics (Penzberg, more than 5000 employees in research and manufacturing); Merck, Sharp&Dohme (more than 1500 employees); AMGEN (with subsidiaries in Regensburg and Munich); LifeTechnologies/GeneArt (Regensburg); Novartis (with several thousand employees at Novartis Pharma in Nuremberg as well as the headquarter of their generics subsidiary Sandoz in Holzkirchen near Munich); Daichii Sankyo (with their German and European headquarters in Munich, as well as a large manufacturing facility nearby and a research unit for oncology - the previously independent U3 Pharma in Martinsried). In addition to these large pharmaceutical companies, there are a number of



eine Vielzahl weiterer Niederlassungen internationaler Biotechunternehmen von Biogen Idec über Cellgene bis Myriad Genetics.

Eine wichtige Rolle spielen auch bayerische, mittelständische Pharmaunternehmen, die oftmals als Contract Manufacturers von anderen herangezogen werden können, wie Haupt Pharma, Pharmazell, Temmler u.a.

Damit ist die gesamte Wertschöpfungskette für Biopharmazeutika in Bayern hervorragend aufgestellt. Aber auch im Sektor der small molecules oder innovativer APIs bilden bayernweit junge, mittelständische und alteingesessene Unternehmen das ganze Spektrum der Möglichkeiten ab, um nur einige zu nennen: die 2012 neu ausgegründete 4SC Discovery und am anderen Ende der Skala die seit 1788 aktive nordbayerische CFM Oskar Tropitzsch, bei der schon Johann Wolfgang von Goethe seine Experimente zur Farbtheorie durchführte.

Mit dieser Vielfalt an Firmenausrichtungen bilden die Unternehmen eine bayerische Pharma- und Biotechnologiebranche von über **300 Unternehmen mit über 26.000 Beschäftigten und einem Gesamtjahresumsatz von rund 10 Milliarden Euro.**

Industrielle Biotechnologie – neue Materialien:

Weitere biotechnologisch aktive Unternehmen sind in der Chemie, der Materialindustrie sowie auch im Bereich „neue Energien/nachwachsende Rohstoffe“ in Bayern zu finden.

So bildet die neue Demonstrationsanlage für Bioethanol aus Pflanzenreststoffen in Straubing, die mit dem SunLiquid-Verfahren für das Unternehmen Clariant industrielle Tauglichkeit austesten soll, den Kristallisationskeim für ein Kompetenz-Zentrum „neue Energie“ an der bayerischen Donau. Gut 30 Millionen Euro steckt Clariant derzeit jährlich in den Forschungsbereich Biotechnologie (industrielle Produktion), der von München aus koordiniert wird.

Ein besonderer Bereich wird in Bayern durch die Biotechnologiefirma Amsilk vertreten: **Neue Materialien** – in diesem Fall angelehnt an die Spinnenseide (siehe Seite 16).

subsidiaries of international biotechnology enterprises in the region, including Biogen Idec, Cellgene and Myriad Genetics.

Several mid-sized Bavarian pharmaceutical companies are also playing an important role in the region, for example HauptPharma and Pharmazell, as they are often involved as contract manufacturers in various other companies and projects.

Therefore, the entire value chain for biopharmaceuticals is very well represented in Bavaria. In addition, there is a broad range of small as well as mid-sized, young as well as long-established companies working in the field of small molecules and innovative APIs, offering a large spectrum of opportunities, services and solutions. Good examples are 4SC Discovery, which was newly founded in 2012, and – at the other end of the scale – Cfm Oskar Tropitzsch in Northern Bavaria, active since 1788 and counting Johann Wolfgang von Goethe among their early customers for his research on colors.

*With this variety of expertise and focus areas, the local companies are contributing to a Bavarian pharma and biotechnology sector with more than **300 companies, more than 26,000 employees and total annual revenues of around 10 billion Euro.***

Industrial biotechnology:

This is a further area of biotechnology with companies active in Bavaria, especially in chemistry, materials and renewable energies/resources. A corresponding recent development is a new demonstration facility in Straubing, where bioethanol is obtained from plant material (agricultural non-food residues) applying the new SunLiquid technology by the company Clariant, and where this process is evaluated for potential industrial use. This facility is the initial nucleus for the development of a new “Competence Centre” for renewable energies along the Bavarian Danube river. Clariant is currently investing 30 million Euro annually in their research department for biotechnology (industrial production), which is coordinated from Munich.

The biotechnology company Amsilk is representing a particularly innovative area of research in Bavaria: new materials, in this case inspired by spider silk (see P. 16).

Öffentlicher Anschub – private Unterstützung

Rund 500 Millionen Euro hat die bayerische Staatsregierung in den Aufbau der Biotechnologiebranche in den letzten 40 Jahren investiert. Das meiste davon in neue Forschungs- und Hochschulgebäude sowie u.a. in Gründerzentren. Hinzu kommen anteilige Gelder des Bundes für diese Neubauten aber auch spezifische Programme für Spitzenforschung (z.B. Exzellenz-Initiative). An privaten Investitionen sind in dieser Zeit deutlich über 3 Milliarden Euro in die bayerischen Biotech-Unternehmen geflossen.

Public but even more private investments for better health:

The Bavarian government has invested around 500 million Euro for supporting and fostering the biotechnology sector in the last 40 years. Most of this funding went into creating new research centres, academic institutes and incubation centres. Additional financial support for such infrastructural projects was received from the federal government, as well as specific funding for cutting-edge research initiatives (e.g. the Excellence Initiative). Private investments into innovative biotechnology enterprises in the region have now reached a total of a good 3 billion Euros.



Smart Capital and MORE

In 2012, MorphoSys launched a new initiative through which the Company provides innovation capital to promising start-ups with technologies and product candidates being close to its areas of interest. MorphoSys seeks to combine the classical corporate venture approach with collaborative elements.

www.morphosys.com/innovation-capital

morphosys

Biotechnology: Regional Profiles in Bavaria

The Greater Munich Area:

The European Metropolitan Region of Munich is home to the most important biotechnology scene in Germany with some 350 life science companies, several incubators for innovative start-ups (with more than 25.000 sqm state-of-the-art lab-space) and a concentration of large global Biotech and Pharma companies.

In science, 2 „elite universities“ - Ludwig-Maximilians-Universität and Technische Universität München -, 2 university clinics and 60 other hospitals as well as universities of applied sciences focusing on production technologies in biotechnology form the academic basis for innovation.

World renowned science institutions are located in this area: like the 3 Max Planck Institutes of Biochemistry, Neurobiology and Psychiatry. They have very different profiles but a very common characteristic: they are home for world leading scientist like **Mathias Mann** (proteomics), **Axel Ullrich** (oncology), **Hartmut Wekerle** (neuro-immunology), **Franz Hartl** (structure biology). And there is the Helmholtz Zentrum München – German Research Center for Environmental Health, with leading expertise in genomewide research, the European Mouse Mutant clinic, leading research in Immunology... to name a few.

Additionally Munich is the only place in Germany where all of the new German Centres for Health Research are located, focussing on Infectious Diseases, Cardiovascular, Diabetics, Neurodegenerative disorders, Lung diseases, Oncology.

Focus on Personalized Medicine

Munich benefits in particular from close interaction between academic research and the biotech industry. The region is characterised by a strong focus on “red biotechnology” – i.e. human or veterinary medicine. Munich’s profile was further sharpened by the national leading-edge cluster programme “m⁴- Personalized Medicine and Targeted Therapies”, which is coordinated by the local cluster management organisation Bio^M. In this particular programme the infrastructural measures for combining biomarker research and validation with drug development and diagnostics will be optimized and a new central

approach to Munich Biobanking and Clinical Trial Services will improve the interaction of industry and academic institutes even further.


In addition a new “m⁴ Award” scouts for and is fostering academic projects in personalized medicine to help business opportunities to get started.

Regensburg and the East of Bavaria:

The BioPark Regensburg GmbH is the management and administrative headquarters of the biotechnology research cluster known as BioRegio Regensburg in East Bavaria. Located strategically at the northernmost point of the Danube, in the Austrian-Czech-German triangle, the area is regarded as the gateway to the East of the extended European Union. Currently 47 firms with 3150 employees are active in the field of life sciences (Biotech + MedTech) in BioRegio Regensburg. As a result it has become the most important region for Biotechnology in Bavaria, second only to Munich.

With its University, the University of Applied Sciences and its Medical Centre, the City of Regensburg possesses the youngest and most modern institutions in Bavaria, where 7,000 employees and 28,000 students have significantly embossed the dynamic economic location of Regensburg. The individual professorial chairs have, through various means, proven the top-class university-standard research achievements in the field of the biological sciences (the so-called life sciences). In addition to special fields of research of the German Research Association (DFG), particularly in metabolic physiology and immunology, several project assistance measures provided by the Federal Ministry of Education and Research have been injected into the neurosciences for example. The José Carreras Foundation has been established for hematological therapies using adult stem cells. The Human Tissue & Cell Research Foundation was founded on site for the development of new methods for therapy for patients with liver diseases. The development of vaccines against the HI virus is funded significantly by the Bill and Melinda Gates Foundation. In the field of infection biology the Medical Centre is a partner of the

Bavaria



World Health Organization (WHO). Since 2008 the Fraunhofer Project Group for the Diagnosis and Treatment of Tumors, Metabolic Diseases and Diseases Associated with Ageing and since 2011 the Fraunhofer Project Group for Sensor Technology Materials has been located in the BioPark as an external university research unit. In 2008 the research network "BayImmNet" has commenced its activities in Regensburg. The goal is the development of new therapies and medicines for infectious, tumor, autoimmune and rheumatic diseases. (see page 18)

Through the foundation of the BioPark Regensburg GmbH in 1999, the City created a further catalyst for this aspiring future-focused sector. With support from the State of Bavaria, the German Government and the European Union, the BioPark was erected for 42 million € in three construction phases in 2001, 2006 and 2011 directly on the grounds of the University. The multifunctional buildings offer in total 18,000 sqm state of the art laboratory, office and storage facilities for companies and institutes in the field of biotechnology, medical technology and associated services.

Würzburg:

With its research centres, research groups, and postgraduate schools of medicine and life sciences, the Julius-Maximilian University ranks among the most successful universities in Germany. The Rudolf-Virchow Centre for Experimental Biomedicine is one of the DFG funded "centres of excellence" focusing on the identification of new target proteins in cancer, cardiovascular, autoimmune and inflammatory diseases, which can

be the basis for improved diagnosis and treatment. The Comprehensive Cancer Centre (CCC) was established at Würzburg university hospital in 2011 and is recognized as a „centre of excellence for oncology“ by the German Cancer Aid (Deutsche Krebshilfe). The new Comprehensive Heart Failure Centre (CHFC) performs excellent research in cardiovascular diseases. Würzburg is home to one of five German banks of biomaterials and data which are an important prerequisite for a better understanding of diseases and disease mechanisms.

Together with local universities and *netzwerk nordbayern*, IGZ Würzburg has developed a comprehensive program for promoting start-up activities in the region. Young scientists are offered advanced training courses with an economic and branchspecific focus. Technology scouts at colleges and research institutions in the region are screening research results for new business concepts with high economic potential at early stages. Once promising concepts and entrepreneurial teams have been identified, startup projects are individually and intensively supported during the whole start-up phase. IGZ Würzburg provides continuous support in team-building right at the academic origins of the startup companies. Through intensive coaching and support the IGZ provides a smooth transition for company founders between their academic and entrepreneurial careers.

(Information about Straubing on page 16)

www.m4.de
www.bioregio-regensburg.de
www.igz.wuerzburg.de
www.medical-valley-emn.de
www.straubing-sand.de

“Since 1998, more than two billion euro have been invested in site expansion projects”

Interview with Claus Haberda, Site Manager, Roche Penzberg



CLAUS HABERDA
Site Manager
Roche Penzberg

How did it come about that Penzberg is now the largest biotechnology centre in Europe and one of the most important biotechnology sites of the Roche Group worldwide?

The birthplace of industrial biotechnology is regarded to be in Tutzing at Lake Starnberg. In Tutzing, the company Boehringer Mannheim began focussing its efforts on researching and developing new biochemical methods to aid disease diagnosis as early as 1946. From 1972, this company division in Penzberg embarked on a further expansion project. A former mine site provided the ideal area for increasing the company's production capacities. Since then, there have been constant investments in the Penzberg site – investments in research, development and the production of medicines and diagnostics. Knowledge of biochemistry extends from the time of classic biotechnology to today's modern biotechnology. Since Roche took over in 1998, over two billion euro have been invested in the site's expansion, which in fact is one of the largest biotechnology centers in Europe to date. Moreover, employee expertise and their enthusiasm for work, teaming-up the pharmaceutical and diagnostics business areas in the context of Personalised Healthcare, reliability when implementing projects and, last but not least, close collaboration with politicians and authorities are all absolutely essential for this success story.

Roche continues its expansion venture of the biotechnology center in Penzberg. In 2011, the Swiss pharma and diagnostics-company invested 158 million euro in the research and development of therapeutic proteins. Roche recently announced an investment of further 200 million euro for a new diagnostics operations plant in 2013.

What other investments are planned in Penzberg?

This investment is of great significance for the Penzberg site and reinforces us as a pillar of strength within the Roche Group. As a general principle, large investments are well discussed and weighed in the Roche Group. We in Penzberg must always compete for these investments anew and we are keen to convince with high levels of productivity, excellent innovative strength and a high quality work force. We were able to prove one more time our competence in process optimization, scale-up technologies and cost efficiency. The market for immune-assays is growing vividly and we can fulfill the demands of the production chain. Further, I am pleased to see an equal allocation of investments in the two divisions pharma and diagnostics here on site and will do my best to keep the site attractive for further investments.

What role does Personalised Healthcare play today and in the future for Roche? What are Roche's special strengths and the strengths of the Penzberg site in particular in this area?

We are fully convinced that the future lies in personalized medicine. It is precisely for this reason that it represents a key element of the Roche strategy. In Penzberg, scientists from the diagnostics and pharmaceutical sectors are working in close collaboration on new therapies. This generates synergies which are not available at other Roche sites.

Generally speaking, how do you view the biotechnology and pharmaceutical sector in Bavaria?

The Bavarian state has introduced initiatives that promote both high-quality training (MINT initiative, elite universities) and cross-linking between science and industry (Leading-edge clusters, IZB Martinsried and Bayern Innovativ). Politics in Bavaria has also laid good founda-

tions for high-tech companies, which has resulted in Bavaria's biotech industry being ranked among the best worldwide. However, we must continue to ensure that research and development in particular remain attractive in Germany. Furthermore, I am of the opinion that the detrimental effects of the healthcare reforms for the pharmaceutical industry should also be discussed in the context of job security.

The interview was conducted by Markus Hofelich.



Constant investments through Roche as well as good foundations laid by politics in Bavaria made Penzberg one of the biggest Biotech locations in Europe.
Photo: © Roche Penzberg

Biotechnology is an industry application in Bavaria

As shown before for Roche in Penzberg, production of goods with help of micro-biological organisms or cell culture ("biotechnology" in its pure meaning) is a longtime practice in Bavarian industry application. Historically one may even reflect on one of the oldest breweries in the world that still produces beer – the Weihenstephan brewery founded 1040 a.c. north of Munich. This perhaps was the fruitful ground on which a modern **Industrial Biotechnology** could emerge from.

Today this key technology delivers important impulses for the intended structural change from an oil to a bio-based economy. Within Germany, Bavaria belongs to the most research-intensive sites worldwide and has a highly developed infrastructure for technology transfer. Thus, Bavaria offers best conditions for the advanced development of Industrial Biotechnology.

For example the company **WACKER**: With more than 20 years of experience in the field of microbial systems, Wacker Biotech GmbH is a skilled partner for the contract-manufacturing of therapeutic proteins. The ESETEC® E. coli secretion technology enables highly efficient extracellular production of proteins using E. coli K12. The biomass produced by the DENSETEC® high-cell-density fermentation system surpasses typical industry standards. But Wacker also produces biological material in tonne weight, for example the amino acid Cysteine: Produced by Wacker in a novel, patented fermentation process, this multifunctional feedstock opens up a wide range of applications, for example as a component of fermentation liquors.

In the field of "new energy from new resources" the company **CLARIANT** (former Süd Chemie) has chosen Straubing in eastern Bavaria as the place to produce "Biofuel of the future". Clariant, headquartered in Switzerland, inaugurated Germany's biggest pilot plant for the production of climate-friendly cellulose ethanol from agricultural waste in July 2012. Located in Straubing and supported by the Bavarian government and the Federal Ministry for Education and Research, the futuristic project will produce up to 1,000 tonnes of cellulose ethanol from around 4,500 tonnes of wheat straw based on the sunliquid®

technology developed by Clariant. It represents an investment of around 28 million euros. Studies show that Germany potentially has around 22 million tonnes of straw that could be used for energy production without compromising essential soil regeneration. This would be sufficient to cover around 25% of Germany's current gasoline requirements.

Spidersilk is the most innovative type of new material produced by microorganisms by the company **AMSILK**, located in Martinsried/Munich. For the very first time they announced an industrial production process for a protein-based fiber with similar characteristics to natural fibers from spiders (see Photo).

Industrielle Biotechnologie Bayern Netzwerk GmbH (IBB Netzwerk GmbH)

coordinates R&D projects of industrial biotechnology in Bavaria. IBB Netzwerk GmbH is an organization focusing on transforming valuable scientific knowledge in the area of industrial biotechnology to innovative marketable products and processes.

One of the main tasks of IBB Netzwerk GmbH is the management and coordination of the network IBB. Within this network, the competences and the potentials of industry, small and medium enterprises, academia, business developers, consultants and associations are combined and mobilized to strengthen as well as to expand industrial biotechnology.



BioPark Regensburg

Successful Innovation Centre on the Danube

Health Industry of Regensburg

- 1.4 billion Euros turnover
- 15,500 employees

Cluster BioRegio Regensburg

- 47 companies (Life Sciences)
- 3,150 employees



BioPark Regensburg

- 35 tenants, 550 employees
- state-of-the-art offices & laboratories (18,000 m² incl. 5,400 m² S1/S2-laboratories)
- flexible leasehold concept & single office
- comprehensive range of technology & services
- excellent location factors (University Campus, motorway connection, childcare facility)

Get information at:

www.bioregio-regensburg.de

phone + 49 941 920 460



UNESCO World Heritage
Old Town Regensburg:
www.regensburg.de



Member of CLUSTER BIOTECHNOLOGIE BAYERN

BIOPARK
REGENSBURG GMBH

Biotechnology: Science in Bavaria

BayGene

The Bavarian Genome Research Network coordinates outstanding projects in the field of functional genome research in Bavaria. Based on a better understanding of gene functions, interactions and regulatory mechanisms, significant progress can be expected in the diagnosis and treatment of illnesses such as cancer and diabetes. The scientific and economic possibilities of functional genome research will significantly change industry and society in the 21st century.

In this program, the Bavarian State Ministry of Sciences, Research and the Arts has funded 12 scientific projects for a time period of five to seven years. (*)

BioSysNet

The **Bavarian Research Network for Molecular Biosystems** aims at expanding the existing Bavarian competencies and skills in the area of biosystems research, based on the expertise of the BayGene Network. This way it will enhance the international attention directed towards Bavaria on this innovative research field.

Within a designated time frame of five years, 24 outstanding projects at different Bavarian universities in Erlangen, Munich, Regensburg and Würzburg are funded by the Bavarian State Ministry of Science, Research and the Arts. Scientific director of this program is **Patrick Cramer**, Munich Gene Center. The main focus is to explore and explain the functions and regulations of molecular biosystems. The program is composed of young junior scientists, who are now establishing new research groups in Bavaria, as well as outstanding research groups already located in Bavaria, who will receive only supplementary funding. The analysis of complex biological regulatory systems is an interdisciplinary undertaking and requires the coordinated cooperation of biochemistry, genetics, bioinformatics, biophysics and medicine. New methods and technologies shall help scientists to investigate the genome regulation on a cellular and molecular level.

BioSysNet focuses on the development of modern diagnostic methods and therapeutic approaches. The network offers the prerequisites for outstanding scientists to do cutting-edge research on an international level. The intensive exchange between groups within the network guarantees a fast and efficient implementation of the envisioned research.

BayImmuNet

Immunotherapy – therapeutic intervention in the human immune system – is one of the most important cornerstones of modern medical research. One of the current challenges is the translation of innovative therapy approaches from the laboratory into clinical application. In the area of Immunotherapy – particularly antibody therapy and cellular therapy – Bavaria has excellent scientific teams and, consequently, a high degree of scientific potential. Many of the projects carried out by those teams are already at a stage in which rapid translation into clinical application can be expected. However, on the part of the university hospitals there is an investment bottleneck due to the Medical Preparations Act that is preventing rapid and efficient translation into clinical application.

BayImmuNet, a unique network established in Bavaria in 2008, has set itself the goal of achieving faster translation of new approaches in immunotherapy into clinical application.

Meanwhile this network is accomplished with further activities in Immunology in Bavaria: The **“Science Alliance in Immune Medicine”** and the **“Regensburg Center for Interventional Immunology”**.

ForPlanta

The scientists of **“FORPLANTA – Plants fit for the future”**, which is also funded by the Bavarian State Ministry of Sciences, Research and the Arts, are investigating the adaptation capacity of plants to stress situations like dryness, heat and pathogens on the model plant *Arabidopsis*. Their aim is to clarify the molecular mechanisms that protect plants against multiple stress conditions with latest technologies and methods. The significance of plant research in times of climate change on the one hand and the benefits of interdisciplinary cooperation between different scientists on the other hand, form a remarkable, contemporary and stimulating background of this funding program. The scientific goal is to discover how plants protect themselves under different stressful circumstances and how these mechanisms can be used optimally in the future.

(*) Websites of each network described can be found on page 20

There are more specialized research programs in Bavaria, for example **FORPROTECT** dealing with Infectious diseases and **FORMOSA** with scientific projects in skeletal muscle diseases of ageing people, or **FORNEUROCELL**, a program in neurodegenerative disorders. All of these can be found in more detail at: www.bayfor.org

Munich Center(s) of Excellence

In 2006 the German Research Organization (DFG) selected in the so called "excellence competition" 3 universities with compelling future concepts. 2 out of the first winners have been the Munich universities LMU and

TUM (later on there was a next competition round, and 2012 there was a third round). Both Munich universities were successful with different thematic concepts interconnecting the both universities. Here we only focus on the meanwhile three "centers of excellence" in or close to LifeSciences.

CIPSM: Center for Integrated Protein Science Munich

In CIPSM internationally recognized scientists in the Munich area from the two leading Universities in Germany, LMU and TUM, as well as from the neighbouring Max Planck Institutes and the Helmholtz society are joined.

 **NORTON ROSE**

FULBRIGHT
& Jaworski L.L.P.



FAST FORWARD TO THE USA

**Norton Rose and Fulbright & Jaworski LLP
are joining forces as Norton Rose Fulbright**

On June 3 2013, Norton Rose and Fulbright & Jaworski LLP will join forces to create Norton Rose Fulbright – a global legal practice with significant depth of expertise in the world's leading business and financial centres and a dedicated Life Sciences team. Our momentum will deliver the US capability and services our clients need for fast forward growth wherever they are in the world.

Norton Rose Fulbright – Law around the world

nortonrose.com/nortonrosefulbright

CISPM forms an umbrella under which the individual research facilities can develop their expertise jointly to form a center of scientific gravity in southern Germany.

Research areas are:

- Protein Biophysics and Imaging
- Folding and Transport
- Protein Structure and Networks
- Protein Nucleic Acid Interactions
- Protein Engineering and Chemical Biology
- Protein Function/Dysfunction 'in vivo'

Munich Cluster in Nanosystems: NIM

The cluster "Nanosystems Initiative Munich" (NIM) brings together research groups in the Munich area covering the fields of physics, biophysics, physical chemistry, biochemistry, biology, electrical engineering, and medicine. It merges their combined expertise on man-made and biological nanoscale systems into a coherent and focused nanoscience cluster. While many individual nanoscale building blocks and components have been devised in recent years using top-down and bottom-up strategies, little is known about their integration into entire functional systems. The overarching vision guiding the research in this cluster will therefore be to design, fabricate and achieve control of a broad range of artificial and multi-functional nanoscale systems, and to unlock their potential for possible applications in fields as diverse as future information technologies, the life sciences, or combinations of both.

Research areas are:

- Biomolecular Nanosystems
- Biomedical Nanotechnologies
- Quantum Nanophysics
- Hybrid Nanosystems
- Nanosystems for Energy Conversion

SyNergy: Munich Cluster for Systems Neurology

Systems Neurology is a new research field where systems biology and systems neuroscience meet with clinical neurology to generate an integrative understanding of how neurological diseases emerge from the interplay of degenerative, immune and vascular mechanisms.

Recent insights have revealed a more complex relationship between different disease mechanisms and prompt a rethinking of the relationship between disease entities and their underlying mechanisms. Such reassessment suggests that distinct disease manifestations can not be explained in isolation but instead all root in an intricate network of shared pathomechanisms.

To appropriately address these entangled "network" relationships, novel research tools and integrated approaches are needed. One approach that has been developed in basic life sciences to decipher such complex interactions and the resulting "emerging properties" is systems biology.

Research areas are:

- Inflammatory Mechanisms of Neurodegeneration
- Bi-directional Relationships between Vascular Dysfunction and Neurodegeneration
- Glio-Vascular Response to Inflammation

www.baygene.de
www.biosysnet.de
www.bayimmunet.de
www.forplanta.de
www.bayfor.org

www.en.uni-muenchen.de/about_lmu/excellence_initiative/clusters

Metagenomics • Biomarker Discovery • Pharmacogenetics

IMGM[®]
LABORATORIES

Find out more at

www.imgm.com



IMGM Laboratories GmbH - your professional outsourcing partner for genomic services

Lochhamer Str. 29 | 82152 Martinsried, Germany | ph.: +49.89.895578.40 | fax: +49.89.895578.41 | info@imgm.com



Facts and Figures 2012


Number of Companies

In our survey we categorize companies into 5 distinct groups: biotech-SMEs (small or medium-sized enterprises according to OECD, as non-subsidiary, independent firms), biotech-non-SMEs (with headquarters outside Bavaria; not implying anything about how many people may work there), pharma, CROs (contract research organizations that support clients through clinical development, as well as CROs that focus on preclinical laboratory research) and suppliers.

According to this, the number of **biotech-SMEs** in Bavaria in 2012 amounts to 178 (+ 3 compared to 2011). Additionally, there are 37 national or international (the majority) subsidiaries – or **biotech-non-SMEs** – which are mainly working in the field of biotechnology. The most prominent of these, Roche Diagnostics in Penzberg, 60 kilometers south of Munich, has built a local history of its own: By taking over Boehringer Mannheim in 1998, the Roche Group decided to modernize the acquired Penzberg site as a major production plant for biopharmaceuticals. At


this time around 2,500 people worked at Roche-Penzberg. Since then, Roche has invested more than 2 billion Euros and has expanded the location massively to now more than 250,000 sqm of laboratory and production buildings – and doubled the work force to more than 5,000 today. The Penzberg site combines the two worlds of pharma and diagnostics in R&D and production and implements “companion diagnostics development” in their daily business – a perfect link to the Munich Biotech Cluster m4, focusing on “Personalized Medicine”. (see pages 12, 14) Another heavyweight in Bavaria has emerged from the **pharma** sector: Novartis. Novartis Pharma in Nuremberg with almost 2,000 employees has established the international headquarter for their generics and “biosimilars” branch Sandoz in Holzkirchen near Munich, with further members of the Novartis Group like Hexal, Novartis Consumer Health and Novartis Vaccines and Diagnostics in the area – all in all about another 5,000 employees. Apart from this, there are other global pharma players like GSK, BMS, MSD or Daiichi Sankyo domiciled in the greater Munich area with several thousands more in staff numbers – in total the pharma sector counts for nearly 9,700 employees in Bavaria.

BIOTECH/PHARMA COMPANIES IN BAVARIA



Before the final production and marketing efforts for a new drug, the most important steps have to be taken during the clinical development and approval phases. Because of the large number of companies developing new drugs, an entire sector of consulting and clinical trial services has been established in this region. Such services are now professionally provided by nearly 60 international **CROs** employing more than 2,300 people.

BAVARIAN BIOTECH SME IN 2012



In addition, successful drug development could not be done and better medicines and diagnostics could not be developed if there weren't the **suppliers** equipping the labspace and the **CMOs** (contract manufacturing organizations) with their expertise in the professional production of pharmaceuticals. Bavaria is in the fortunate position to have them all – and thus to provide for the whole value added chain of (bio)pharmaceuticals.

Company Foundations

In 2012, quite a number of newly established companies (SMEs and international subsidiaries) started operating in Bavaria, many of which are “real” new foundations, but also some relocations into the Munich Biotech Cluster. On the other side, there have been some relocations out of Bavaria (Octapharma, Agennix) and a few closures. This report is foremost a place for statistics, facts and figures, but of course the fate of the employees in such cases should also be considered worth a few thoughts in the readers’ minds. In line with the roller coaster ride that biotechnology R&D can be for many companies, there is another aspect which is also highlighted in this report: company closure and foundations at the same time. During the acquisition of Munich’s Micromet, Californian AMGEN decided to keep business and research for this special technology platform (bifunctional antibodies) in Munich – with their new branch Amgen Research Munich, which emerged directly from the previous Micromet enterprise (see page 30).

Another acquisition put the successful entrepreneurs straight back into a promising “restart” position – after selling the most advanced project of Munich’s Corlmmun to Janssen-Cilag/Johnson&Johnson in 2012, the two CEOs are now “back in business”, transferring the remainder of their interesting pipeline into the new start-up Advance-COR.

Many additional foundations are not academic start-ups but spin-outs from existing companies, often led by local serial entrepreneurs. The existence of such highly experienced people in the Bavarian Biotech Cluster is a good sign for a successful future of biotechnology in the region.

All in all, in times of “Greek” headlines and a never-ending European crisis of trust in financial and political actionability, it is good and reassuring to see the number of Bavarian biotech companies remaining stable and even having grown slightly (by 3 enterprises) to 178.

On the next pages, we will take a closer look at the state of employment in Bavarian companies.

NEW COMPANIES (FOUNDED & RELOCATED)

COMPANY	CATEGORY	ORIGIN
4SC Discovery GmbH	Biotech & Therapeutics	founded
Actavis Deutschland GmbH & Co. KG	Pharma	relocated
advanceCor GmbH	Biotech & Therapeutics	founded
Alcon Pharma GmbH	Pharma	relocated
Amgen Research Munich GmbH	Biotech & Therapeutics	founded
AptalT GmbH	Bioinformatics	founded
BioVariance	Bioinformatics	founded
CROMSOURCE GmbH	CRO	founded
Dojindo EU GmbH	Devices/Reagents	relocated
eADMET GmbH	Preclinical Services	founded
Formycon AG	Preclinical Services	founded
Hikma Germany	Pharma	relocated
ImmunoQure AG	Biotech & Therapeutics	founded
Molekula	Devices/Reagents	relocated
numares GmbH	Biotech & Diagnostics	renamed
Pelo Biotech GmbH	Devices/Reagents	founded

Employment

Jobs in Biotechnology and Pharma Companies

For 2011 we reported an all time high in Bavarian biotech SMEs of more than 4,000 employees. Again in 2012 we are fortunate to report an increase to this, with a total of 4,336 employees in 2012 (+ 3.6 % compared to 2011). From 2009 to the end of last year the overall increase was + 12 %. This positive trend can also be seen in the biotech non-SMEs, which employed 6,550 people in 2012 (+ 4.6 % compared to 2011; showing an increase from 2009 of + 10 %).

However, other areas of Bavaria's biotech and pharma landscape showed setbacks, like the pharma sector with a decrease in employee's number of about 4 % (2012: 9,672 employees; 2011: 10,066) or – even more so – the CROs with now 2,356 employees (– 10 % compared to 2011: 2,623). For pharma companies, this might follow an international trend of “downsizing”, even if to a lesser extent, whereas in the area of CROs some companies are strongly expanding while others are declining, which might eventually lead to a market adjustment.

Fields of business of biotech SMEs


As shown in the figure on page 22, the majority of Bavarian biotech SMEs is focusing on development and marketing of therapeutics or diagnostics – and therefore it does not come as a surprise that these companies still have the largest percentage of employees in the category of small and medium-sized biotechnology companies. This sector employs 2,393 people, more than 55 % of all employees in the SMEs.

Total number of employees in the Bavarian Life Science industry

Taking together in the entire pharmaceutical and biotechnology industry in Bavaria, employee numbers reached a total of around 26,000 in 2012, more or less the same as in 2011.

There was a slight shift between the different areas of Bio-Pharma industry: an **increase of employees in the biotech companies** (SMEs plus non-SMEs) of approximately + 4 % compared to a **decrease of employees in**

NUMBER OF EMPLOYEES IN THE BAVARIAN BIOTECH CLUSTER




pharma (– 4 %) as well as in CROs (– 10 %). It is remarkable that the increased head count in the biotech SMEs easily "compensated" for the change in "category" for the approx. 180 employees of former Micromet (being counted as biotech-SME before) to Amgen Research Munich (now counted as biotech-non-SME) and this trend is still ongoing in early 2013.

In addition to the overall stable employment figures within the industry, there are also around 10,000 people working in the life science departments of Bavarian research institutions.

Altogether, the sector provides more than 36,000 jobs in (academic) science and industry throughout Bavaria.

NUMBER OF EMPLOYEES IN THE BIOTECH SME IN BAVARIA (2012)



Products and Pipeline

Drug Development

Drug development is a rollercoaster ride of its own. Many ups and downs in clinical development, delays and failures are absolutely normal but have to be counterbalanced by at least some success stories. Like the rollercoaster falls the furthest after having reached the highest peak, the same is true for clinical failures in late stage development. In Bavaria in 2012 two drug development companies struggled in the very late stage development; nevertheless a few companies achieved positive milestones in early stage development. As a consequence, many drug developers have decided to restructure their clinical development pipeline and thereby their development expenditures.

But starting with the positive news: **Wilex AG** (Munich) has successfully finished a phase I dose escalation study with its oral MEK inhibitor WX-554. The drug candidate was safe and well tolerated when administered as capsules in four healthy male volunteers. **4SC AG** (Martinsried) announced positive results for their compound resminostat, which reached the primary endpoint in a phase II trial in advanced liver cancer. Resminostat/sorafenib combination therapy stopped disease progression in two thirds of patients (PFSR 66.6 %) and attained median progression-free survival (PFS) of 4.6 months. In addition, **Supremol GmbH** (Martinsried) published positive interim results on SM101 in its phase Ib/IIa clinical trial for primary immune thrombocytopenia. The study demonstrated that SM101 is safe and well tolerated and shows excellent therapeutic activity. **Morphosys AG** (Martinsried) announced the successful completion of patient enrollment in its phase Ib/IIa for MOR103, a HuCAL antibody targeting GM-CSF. The study includes 96 patients with active rheumatoid arthritis in a randomized, double-blind and placebo-controlled trial at various clinical centers in Europe.

In May 2012, the Japanese company **Yakult Honsha** successfully started the clinical development of 4SC's cancer compound resminostat in Japan with advanced solid tumors patients. This phase I study investigates safety of resminostat in Japanese patients. The open-arm, dose-escalating study was implemented by Yakult Honsha, 4SC's Japanese codevelopment and marketing partner. Fortunately, 4SC's resminostat accomplished progression-free survival of 4.7 months in a phase II trial in advanced liver cancer (HCC). In combination with sorafenib, the therapy stops further disease progression for at least 12 weeks in 70 % of HCC patients (PFSR 70 %). In September 2012, resminostat was shown to provide median overall survival of 8.0 months in Second-line advanced liver cancer patients.


Vasopharm GmbH (Wurzburg) with its lead candidate VAS203 has fulfilled all clinical endpoints for safety and showed strong evidence of clinical benefit in patients within its phase IIa NOSTRA trial in traumatic brain injury. The NOSTRA (NO-synthase inhibition in traumatic brain injury) trial was a European, multi-center, placebo-controlled, double-blind study with safety and tolerability as primary endpoints.

By the end of the year, **4SC AG** (Martinsried) revealed positive data from a clinical phase I trial with its compound 4SC-205 in cancer patients. All primary objectives of the clinical study have been achieved, moreover the safety profile and maximum tolerated dose have been successfully verified.

DRUG PIPELINE IN BAVARIA

number of clinical studies/drugs

■ 2009 ■ 2010 ■ 2011 ■ 2012



PHASE II	PHASE III	APPROVED
<p>4SC AG: hepatocellular carcinoma, hodgkin's lymphoma, colorectal cancer, mild to moderate rheumatoid arthritis, inflammatory bowel disease.</p> <p>Antisense Pharma: glioblastoma, malignant melanoma, pancreatic cancer</p> <p>Bavarian Nordic: small pox, breast cancer</p> <p>AdvanceCor: acute coronary syndrome, stroke</p> <p>Donatur: periarthritis</p> <p>MediGene: triple negative breast cancer, pancreatic cancer, rheumatoid arthritis</p> <p>MorphoSys (with Novartis): oncology, musculoskeletal diseases, ophthalmology</p> <p>MorphoSys (with Janssen Biotech): psoriasis, rheumatoid arthritis</p> <p>MorphoSys (with Oncomed): oncology</p> <p>MorphoSys: rheumatoid arthritis, multiple sclerosis, chronic lymphocytic leukemia</p> <p>Scil Technology/Formycon: implantology, periodontal diseases</p> <p>SuppreMol: idiopathic thrombocytopenic purpura, systemic lupus erythematosus</p> <p>Trion Pharma/Fresenius Biotech: metastatic breast cancer, gastric cancer, ovarian cancer, malignant ascites</p> <p>Vasopharm: traumatic brain injury</p> <p>Willex: advance non-metastatic pancreatic cancer, breast cancer</p>	<p>Antisense Pharma: anaplastic astrocytoma</p> <p>Bavarian Nordic: advanced prostate cancer</p> <p>Fresenius Biotech: stem cell transplantation, immunology therapy</p> <p>MorphoSys (with Roche): Alzheimer's disease</p> <p>Willex: clear renal cell cancer</p>	<p>Fresenius Biotech: transplantation (ATG-Fresenius S)</p> <p>Medigene: genital warts (Veregen®), prostate cancer (Eligard®, sold), Rosacea, inflammatory lesions (Oracea®, sold)</p> <p>Trion Pharma/Fresenius Biotech: malignant ascites (EU, Removab®)</p>

Late stage druggipeline in more detail, indications.

Some drug development companies have, on the other hand, suffered from significant setbacks in 2012:

Antisense Pharma GmbH (Regensburg) terminated its 2nd line phase III trial with Trabedersen for high grade glioma due to patient recruitment problems. The company has continued the 1st line treatment of glioblastoma and pancreatic cancer patients in combination with standard of care. For these indications, the company plans to re-start its phase II trial.

Agennix AG (Munich) released the negative results of its FORTIS-M phase III trial with talactoferrin alfa, which did not reach the primary endpoint of improving overall survival. Moreover, the company has terminated further enrollment and treatment in the phase II/III OASIS trial for severe sepsis. **Willex AG** (Munich) did not achieve its primary endpoint in its phase III ARISER trial with Rencarex® for the treatment of clear cell renal cell carcinoma. Rencarex® was safe and well tolerated in clinical studies.

Due to the negative results, the Independent Data Monitoring Committee recommended to terminate the phase III trial. But after hitting the ground rather heavily with this setback, the momentum of roller coasting is back, as a detailed analysis of patients' subpopulations in the ARISER-trial showed a minor group that benefitted significantly which is now under further investigation.

In summary, the Bavarian biotech drug development pipeline has decreased due to a number of failures as well as some successful exits. Compared to last year, the number of preclinical studies decreased slightly to 57. In clinical phase I and clinical phase I/II the number of clinical studies declined compared to 2011, while only a small drop has been observed in clinical phase II/III. 37 clinical studies in phase II/III and 6 clinical studies in clinical phase III have been carried out during the year 2012.

Deals, Cooperation, Mergers, Financing

Deals and Cooperation

In 2012, the deal flow for Bavarian biotech companies was very high. Biotech companies closed many licensing agreements, merger-, acquisition- and co-development-deals with international pharmaceutical and biotech companies. Medigene AG (Martinsried) signed ten new agreements for the commercialization of its drug Veregen® in Europe, America and Asia with international pharma companies. In addition, The company announced a partnership with SynCore, a subsidiary of the Sinphar Pharmaceutical Group, for the co-development and commercialization of the clinical drug candidate EndoTAG®-1 in Asia. The biotech company SuppreMol GmbH (Martinsried) closed a licensing agreement with the University Hospital of Regensburg for the development of the preclinical compound SM401, a humanized anti-IL-3 monoclonal antibody. This antibody could be used for the early diagnosis and treatment of rheumatoid arthritis. The development of SM401 has been funded by a € 1.4 million grant from the German Federal Ministry of Education and Research (BMBF).

Leukocare AG (Martinsried) has also signed a licensing agreement with a focus on personalized medicine. The US-based diagnostic company **Trillium Diagnostics** and Leukocare have formed a strategic alliance concerning the development and marketing of Leukocare's patented method for the detection of inflammatory activity by novel biomarkers. Trillium uses the biomarker method to develop a commercial assay for the diagnosis of sepsis. Furthermore, **AbD Serotec**, MorphoSys' former division for research and diagnostic antibodies has out-licensed two HuCAL antibodies to **DiaSorin S.p.A** (Italy), a worldwide provider of specialty assays. The "Blood Donor Biobank" (the Bavarian Red Cross (BRK) **Blood Donor Service**) has successfully closed a licensing agreement with **Myriad RBM** (Texas) and the Max Planck Institute of Biochemistry for the identification of new plasma biomarkers in colorectal cancer.

During 2012, over 15 research and development collaborations have been agreed; of these the majority of R&D alliances have been started with global pharmaceutical companies. Compared to 2011, the number of research & development collaborations is still very high. Fortunately, some biotech companies were able to expand existing collaborations with their long-term partners: **Priaxon AG** (Munich) has prolonged their drug discovery collaboration with **Boehringer Ingelheim** (Ingelheim) on mdm2/p53 inhibitors for the treatment of cancer. Priaxon will receive up to € 86 million in milestone payments upon achievement of certain development, regulatory and commercial milestones and royalties on future net sales of products. **Proteros biostructures GmbH** (Martinsried) and **UCB** (Belgium) have continued their structural biology colla-

boration for additional therapeutic areas. Since 2007, Proteros and UCB have been running common drug discovery programs in the area of immunology. Since September 2012, the collaboration has included extra programs/targets for CNS discovery research. In November 2012, **MorphoSys AG** (Martinsried) and **Novartis AG** (Switzerland) announced the expansion of their strategic alliance, which had begun in 2004. Their long-term alliance now includes MorphoSys' new technology platform Ylanthia®, which increases the productivity for development of new therapeutic antibodies. **XL-protein GmbH** (Freising) has closed a long-term agreement with **Wacker Biotech GmbH** (Jena) to produce more PASylated® therapeutic proteins.

Moreover, **4SC Discovery GmbH** (Martinsried) has successfully closed several partnerships, e.g. with **Henkel KGaA** for the identification of new and more effective laundry detergent ingredients and also with **Crelux GmbH** (Martinsried). Crelux and 4SC Discovery have agreed on a strategic partnership for integrated drug discovery services. As first result of this local partnership, 4SC Discovery and Crelux together entered into research collaboration with **Ribological GmbH** (Mainz) for the identification of new and more effective anti-cancer compounds. By the end of 2012, 4SC Discovery and Crelux again announced in tandem their latest collaboration agreement with **BioNtech AG** (Mainz). This partnership includes an exclusive worldwide research and license agreement for the development and commercialization of 4SC's new small molecule toll-like receptor agonists in oncology. (**)

(**) to be continued on page 32

“The investment of Amgen Research Munich is the largest single one Amgen has ever made”

Interview with Richard Paulson, VP & General Manager, Amgen GmbH in Germany



RICHARD PAULSON
VP & General Manager
Amgen GmbH

Mr. Paulson, last year, Amgen acquired Micromet for USD 1.16 billion. It was the largest ever transaction involving a German biotechnology company. What made Micromet so special?

Amgen has always been committed to developing the most innovative new medicines, based on the most advanced understanding of disease states, to treat patients with serious illnesses. Micromet had brought excellent scientists together, and built a promising late-stage cancer drug pipeline, as well as an R&D engine with the potential to generate many more cancer drug candidates well into the future. We believe the Bispecific T cell Engager (BiTE) antibody technology developed by Micromet is one of the most exciting platforms in the world, to develop safe, effective new medicines for cancer patients. Amgen and Micromet were an excellent fit, given our people and our corporate cultures, both of which were science-based and values-driven. We wanted to put Micromet’s science and people right at the heart of Amgen’s continuously growing R&D efforts, and that’s exactly the role they will play, as the new Amgen Research (Munich) GmbH. This is the largest single investment Amgen has ever made, and it signals our

commitment to pursuing the very best medical science, both through our in-house R&D capabilities, and through technologies and compounds from partners around the world.

What is the potential you see for Amgen, from the BiTE technology platform?

With BiTE, we see the potential for a whole new generation of novel therapies, to help patients with cancers that are insufficiently treatable today, and for whom other medicines are not working. For example, the molecule blinatumomab is in development right now for a type of blood cancer – acute lymphoblastic leukemia (ALL) – for patients who have exhausted all other treatment avenues. In clinical studies, this drug has also shown to be active in some patients with non-Hodgkin’s Lymphoma, as well as those with ALL. The BiTE technology takes a new approach to treating cancer. It aims to enable a patient’s own natural defenses – the immune system – to mobilize the body’s T cells to reach cancer cells, attack them, and induce apoptosis (programmed cell death) of just the cancer cells. If successful, this should result in medicines that are both extremely effective in fighting tumours, and also safe and well-tolerated by patients. BiTE is a unique, innovative and clinically confirmed platform. And Amgen’s skill in developing and manufacturing complex biopharmaceutical treatments will advance this technology, with the potential to benefit millions of patients around the world.

How important is the German market for Amgen in terms of R&D and sales?


Germany is vital to the future of Amgen, and we have a strong and growing presence

here. With Amgen Research in Regensburg and Amgen Research in Munich, we are the only global Amgen affiliate with both research and clinical facilities. That's a testimonial to the strength of medical science and R&D in Germany. At the moment we have approximately 100 active studies under way across Germany. In Germany we are the leading Biotech company delivering new and innovative medicines to treat serious illnesses such as cancer, osteoporosis and kidney diseases. We are proud that we have introduced three new products in the last two years for the indications skeletal-related events, metastatic colorectal carcinoma and osteoporosis.

The interview was conducted by Markus Hofelich.



With sites in Regensburg and Munich, Germany is Amgen's only global affiliate with both research and clinical facilities. Photo: © Amgen GmbH, Deutschland



M&A Activity

During the year 2012, the M&A activity in the biotech sector has been very dynamic. The peak news – in “roller coaster speech” – was published by the end of January 2012: **Amgen** announced the acquisition of **Micromet, Inc** (Munich). The transaction reached the value of \$ 1.16 billion and included *blinatumomab*, a bispecific T cell engager (BiTE) antibody in phase II clinical development for the treatment for acute lymphoblastic leukemia (ALL) and Micromet’s proprietary BiTE platform to improve the treatment in multiple tumor types. As a consequence, the former Micromet has been transformed to the largest R&D facility of Amgen outside the US: **Amgen Research (Munich) GmbH** (see page 30).

Another highlight last year was announced in June: **Janssen-Cilag GmbH** (European subsidiary of **Johnson & Johnson**) acquired **Corlmmun GmbH** (Martinsried), a Bavarian drug development company, for an undisclosed upfront payment and future clinical milestone payments in the three-digit range of US\$ million. Corlmmun’s lead compound, COR-1, had been in early clinical development for the treatment of heart failure to improve heart function by decreasing autoimmune, beta-1-receptor-simulating antibody effects – with this approach, COR-1, was one of the “lighthouse projects” in Munich’s special programme “m⁴ – personalized medicine”. Under terms of the agreement, all rights on COR-1 were transferred to Janssen-Cilag – the remaining projects are continued in the new company named **advanceCOR GmbH** (Martinsried). COR-1 will be developed and globally commercialized by Janssen-CILAG.

Nomad Bioscience GmbH (Munich), a biotechnology company, which develops agronomic traits and plant-made biomaterials (re-)acquired **Bayer’s Icon Genetics GmbH** for an undisclosed sum. The acquisition includes

all of ICON’s assets, liabilities and obligations, including personnel, patent portfolio and its GMP-certified manufacturing facility in Halle (Saale), Germany. The patent portfolio of ICON includes over 320 issued patents representing over 40 patent families, and it includes broad patent protection of the magnICON™ transient expression technology as well as a set of technologies for designer glycosylation.

Nanohale AG (Dortmund) acquired all assets from **Scil Technology GmbH** (Martinsried) and is now developing Scil’s technology platform for protein drug development, formulation and analytics under Nanohale’s newly formed subsidiary **Formycon GmbH**.

The year 2012 closed with two further M&A deals. Firstly, **MorphoSys AG** (Martinsried) sold its research and diagnostic antibody segment **AbD Serotec** to **Bio-Rad Laboratories, Inc**. The total deal volume added up to approximately € 53 million in cash. MorphoSys wanted to strengthen its rich therapeutic pipeline by divestment of the research and diagnostic business unit AbD Serotec. Secondly, two contract research organizations, **Harrison Clinical Research GmbH** (Munich) and **Synteract Inc.**, announced their merger to form a multinational CRO under the new name of **SynteractHCR**.

And sneaking up 2013, news came from the manufacturing area in spring: **Aenova Holding** acquired **Temmler Group**.

Innovation and Entrepreneur Center Würzburg



- ⊙ **renting of lab and office space**
- ⊙ **coaching of start-ups**
- ⊙ **consulting on financing**
- ⊙ **support of the management**
- ⊙ **networking / business contacts**

Milestone Payments

A huge number of Bavarian biotech companies has obtained milestone payments from their collaboration partners during the last year. By the end of April, **4SC Discovery GmbH** (Martinsried) got a milestone payment from their research collaboration with **Sanwa Kagaku Kenkyusho Co. Ltd.** (SKK) from Japan. SKK had achieved certain milestones with an optimized compound which had been identified by 4SC Discovery within of this collaboration.

One month later, **Medigene AG** (Martinsried) received a € 5 million milestone payment from **Astellas Pharma Europe Ltd** (London). This tranche was the final payment for the transfer of the rights of Eligard® from Medigene to Astellas. The total sum of all milestone payments from Astellas amounts to € 25 million. In addition in June, the company increased its financial capabilities by transferring Eligard® royalty payments to US-based investor Cowen Healthcare Royalty Partners II, L.P. in return for \$17.68 million (approx. € 14.1 million).

In March **MorphoSys AG** (Martinsried) announced the achievement of a milestone payment from **Novartis AG** (Switzerland) due to the clinical trial application (CTA/IND) and the projected clinical initiation of a phase I clinical trial. **Evotec AG** (Martinsried/Hamburg) gained a milestone payment of € 2.5 million from **Boehringer Ingelheim Pharma GmbH & Co.KG** (Ingelheim) for preclinical profiling. Since 2004, Evotec and Boehringer Ingelheim are collaborating in a multi-year discovery alliance for the joint development of new candidates in several diseases. In October 2012, **Pieris AG** (Freising) announced that they received the first milestone payment from **Daiichi Sankyo** (Japan) for the development of Anticalin candidates against two undisclosed targets selected by Daiichi Sankyo. Pieris AG is looking forward for the next milestone payment in the year 2013.

Financing

Again a roller coaster ride comes easily to mind when thinking of financing in the biotech industry. This holds true for Germany and Europe in toto in the last few years, where only a small number of privileged companies were fortunate enough to get the biggest slice from the " financing cake". And this cake – to follow this picture – was getting smaller and smaller itself. This is also true for Bavaria, where the total amount of follow on, venture capital and debt financing in the year 2012 was stable compared to last year but again reached only the minor value of € 72.8 million.

Venture capital: In the year 2012, private companies raised € 24.4 million in venture capital – an amount that even declined in comparison to 2011 and seems no longer to be substantial at any rate.

A good thing and interesting fact is, however: Financing is back for early stage projects. Three series A financing rounds have been successfully closed. This represents over 30% of all venture capital rounds in Bavarian biotech for the year 2012. Here, Bio^M AG – Bio^M's seed financing organ – participated in all three financings and could guide other public, semi-public or private investors to these innovation start-ups. For example, **Dynamic Biosensors GmbH** (Munich) was able to close a series A investment round with a consortium of venture capital investors like Extorel GmbH, Bayern Kapital GmbH, Unternehmer-


TUM Fund and Bio^M AG. The company plans to launch its technology switchSENSE System in the second half of 2013.

In addition to the high number of seed investments, some rather established companies were able to close B and C/D financing rounds. **Definiens AG** (Munich) successfully closed a financing round of € 10 million, which was realized by new investor Gilde Healthcare Partners and existing investors, including TVM, Cipio and Definiens' management. This fun-

ding is used for commercial expansion of Definiens' current business and for the development and commercialization of innovative products for clinical digital pathology imaging.

Also, **Proteros biostructures GmbH** (Martinsried) could finalize a further financing round of € 5 million to boost further expansion and growth of the company. The investors

EXTERNAL FINANCING AND DEALS



were BayBG, a key equity investor for Proteros, and two new debt financial institutions. The capital will be used for further development, with a particular focus on investment into Proteros' further downstream drug discovery capabilities.


Follow-on investments: Capital raised from publicly listed companies slightly declined by 2 % and amounted € 38.4 million for the year 2012. With the capital increase in February 2012, **Wilex AG** planned to use the gross proceeds of approximately € 9.93 million to finance its ongoing clinical studies as well as to enhance its equity position by exercising 3,201,928 new no-par value bearer shares for € 3.10. By the end of June 2012 **4SC AG** (Martinsried) announced, that a total of 8,403,510 new no-par value bearer shares with a subscription price of € 1,50 per share were placed with existing shareholders and institutional investors. The company thereby realized gross proceeds in the amount of € 12.6 million. In June, **Wilex AG** (Munich) exercised 6,460,544 new no-par value bearer share for 3,70 Euro per share. Wilex shareholder dievini Hopp Biotech holding GmbH & Co.KG (Walldorf, Germany) changed its existing loan plus interests with the value of € 7.77 million to 2,100,337 new shares. This represents 32.5 % of the total volume of the capital increase. In total, the company's equity base reached € 23.9 million.

Currently, the roller coaster of external financing is still going downhill in the biotech sector, but there is light at the end of the tunnel: Most of the companies are independent on external financing and the companies performed very well in closing attractive deals, improving revenues or receiving grants. During 2012, the total deal value was approximately € 1 billion – again, one has to add, after the € 1 billion hurdle was already reached in 2011.

Revenues

Because of the delisting of some Bavarian companies from the stock exchange - by mergers and acquisitions (like Geneart/LifeTechnologies and Micromet/Amgen) – the revenues of all Bavarian biotech-SMEs are counted in total (in contrast to previous surveys). According to the 90 % feedback from our questionnaire, **total revenues in 2012 for all biotech-SME companies can be estimated at around € 525 million. This represents an increase of about 2 % compared to 2011 revenues.**

REVENUES ALL BIOTECH SME
IN MIO. €



Summary

In the past years, the Bavarian biotechnology sector has shown its strength despite the economically unstable times and the lack of a vital Venture Capital scene in Germany. It showed stable growth rates almost every year since 2005 in terms of sales and employees. Bavaria can count on an intact technology leadership position which attracts the most famous global companies.

The roller coaster ride, which the course of innovation offers to all stakeholders, is neither always going up nor going always down – and Bavaria is still aiming high and reaching out for success!

4 Strong Partners

for Personalized Medicine

- Excellent Universities and Research Institutes
- 350 Life Science Companies
- World renowned Hospitals
- Professional Cluster Management



Company Profiles



Contact:

Prof. Dr. Gernot Längst
Dr. Thomas Schubert

Josef-Engert-Str. 13
BioPark III
D-93053 Regensburg
Phone Dr. Thomas Schubert:
+49 (0) 160 96938061
E-Mail: info@2bind.de
Internet: www.2-bind.com



Contact:

Jochen Orłowski

Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 700763-0
Fax: +49 (0) 89 700763-29
E-Mail: jochen.orlowski@4sc.com
Internet: www.4sc.com

2bind GmbH

BIOTECH DNA & PROTEIN ANALYTICS

Keywords: Antisense/Nucleotides, Drug Development, Peptide/Protein, Molecular Diagnostics, Antibiotics, Small Molecules

The 2-bind GmbH is a service provider for molecular interaction analyses based on the patented and powerful Microscale Thermophoresis technology of Nano Temper. This new technology detects changes in the hydration shell of molecules in solution and is the ideal assay for measuring biomolecule interactions and for determination of dissociation constants. Applications range from the analysis of molecular interactions to enzymatic assays.

- Advantages of Microscale Thermophoresis
- Measurement in solution without surface immobilisation
- Free choice of reaction conditions
- Small reaction volumes (3 µl) with low material requirement
- Fast measurements in a dynamic range (nM-mM)
- Interactions between very small and very large molecules can be determined

4SC AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Autoimmune Diseases, Small Molecules, Molecular Modelling, Medicinal Chemistry, Drug Development, Oncology

The Group managed by 4SC AG discovers and develops targeted small-molecule drugs for the treatment of diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical companies. At the end of 2012, 4SC Group had 90 employees. The company was founded in 1997 and has been listed on the Prime Standard of the Frankfurt Stock Exchange since 2005 (ISIN DE0005753818).

4SC Discovery GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Medicinal Chemistry, Analytical Chemistry, Small Molecules, Autoimmune Diseases, 3D-Structural Analysis, Molecular Modelling, Inflammation

4SC Discovery GmbH is a 100% subsidiary of 4SC AG that offers integrated drug discovery services, from hit finding and chemical lead optimisation through to early development candidates. The company offers customers in the pharmaceutical, biotech and chemical industries the cost and time-to-market benefits that result from a drug discovery process based on a powerful, computer aided screening and discovery platform. 4SC Discovery also applies its comprehensive pharmacological expertise to the investigation of new compounds in the areas of cancer and autoimmune disease. The company aims to engage in partnerships with pharmaceutical and biotech companies to accelerate further development and commercialisation of these research programmes.

Acino AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Pharmacology, Drug Delivery, Medicinal Chemistry

Acino has specialised in the development, registration and manufacture of generic and innovative pharmaceutical products using sophisticated formulation technologies, for which Acino also holds patents. By focusing on solid oral dosage forms with modified release as well as therapeutic systems for transdermal drug delivery such as patches and biodegradable, subcutaneous implants, Acino supplies the leading companies in the European drug markets. Acino offers the pharmaceutical industry a comprehensive range of services from product development and registration through procurement and contract manufacturing to packaging and logistics. Headquartered in Basel, the Acino Group currently employs a staff of close to 850. In 2011, it generated a total sales revenue of EUR 134,9 million. Acino Holding AG is quoted on the SIX Swiss Exchange (SIX: ACIN).

Actavis Deutschland GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

Keywords: Biosimilars, Generics

The new Actavis Inc. is a powerful combination of the highly successful and previously separate Watson Pharmaceuticals Inc. (NYSE:WPI) and privately held, Swiss-based Actavis Group. Actavis is the world's third-largest generic pharmaceutical company, with more than 750 molecules in 1,700 dosage combinations marketed globally through operations in more than 60 countries. Actavis' branded pharmaceutical business, which operates under the name Actavis Specialty Brands, develops and markets products principally in Urology and Women's Health. Actavis is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories.



Contact:
Dr. Andrea Aschenbrenner

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 700763 0
Fax: +49 (0) 89 700763 29
E-Mail: discovery@4sc.com
Internet: www.4sc-discovery.com



Contact:
Heike Pauly

Am Windfeld 35
D-83714 Miesbach
Phone: +49 (0) 8025 2867-0
Fax: +49 (0) 8025 2867-28
E-Mail: info.miesbach@acino-pharma.com
Internet: www.acino-pharma.com

Actavis Deutschland

Willy-Brandt-Allee 2
D-81829 München-Riem
Phone: +49 (0) 89 558909-0
Fax: +49 (0) 89 558909-240
E-Mail: info.de@actavis.de
Internet: www.actavis.de



Contact:
Bernhard Müllinger

Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 897969-0
Fax: +49 (0) 89 897969-22
E-Mail: info@activaero.de
Internet: www.activaero.de



Contact:
Dr. Jörg Plümpe

Von-Heyden-Str. 12
D-93105 Tegernheim
Phone: +49 (0) 9403 95449-10
Fax: +49 (0) 9403 95449-15
E-Mail: chromeonsales@activemotif.com
Internet: www.activemotif.com



Contact:
Dr. Christian Kühne

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7007649-1
Fax: +49 (0) 89 7007649-9
E-Mail: izb.business@adriacell.com
Internet: www.adriacell.com

Activaero GmbH

MEDTECH

Keywords: Inflammation, Respiratory Diseases, Infectious Diseases, Small Molecules, Peptide/Protein, Devices, Drug Delivery

Activaero is a therapeutic area specialist developing cutting-edge solutions for treatment of severe respiratory diseases, including Asthma, COPD, CF and other severe lung diseases. Activaero's clinically proven treatment approach ensures highly efficient and safe local drug deposition in the lungs to fight severe respiratory diseases with dramatically better therapy outcomes. The unique combination of effective but underutilized drugs with Activaero's inhalation technology is fuelling a pipeline of highly differentiated respiratory therapeutic solutions. Activaero has a comprehensive proprietary clinical development program under way and its treatment strategies are validated by partnerships with leading pharma and biotech companies.

Active Motif Chromeon GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Microscopy, Fine Chemicals/Reagents

Active Motif Chromeon provides innovative fluorescent reagents for Life Science research applications including several lines of fluorescent chromophores: Chromeo Dyes, RuLabels and Py-Dyes. Chromeo Dye excitation and emission properties match common excitation sources and filter sets, ideal for microscopy and plate-based assays. RuLabels are phosphorescent ruthenium probes that emit strongly polarized light with a long decay time, which enhances sensitivity and reduces background. The Py-Dyes possess unique physical and spectral properties that make conjugation simple, while greatly reducing background. As alternative to organic dyes, a set of bright and biocompatible fluorescent nanoparticles is offered. They represent excellent tools for increasing the sensitivity of your assays.

Adriacell SpA

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology

Adriacell is a biotechnology company focused on the research and development of new generation biopharmaceuticals for the diagnosis and treatment of cancer located in Trieste (Italy) and Martinsried (Germany).

advanceCOR GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Peptide/Protein, Drug Development, Inflammation

advanceCOR is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. They concentrate on innovative biological drugs in indications with unmet medical needs. One innovative drug, Revacept is currently in phase II clinical development for the treatment of stroke and acute coronary and cerebral vascular syndromes. Revacept is a lesion-specific inhibitor of atherothrombosis. Further preclinical candidates are under development, i.e. COR-2 and COR-3. COR-2 is a biological which prevents foam cell formation in atherosclerotic plaques. COR-3 is a recombinant protein which binds to atherosclerotic plaques and then bi-specifically binds to circulating progenitor cells. advanceCOR is financed by the MIG AG, KfW Bank, Bayernkapital, HTGF and Bio^M AG. The founders and management of advanceCOR bring together knowledge and reputation in research and clinical medicine together with biotech experience.

Aenova Holding GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: CMO, Manufacturing

The Aenova Group is one of the world's largest full-service suppliers to the pharmaceutical and healthcare industries. We have around 1600 employees at nine sites in Europe and the USA developing and implementing efficient solutions that cover all aspects of solid dosage forms. The Aenova Group was established in 2008 following the merger between Dragenopharm Apotheker Püschl GmbH and Swiss Caps AG. We have continued to grow and since then have become one of the most competitive and efficient companies in the industry employing 1600 people at nine sites in Europe and the USA. Aenova's headquarters is in Pähl on the southern outskirts of Munich. All our production facilities comply with the relevant international standards. We have GMP and FDA certification for soft capsules, tablets and packaging solutions and this guarantees high levels of product quality. Our extensive expertise and comprehensive range of services allow us to generate significant added value for our customers. A glance at our annual production output will explain our leading market position. Annual capacity for different dosage forms: 20 billion soft gelatin capsules, 14 billion tablets, 1 billion VegaGels[®], 600 million hard capsules, 400 million effervescent tablets, Annual capacity for packaging: 600 million blisters, 200 million folding boxes, 20 million bottles and 1 million sachets. In 2013 Aenova acquired Temmler Group.



Contact:
Prof. Dr. Götz Münch
Prof. Dr. Martin Ungerer

Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 8565 2010
Fax: +49 (0) 8565 2020
E-Mail: info@advancecor.com
Internet: www.advancecor.com

Aenova Holding

Contact:
Karl-Heinrich Hoppmann

Gut Kerschlach 1
D-82396 Pähl
Phone: +49 (0) 8808 9243-111
Fax: +49 (0) 8808 9243-100
E-Mail: info@aenova.de
Internet: www.aenova.de



Contact:
Marion Kersting

Fraunhoferstr. 13 / 4.OG
D-82152 Martinsried
Phone: +49 (0) 89 4161 4865
Fax: +49 (0) 89 4161 4867
E-Mail: info@affectis.com
Internet: www.affectis.com



Contact:
Dr. Monika Leder

Larezhhausen 2
D-86567 Hilgertshausen
Phone: +49 (0) 8250 9279040
Fax: +49 (0) 8250 9279049
E-Mail: labor@agrobiogen.de
Internet: www.agrobiogen.de

Agrolytix

Contact:
Dr. Stefan Schwab

Cauerstr. 4
D-91058 Erlangen
Phone: +49 (0) 9131 8529452
Fax: +49 (0) 9131 8529449
E-Mail: info@agrolytix.com
Internet: www.agrolytix.com

Affectis Pharmaceuticals AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [CNS](#), [Drug Development](#), [Inflammation](#), [Small Molecules](#)

Affectis is a pharmaceutical company focusing on novel drugs for the treatment of neuroinflammatory diseases. The company is developing AFC-5128, a potent orally active brain-penetrant P2X7 antagonist which shows strong analgesic effects animal models of neuropathic pain and significantly reduces clinical scores and frequency of relapse in models of multiple sclerosis. The company is also developing AFC-5278 for osteoporosis. Affectis' programs thus carry the promise of bringing to market new classes of drugs that address and satisfy unmet medical needs.

Agrobiogen GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: [Agrobiotechnology](#), [Transgenic Animals](#), [Gene Transfer](#), [Genomics](#), [Xenotransplantation](#), [Automation](#)

Agrobiogen focuses on and is experienced in the application of molecular-genetic techniques in livestock animals (especially molecular-genetic diagnostics and gene transfer). Many transgenic rabbit lines and several cattle clones have been established. As a service for other biotech companies transgenic farm animals are generated using conventional microinjection procedures and nucleus transfer. Detection of pathogens like BVDV, as well as parentage control of animals, SNP genotyping and analysis of DNA markers are offered as a service for breeders, veterinarians and companies. Agrobiogen has developed a simple labour-saving system for collection of tissue samples and extraction of DNA from millions of animals for high-throughput analysis.

Agrolytix GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: [Agrobiotechnology](#)

Agrolytix is specialized in microcapsulation of biological active substances like plant-virus derivatives. Further information about the application of our technology can be obtained at our website.

Alcon Pharma GmbH Division Vision Care

PHARMA & CHEMICAL INDUSTRY

Keywords: Ophthalmology, Surgical, Vision Care

Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide to see better. The three Alcon businesses - Surgical, Pharmaceutical and Vision Care – offer the widest spectrum of eye care products in the world. Alcon is the second largest division of the Novartis Group with pro-forma sales of USD 10.2 billion in 2012.

Headquartered in Fort Worth, Texas, U.S.A., Alcon has 24,000 employees worldwide, operations in 75 countries and products available in 180 markets.



Contact:
Jan-Thore Foehrenbach

Bauhofstr. 16
D-63762 Großostheim
Phone: +49 (0) 6026 941 0
E-Mail: info@cibavision.de
Internet: www.alcon-pharma.de

ALGORA Gesellschaft für Medizinstatistik und Vertriebssysteme mbH

CRO

Keywords: Infectious Diseases, Oncology

Algora is a niche CRO successfully operating on clinical trials in Germany. Services include phase II-IV trials as well as large observational studies and range from protocol development to final study reports. Algora manages complete study projects or delivers individual services, such as clinical monitoring, data management or statistical analysis. Experienced in oncology since the first days of the company in 1989, Algora always had a focus on innovative therapies, leading to close relationships to university hospitals and medical societies. Since 1995 another focus developed in large pediatric studies. Customers are pharmaceutical and medical device companies, independent research groups, and other CROs.



Contact:
Dr. Karl Fehnle

Münchner Str. 11
D-85540 Haar
Phone: +49 (0) 89 613727-0
Fax: +49 (0) 89 613727-20
E-Mail: cro@algora.de
Internet: www.algora.de

AMGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Research, Nephrology, Bone/Joint Diseases, Oncology

Amgen GmbH is an affiliate of Amgen Inc. (Applied Molecular Genetics). The US based company discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, osteoporosis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.



Contact:
Fulvia Kipper

Hanauerstr. 1
D-80992 München
Phone: +49 (0) 89 149096-1601
Fax: +49 (0) 89 149096-2601
E-Mail: fulvia.kipper@amgen.com
Internet: www.amgen.de



Research GmbH

Contact:
Susanne Sporer

Staffelseestr. 2
D-81477 München
Phone: +49 (0) 89 895277-0
Fax: +49 (0) 89 895277-205
E-Mail: susanne.sporer@amgen.com
Internet: www.amgen.de



Research GmbH

Contact:
Mirko Stemmler

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 465-20000
Fax: +49 (0) 941 465-20100
E-Mail: Mirko.Stemmler@amgen.com
Internet: www.amgen.de



Contact:
Dr. Lars Wassill

Werkstr. 2
D-83555 Gars-Bahnhof
Phone: +49 (0) 8073 91693-0
Fax: +49 (0) 8073 91693-33
E-Mail: info@amplexdiagnostics.de
Internet: www.hyplex.info

AMGEN Research (Munich) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy, Drug Development, Antibody, Oncology

Amgen Research (Munich) GmbH, former Micromet, puts novel concepts in immunotherapy to work. Using proprietary technologies, the company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. It has established a powerful drug development platform: BiTE™ („Bispecific T cell engagers“), a unique drug format that leverages the outstanding cytotoxic potential of T cells to precisely eliminate pathogenic cells. Amgen Research (Munich) is an affiliate of Amgen Inc. (Applied Molecular Genetics Inc.). The US based company discovers, develops, manufactures and delivers innovative human therapeutics.

AMGEN Research GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Oncology, Neurology, Inflammation, Hematology, Small Molecules, Drug Development

AMGEN Research GmbH was founded in Regensburg in 2000. Basic research is conducted with the aim of identifying new pharmaceutical lead structures for the development of innovative drugs. Low molecular weight compounds are identified by high throughput screening (HTS) procedures. Over 10 million compounds are analyzed every year. AMGEN Research GmbH is an affiliate of Amgen Inc. (Applied Molecular Genetics). The US based company discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.

AmplexDiagnostics GmbH Gesellschaft für molekularbiologische Diagnostik

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Infectious Diseases, PCR, Clinical Diagnostics

AmplexDiagnostics GmbH is a privately held company for the development, production and distribution of In Vitro Diagnostics. Our aim is the improvement of the potential of the PCR-technology by implementing the main advantages of this technology into the diagnosis of bacterial infections. Founded in 2002 - Amplex developed its first product (hyplex® StaphyloResist) and entered the market already in 2003. Additional systems for the direct detection of multidrug-resistant bacteria (like VRE, ESBL, KPC and NDM-1) are completing our portfolio of PCR-screening tests for nosocomial infections causing „bugs“. Beside this we offer several PCR-based screening tests for sexual transmitted diseases, EHEC or TBC. For further information please visit our webpage www.hyplex.de or contact us.

AMS Advanced Medical Services

CRO

Keywords: Medical Writing, Pharmacology

AMS Advanced Medical Services GmbH is a privately owned independent European mid-size CRO founded in 1997 in Mannheim by 6 partners, 4 of whom are medical doctors. AMS has also offices in London, Vienna and Munich. AMS has an overall staff of 350 people, approx. half of them are in clinical research, the other half in Marketing and Sales services. AMS invented the 1. Internet-Pharmaschool (1.IPS) with trainers and techniques offering tailor-made training concepts for staff in both clinical research and sales. AMS is a full service CRO with significant experience in multiple therapeutic areas and strong medical expertise covering Phase I to Phase IV, non-interventional programs, pharmaco-epidemiology and -economics. Our staff includes 60 CRAs and more than 50 people in DM and Stats.

AMSilk GmbH

BIOTECH INDUSTRIAL APPLICATIONS

Keywords: New Materials, Fine Chemicals/Reagents, Tissue Engineering/Cell Culture, Drug Delivery

The AMSilk®-Technology enables the production of tailor-made materials which are unrivaled by most common synthetic materials. AMSilk addresses many applications and industry sectors with new materials enabling new products with previously unachievable features. AMSilk has developed a unique process to produce biopolymers like spider silk at an industrial scale. These materials form the basis for coatings, films, non-wovens and monofilament fibers. The resulting products are being developed include medical, pharmaceutical and industrial applications. The name AMSilk and the AMSilk Logo are registered trademarks of AMSilk GmbH, Munich.

AmVac Research GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Vaccines, Gene Transfer, Drug Development

AmVac Research is a biotech company developing highly innovative and multifunctional vaccines. The company is using a novel viral vector technology that combines excellent immunogenicity of live viral vaccines with the high safety profile of inactivated vaccines. This technology serves as a platform for the development of several tailor-made vaccines. One main focus of the company is the development of vaccines against respiratory tract diseases caused by viral agents such as RSV or hPIV3 against which no effective therapeutic or preventive means exist. Related to vaccination, AmVac is developing adjuvant candidates which show superior mucosal efficacy.



Contact:
Frederique Soulie-Redondo

Werner-Eckert-Str. 10
D-81829 München
Phone: +49 (0) 89 2000074-11
Fax: +49 (0) 89 2000074-40
E-Mail: gerlinde.jaenel@ams-europe.com
Internet: www.ams-europe.com



Contact:
Dr. Lin Römer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 38156-4430
Fax: +49 (0) 89 38156-3859
E-Mail: info@amsilk.com
Internet: www.amsilk.com



Contact:
Dr. Marian Wiegand

Lochhamer Str. 29 a
D-82152 Martinsried
Phone: +49 (0) 89 63854363
Fax: +49 (0) 89 99753425
E-Mail: info@amvac-research.de
Internet: www.amvac.eu

amYmed

Contact:
Prof. Dr. med. Reinhold P. Linke

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 52012638
Fax: +49 (0) 89 52389013
E-Mail: linke@amymed.de
Internet: www.amymed.de



Contact:
Dr. Andrea Kottke

BioPark I
Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 92013-0
Fax: +49 (0) 941 92013-29
E-Mail: info@antisense-pharma.com
Internet: www.antisense-pharma.com



Contact:
Dr. med. Christine Günther

Max-Lebsche-Platz 30
D-81377 München
Phone: +49 (0) 89 7009608-0
Fax: +49 (0) 89 7009608-79
E-Mail: c.guenther@apceth.com
Internet: www.apceth.com

amYmed GmbH Referenzzentrum für Amyloidkrankheiten

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Antibody Production Service, Devices, Antibody

We provide high precision immunohistochemical classification of the diverse amyloid diseases with respect to specific and causal treatment as a service for patients and physicians. We are in the process of extending this service by producing and offering test kits in order to enable clinics and institutes of pathology to perform this classification by themselves.

Antisense Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Antisense/Nucleotides, RNAi & Antisense, Drug Development

Antisense Pharma is a biopharmaceutical company based in Regensburg, Germany. The company develops innovative therapies targeting the TGF-beta pathway based on the antisense technology to treat tumor diseases with high unmet medical need. The lead compound trabedersen, an antisense oligonucleotide, has been granted orphan designation for three tumor indications. Trabedersen has been found to be safe with encouraging clinical activity in patients suffering from high grade glioma, pancreatic cancer, or malignant melanoma. Antisense Pharma intends to further validate this promising drug candidate in selected indications. In addition, the company is expanding its pipeline through the development of "next generation" oligonucleotides by identifying novel proprietary compounds to target cancer.

apceth GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Cardiovascular Diseases, Gene Therapy, Cell Therapy, Gene Transfer

apceth is a biopharmaceutical company focused on the development and clinical application of pioneering cell and gene therapies for the treatment of malignant and non-malignant diseases. apceth combines the principles of (stem) cell biology with ground-breaking technologies and the highest standards for GMP manufacturing and quality control according to national and international regulations. These standards are applied in equal measure to apceth's own as well as contract GMP-manufacturing of cell-based products. The company's state-of-the-art GMP/BSL2 facilities comprise 600 m² of cleanroom area (ISO8, ISO7, ISO5), quality control and R&D units, and possess manufacturing license for somatic cell therapeutics (AMG §13, §20b). apceth's first clinical trial phase I/II is in progress.

APEX GmbH

CRO

Keywords: Pharmacology, Drug Development, Pharmacokinetics, Diabetics, Hepatology, Nephrology

- Our Concept... APEX is a highly efficient combination of investigator and CRO. Our aim is to provide our clients with a service which combines the access to patients of an investigator with the expertise to perform a complex, high quality research project of a CRO. We combine high level phase 1 data quality with the typical phase 2/3 study population.
- Our Service... Is the clinical performance of pharmacokinetic and proof-of-concept / PKPD studies.
- Our Study Population...are patients with impaired renal or hepatic function and patients with other chronic stable diseases (diabetes, hypertension, asthma etc.). Since the patients come into our clinic, rather than us having to go to them via their GP's, the data we generate are more complete and accurate, fewer patients are required and the project can be completed faster.
- Our Clients... are international pharmaceutical companies from medium sized to members of the world's top ten.

AptaIT GmbH

BIOTECH BIOINFORMATICS

Keywords: Bioinformatics, NGS, Phage Display, SELEX, T-cell/B-cell receptor analysis, Software

AptaIT is a bioinformatics company providing advanced software solutions to sequence driven biomedical research. AptaIT's core area is the identification of frequent patterns in giant nucleic acid data sets derived from Next Generation Sequencing (NGS). The NGS technology currently transforms drug discovery. AptaIT is anticipating this development and provides respective solutions. AptaIT's complementary team of experts in life science and bioinformatics ensure effective support to implement the software tool COMPAS into versatile drug discovery procedures.

ARTHROGEN GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Regenerative medicine

Arthrogen is a young biotechnology company specializing in the development of effective methods and technologies for the treatment of degenerative and inflammatory diseases. The products and methods of Arthrogen are based on stimulating the body's own proteins, growth factors and cytokines such that the body can repair injured or damaged tissue by itself. These technologies are protected by worldwide patents.




Contact:
Dr. med. Gertraud Haug-Pihale

Landsberger Str. 476
D-81241 München
Phone: +49 (0) 89 896016-0
Fax: +49 (0) 89 896016-33
E-Mail: apexkpd@aol.com
Internet: www.apex-research.com



Contact:
Dr. Raymund Buhmann

Goethestr. 52
D-80336 München
Phone: +49 (0) 89 59918 123
Fax: +49 (0) 89 59918 125
E-Mail: info@aptait.de
Internet: www.aptait.de



Contact:
Prof. Dr. Ulrich Schneider

Wiesseerstr. 103
D-83707 Ringsee
Phone: +49 (0) 8022 187978
Fax: +49 (0) 8022 187978
E-Mail: info@arthrogen.de
Internet: www.arthrogen.de



Assign Group

>> Integrity in all that we do <<

Contact:

Dr. Marc Buggelshein

Fraunhoferstr. 22

D-82152 Martinsried

Phone: +49 (0) 89 741206-80

Fax: +49 (0) 89 741206-88

E-Mail:

claudia.pfannschmidt@assigngroup.com

Internet: www.assigngroup.com

Assign International GmbH

CRO

Keywords: Toxicology, Pharmacology, Medical Writing, Logistics

The Assign Group, an international expert in pharmaceutical development offering full service globally to Biotechnology, Pharmaceutical and Medical Device Companies. We support pharmaceutical development from preclinical to clinical phase I to IV. Our broad expertise covers the entire development process, reduces the clients development time at affordable budget and supports the projects to become a success. We are right there where you need us.

Astellas Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Inflammation, Infectious Diseases, Immune Therapy, Autoimmune Diseases, Allergy, Antibiotics, Oncology, Pain, Drug Development

Astellas Pharma Inc. was formed in April 2005 from a merger with Yamanouchi and Fujisawa. Astellas Pharma ist Japan's second largest pharmaceutical company and is headquartered in Tokio. It has operations in Europe, Asia, North and South America, South Africa and Japan. Astellas is focused on the following key therapeutic areas: Transplantation, urology, dermatology, anti-infectives, pain and oncology. Astellas employs approx. 3,300 people in Europe across Sales & Marketing, Research & Development and Manufacturing. Astellas has 21 Sales & Marketing affiliates, 3 manufacturing plants and 1 R&D site in Europe. Astellas Europe is headquartered just outside London in Chertsey. The German headquarters are based in Munich. Located here are Sales, Marketing and Medical. The product portfolio includes therapies in transplantation, urology, oncology, dermatology, asthma/COPD, cardiology, infectious diseases, gastroenterology and pain. Astellas Pharma GmbH employs approx. 380 people including 230 sales representatives.

Aurigon Life Science GmbH

CRO & NONCLINICAL SERVICES

Keywords: Analytics, Drug Development, Pharmacology, Toxicology

Aurigon is an independent contract research organization supporting the development of innovative therapies, medical devices, foods and chemicals. With more than 10 years of experience and dedicated expertise in all aspects of pharmacology, safety and efficacy testing, we offer the full range of preclinical services from early study design through to expert reports, in line with international regulatory standards. Over the years, we have helped companies of all sizes from around the world to move their projects forward. Our reputation is based on the extensive knowledge of our interdisciplinary teams in Munich and Budapest, their open communication culture and the excellent quality of results they deliver in every project.



Contact:

Dr. Martin Marhoefer

Georg-Brauchle-Ring 64-66

D-80992 München

Phone: +49 (0) 89 4544-1440

Fax: +49 (0) 89 4544-5440

E-Mail: info@de.astellas.com

Internet: www.astellas.de



Contact:

Dr. Gundel Hager

Bahnhofstr. 9-15

D-82327 Tutzing

Phone: +49 (0) 8158 2597-30

Fax: +49 (0) 8158 2597-31

E-Mail: info@aurigon.de

Internet: www.aurigon.de

AVIRU GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infection

AVIRU stands for anti virulence and is a biotechnology start-up that is funded as an GO-Bio and EXIST transfer of technology project by the German Federal Ministry of Education and Research and the German Federal Ministry of Economics and Technology in compliance with a resolution of the German Parliament. AVIRU aims to develop the proof-of-concept for an innovative anti-infective drug for the treatment of infections by multi-drug resistant bacterial pathogens.

Axolabs GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: RNAi & Antisense, Antisense/Nucleotides, Aptamer Technology, Pharmacokinetics, Pharmacology

Axolabs is a preclinical research organization for oligonucleotide therapeutics. Based on the foundations of the former Roche Center of Excellence for RNA Therapeutics, we leverage our world-leading know-how and 12+ years of experience to provide high-end preclinical solutions and consultancy tailored to your specific needs.

- Oligonucleotide Manufacturing: High-throughput up to large scale, sequence/structure optimization, drug substance production for GLP-Tox, process development, regulatory documentation;
- Analytics and Bioanalytics: HPLC, UPLC, MS, CAD, CE, DSC, thermophoresis etc., pharmacokinetics and biodistribution, ADME and DMPK;
- Pharmacology: Lead identification and optimization, in vivo efficacy and early safety, delivery.ii

baseclick GmbH

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Nanobiotechnology, Chip/Array Technology, New Materials, Fine Chemicals/Reagents, Clinical Diagnostics

baseclick GmbH is a young and dynamic company funded and founded by BASF Venture Capital GmbH. The baseclick IP was generated at the University of Munich in the group of Prof. Thomas Carell. Core technology of our company is the modification of nucleic acids via click chemistry. baseclick holds the IP for the technology and offers this for licensing, purchasing of our products, and cooperation for the further development. We provide innovative products to improve and enhance your research in the fields of: Oligonucleotide-, DNA- and RNA-labeling, PCR assays, cell proliferation assays, FISH probes and many more.

AVIRU

Contact:
Dr. Oliver Baron

Hildegardstr. 11
D-80539 München
Internet: www.aviru.de



Contact:
Dr. Roland Kreuzer

Fritz-Hornschuch-Str. 9
D-95326 Kulmbach
Phone: +49 (0) 9221 827620
Fax: +49 (0) 9221 8276299
E-Mail: info@axolabs.com
Internet: www.axolabs.com



Contact:
Dr. Thomas Frischmuth

Bahnhofstr. 9-15
D-82327 Tutzing
Phone: +49 (0) 8158 903867
Fax: +49 (0) 8158 903894
E-Mail: info@baseclick.eu
Internet: www.baseclick.eu



BAVARIAN NORDIC

Contact:
Derek Beggs

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 8565 0030
Fax: +49 (0) 89 8565 1333
E-Mail: derek.beggs@bavarian-nordic.com
Internet: www.bavarian-nordic.com

Baxter

Contact:
Lutz Knabe

Edisonstr. 4
D-85716 Unterschleißheim
Phone: +49 (0) 89 31701-0
Fax: +49 (0) 89 31701-277
E-Mail: info_de@baxter.com
Internet: www.baxter.de



Contact:
Dr. Gerhard Gunzer

Sauerbruchstr. 50
D-81377 München
Phone: +49 (0) 89 579589-0
Fax: +49 (0) 89 579589-3503
E-Mail: info@beckman.com
Internet: www.beckmangenomics.com

Bavarian Nordic GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Vaccines, Drug Development

Bavarian Nordic (BN) is a leading international biopharmaceutical company developing innovative vaccines to prevent and treat infectious diseases. The company is capable to meet the growing demand for safe 3rd generation smallpox vaccines due to its proprietary vaccine technology MVA-BN®. BN was founded in 1994 and is headquartered in Kvistgaard, Denmark with subsidiary operations in Martinsried and Berlin, Germany. BN recently founded in the US an operating company, BN ImmunoTherapeutics Inc., for research and development of cancer vaccines. The company employs about 180 people and is listed on the Copenhagen Stock Exchange. More than 450 healthy and immune compromised subjects so far vaccinated with MVA-BN®, suggest an excellent safety and efficacy profile of the vector.

Baxter Deutschland GmbH

PHARMA & MEDICAL DEVICES

Keywords: Nephrology, Autoimmune Diseases, Oncology, Pain, Immune Therapy, Vaccines, Tissue Engineering/Cell Culture

Baxter International Inc. (NYSE: BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Beckman Coulter Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology, Automation, PCR

Beckman Coulter develops, manufacturers and markets products that simplify, automate and innovate complex biomedical testing. Our diagnostic systems are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Scientists use our life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs. Hospital laboratories are our core clinical diagnostic customers. Our life science customers include pharmaceutical and biotechnology companies, universities, medical schools and research institutions. Beckman Coulter has an installed base of more than 200,000 clinical and research systems operating in laboratories around the world. Beckman Coulter has a leading position in Laboratory Automation. Research & Development as well as Production of our stand alone automation systems, the AutoMate 2500 Family (formerly known as OLA 2500), are located in Munich, Germany.

bene-Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, contract manufacturing

People have been relying on our top quality pharmaceuticals for over 50 years. Our painkiller ben-u-ron has accompanied many of them through their lives, from early childhood to advanced age. And then as now, as a quality goods manufacturer the pharmaceutical drugs we offer are exclusively produced by us in Germany. As a medium-sized business it makes us particularly proud that our research and development efforts have produced a stream of new and innovative drugs which we distribute successfully not only in Germany but also in over 35 other countries.

Bernina Plus GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Liposomes, Nanobiotechnology

Bernina develops smart oral drug delivery systems for therapeutic peptides. The proprietary technology is based on artificial envelopes created by lipids. In addition, these nano-particulate natural and synthetic lipids are used in coating and drug elution processes.

betapharm Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Generics

Betapharm was founded in 1993 in Augsburg. betapharm delivers generic drugs and is one of the leading generic companies in Germany. In 2006 the company was bought by globally active Dr. Reddy's Laboratories, Hyderabad, India.



Contact:
Dr. Helmut Benend

Herterichstr. 1-3
D-81479 München
Phone: + 49 (0) 89 74987-0
Fax: + 49 (0) 89 74987-200
E-Mail: contact@bene-gmbh.de
Internet: www.bene-arzneimittel.de



Bernina Plus

Contact:
Dr. Felix Gropp

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 52388-740
Fax: +49 (0) 89 52388-333
E-Mail: gropp@berninaplus.de
Internet: www.berninaplus.de

beta pharm

Contact:
Michael Ewers

Kobelweg 95
D-86153 Augsburg
Phone: +49 (0) 821 74 88 1-0
Fax: +49 (0) 821 74 88 1-420
E-Mail: info@betapharm.de
Internet: www.betapharm.de



Contact:

Dr. Kai Lamottke

Richard-Riemerschmid-Allee 27

D-81241 München

Phone: +49 (0) 89 82072564

Fax: +49 (0) 89 529178

E-Mail: lamottke@bicoll-group.com

Internet: www.bicoll-group.com

Bicoll GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Nutraceuticals, Small Molecules, Natural Compounds, Infectious Diseases, Oncology, Medicinal Chemistry, Drug Discovery

Bicoll is a biopharmaceutical company, offering pre-clinical support in the area of Drug Discovery from Natural Products and Medicinal Chemistry. To speed up drug discovery processes, Bicoll offers its drug like compound library BILOBAC N, consisting of already fractionated plant extracts, to global clients in drug discovery and related innovative fields. BILOBAC N provides enhanced probability of biological activity and reduced complexity of fine fractions, thus it's ready to use in client's screening systems. With innovative strategies and a proprietary technology platform, Bicoll is able to rapidly select only the best leads with superior drug-like profiles for further development. Subsequent medicinal chemistry and custom synthesis complete Bicoll's seamless substantial services.

Biogen Idec GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Biogen Idec, Inc., winner of the 1998 U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company's revenues are generated from U.S. and European sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen Idec's research and development activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases and in developmental biology and gene therapy.



Contact:

Carl-Zeiss-Ring 6

D-85737 Ismaning

Phone: +49 (0) 89 99617 0

Fax: +49 (0) 89 99617 199

E-Mail: lydia.krybus@biogenidec.com

Internet: www.biogenidec.com

BIOBANK der Blutspender Blutspendedienst des BRK

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Autoimmune Diseases, Cardiovascular Diseases, Diabetics, Metabolic Diseases, Oncology

With its »Blood Donor BIOBANK«, the Bavarian Red Cross Blood Donor Service offers a unique resource for biomarker research: the world's first blood donor based biobank. A large pool of more than 400,000 active blood donors enables the identification of several thousands of diseased BIOBANK participants per year. Their serial, pre-diagnostic blood samples are a unique resource for investigating markers associated with the onset and progression of diseases. With a collection of more than 4 Mio plasma samples processed and stored using highly standardized, qualified processes (ISO9001:2008 certification) the »Blood Donor BIOBANK« is one of the largest biobank projects worldwide.

Biogents AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Biogents develops, produces & sells innovative trapping systems against mosquitoes & flies, especially against dangerous vectors such as aedes aegypti, aedes albopictus & sand flies. These systems are already being used by leading health organisations (e.g. CDC, USA), several armed forces (e.g. "Bundeswehr", Germany), other governmental bodies & public entities (incl. quarantine departments, research institutes & universities). Several consumer versions are marketed since 2009. The technology is protected by two granted patents and was awarded in 2007 by the world bank with money from the Bill & Melinda Gates Foundation. Biogents also offers a fee-for-service business for insect repellents and attractants. The company was started in 2003 as a Spin-off from the University of Regensburg.



BIOBANK
DER BLUTSPENDER

Contact:
Dr. Silke Martin

Herzog-Heinrich-Str. 2
D-80336 München
Phone: +49 (0) 89 5399-4500
Fax: +49 (0) 89 5399-4505
E-Mail: biobank@blutspendedienst.com
Internet: www.biobank.de



Contact:
Dr. Andreas Rose

Bruderwöhrdstr. 15 b
D-93053 Regensburg
Phone: +49 (0) 941 604889-857
Fax: +49 (0) 941 604889-856
E-Mail: biogents@biogents.com
Internet: www.bg-sentinel.com



Contact:
Dr. Shannon Frances

Robert-Koch-Str. 2
D-82152 Planegg
Phone: +49 (0) 89 895574-0
Fax: +49 (0) 89 895574-825
E-Mail: info@biomax.com
Internet: www.biomax.com



Contact:
Claudia Caspers

Bruckmannring 32
D-85764 Oberschleißheim
Phone: +49 (0) 89 3157000
Fax: +49 (0) 89 3153242
E-Mail: info@biomed.de
Internet: www.biomed.de

Biomer

Contact:
Dr. Urs J. Hänggi

Forst-Kasten-Str. 15
D-82152 Krailling
Phone: +49 (0) 89 12765-136
Fax: +49 (0) 89 12765-137
E-Mail: mail@Biomer.de
Internet: www.biomer.de

Biomax Informatics AG

BIOTECH BIOINFORMATICS

Keywords: Proteomics, Genomics

Biomax provides computational solutions for better decision making and knowledge management in the life science industry. We offer an innovative and powerful solution to accelerate knowledge-driven research processes. We support our customers with a platform that combines software products with knowledge resources, including oncology, nutrigenomics, plant research and functional genomics. Our flexible and comprehensive solutions provide access to relevant knowledge at the right time & in the right context. We help customers generate value from proprietary and public resources by extracting the knowledge indispensable for efficient data exploration and interpretation. We focus on integrating information to enable a knowledge-based approach to develop innovative life-science products.

Biomed Labordiagnostik GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Analytical Chemistry, ELISA/EIA, PCR, Clinical Diagnostics

Our core competence is the manufacture and distribution of CE marked products for clinical chemistry and quality control according to IVD Guidelines. Our area of activities covers also Infectious Disease Diagnostics. We are currently extending our focus to the Molecular Diagnostics field, for which we aim to develop and to market new products leveraging on our years of experience at home and abroad. Our success is tied to a continuous increase of know-how, an extensive expertise in the healthcare marketplace and specialized system solutions in the field of Laboratory Diagnostics. We work tightly with our customers ascertaining their requirements in relation to new and existing products and create solutions optimized to their needs.

Biomer – biodegradable polymers

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Disposals, biopolymers

Biomer develops and produces raw materials such as PHB (polyhydroxybutyrate) which can be processed and used in the same way as classic thermoplasts, but are fully biodegradable. Articles made of Biomer formulations can be disposed of by composting. Being made from renewable feed stocks they do not add to the carbon dioxide concentration of the atmosphere even when they are burned. The core competence covers the production of biopolymers in microorganisms and formulation of the extracted polymers into resins for use by plastics processors.

Biometric GmbH

BIOTECH ANALYTICS & DIAGNOSTICS

Biometric GmbH is a laboratory for microbiological and chemical analysis – dealing with the analysis of water, hygienic control and providing microbiological analyses of pharmaceutical products, medical devices, cosmetics and food.

BIONORICA SE

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Analytical Chemistry, Oncology, Respiratory Diseases, Pain, Neurology

Bionorica SE is one of the leading companies in the area of phytopharmaceuticals worldwide. The product range focuses mainly on diseases of the respiratory tract, urinary tract, gynaecological disorders and on medications for the treatment of pain. As an essential Bionorica follows the principle of phytoneering as gold standard in modern phytotherapy. Phytoneering combines the huge potential of natural active substances (phytos) with the knowledge and methodology of modern pharmaceutical research (engineering) in order to develop efficant and safe preparations. The expressed goal is to discover new active substances in order to develop effective drugs with minimized side effects. Bionorica has established an impressive network of scientists working in about 490 renowned universities, institutions and organisations worldwide.

Biontix Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Fine Chemicals/Reagents, Gene Transfer, Liposomes, RNAi & Antisense, Gene Therapy, Nanobiotechnology, Microscopy

Biontix is a genetic engineering company offering comprehensive range of products in field of transfection technology. Our new development METAFECTENE EASY is a GLOBAL INNOVATION in this product sector eliminating need for time-consuming optimization, while METAFECTENE SI is a reagent designed for efficient siRNA transfection. A major alternative is the direct transport of proteins into cells; a purpose for which the new reagents in the PROTEOfectene series were specifically developed. Our groundbreaking new Microfection product series enables the outstanding optical properties of μ -Slides in live-cell imaging to enhance the versatility and efficiency of nucleic acid and protein transfection applications. The product portfolio is completed by mycoplasma detection and removal kits.



Contact:
Sabine Zirngibl-Brandl

Im Gewerbepark B49
D-93059 Regensburg
Phone: +49 (0) 941 454 41
Fax: +49 (0) 941 461 68 31
E-Mail: biometric@t-online.de
Internet: www.biometric-gmbh.de



Contact:
Thomas Jaik

Kerschensteinerstr. 11–15
D-92318 Neumarkt
Phone: +49 (0) 9181 231 90
Fax: +49 (0) 9181 231 265
E-Mail: info@bionorica.de
Internet: www.bionorica.de



Contact:
Dr. Stephan König

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 324799-50
Fax: +49 (0) 89 324799-52
E-Mail: contact@biontix.com
Internet: www.biontix.com



Contact:
Martina Fuss

Heidemannstr. 164
D-80939 München
Phone: +49 (0) 89 31884-120
Fax: +49 (0) 89 31884-123
E-Mail: martina_fuss@bio-rad.com
Internet: www.bio-rad.com



Contact:
Dr. Günter Bertholdt

Eichenstr. 15
D-82061 Neuried
Phone: +49 (0) 89 7494771 0
Fax: +49 (0) 89 7494771 19
E-Mail: mail@bioregeneration.com
Internet: www.bioregeneration.eu



Contact:
Josef Scheiber

Garmischer Str. 4/V
D-80339 München
Phone: +49 (0) 89 1896582-80
Fax: +49 (0) 89 1896582-99
E-Mail: josef.scheiber@biovariance.com
Internet: www.biovariance.com

Bio-Rad Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Chip/Array Technology](#), [PCR](#), [Peptide/Protein](#), [Proteomics](#), [Genomics](#), [Gene Transfer](#), [Clinical Diagnostics](#)

Bio-Rad Laboratories continues to play a leading role in the advancement of scientific discovery by offering a broad range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 7,000 employees and serves more than 100,000 research and industry customers worldwide through the company's global network of operations. Throughout its existence, Bio-Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, medical diagnostics, and more.

bioregeneration GmbH

BIOTECH

Keywords: [Devices](#), [Cell Therapy](#), [Nanobiotechnology](#), [New Materials](#), [Tissue Engineering/Cell Culture](#)

bioregeneration GmbH works in the field of tissue engineering using a proprietary technology. The technology comprises of the newly developed bio-material "Xellulin", which can be individually shaped and causes no graft-reaction in the human body.

BioVariance GmbH

BIOTECH BIOINFORMATICS

Keywords: [Personalized Medicine](#), [Informatics](#), [Data Management](#), [Biomarker Discovery & Development](#), [Toxicology](#), [Pharmacogenomics](#), [NGS](#)

BioVariance – the data source for therapeutics knowledge. Our offering touches on the knowledge that thousands of scientists and doctors have gathered over many years. We prepare this knowledge and offer it in an easily accessible and useful form. Initially our focus is on applications for pharmaceutical research, which we support with our services. Herewith we are specialists for the area where new molecules meet human biology. In the context of genetic and drug data we generate testable hypotheses to advance your project. Besides this we are currently working on a software product that makes this knowledge accessible for the healthcare system so that with drug treatments all options can be considered equally, because every patient is unique – and so is his therapy.

BIOZOL Diagnostica Vertrieb GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody, Peptide/Protein, ELISA/EIA, Proteomics, Small Molecules, Clinical Diagnostics

BIOZOL Diagnostica Vertrieb GmbH markets and distributes products for immunology, cell biology, molecular biology, biochemistry and human and veterinary diagnostics, such as antibodies, recombinant proteins, ELISA/EIA, detection kits, biochemicals and further reagents for cell culture, flow cytometry, immunohistology and cytogenetics. The company represents almost 50 different worldwide known suppliers in Germany. Biozol offers additionally different types of services such as free product search.

Bristol-Myers Squibb GmbH & Co. KGaA

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Cardiovascular, Metabolics, Immunoscience and Virology

Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of people in their fight against diseases such as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, rheumatoid arthritis and after kidney transplant.

BSL BIOSERVICE Scientific Laboratories GmbH

CRO

Keywords: Laboratory, Drug Development, Pharmacokinetics, Toxicology, Pharmacology

Since 1984, BSL BIOSERVICE is world-wide active as an CRO that concentrates on biological trials of pharmaceuticals, biologics, chemicals, agrochemicals, medical devices, cosmetics and food. The internationally accepted approach of the institute with its various accreditations and certifications (GLP, GMP, DIN EN ISO 17025, FDA approved) guarantees high-quality services. Areas of expertise include e.g. ADME and Metabolism, Bioassays, Cell-Based Immunoassays and Immunotoxicological Investigations, Clinical Sample Services, Toxicology, Pharmacology, Microbiology and Analytics. BSL BIOSERVICE also offers comprehensive services for REACH. BSL BIOSERVICE is also active in the development of alternative test methods to animal experiments.



Contact:
Dr. Ralf Bäuerle

Obere Hauptstr. 10 b
D-85386 Eching
Phone: +49 (0) 89 3799666-6
Fax: +49 (0) 89 3799666-99
E-Mail: info@biozol.de
Internet: www.biozol.de



Bristol-Myers Squibb

Contact:
Friederike Herrfurth

Arnulfstr. 29
D-80636 München
Phone: +49 (0) 89 12142-0
Fax: +49 (0) 89 12142-392
E-Mail: info@b-ms.de
Internet: www.b-ms.de



Contact:
Dr. Christina Grimm

Behringstr. 6 / 8
D-82152 Planegg
Phone: +49 (0) 89 899650-0
Fax: +49 (0) 89 899650-11
E-Mail: info@bioservice.com
Internet: www.bioservice.com



We make it visible.

Contact:
Dr. Richard Ankerhold

Kistlerhofstr. 75
D-81379 München
Phone: +49 (0) 89 909000-800
Fax: +49 (0) 89 909000-820
E-Mail: info@zeiss.de
Internet: www.zeiss.de/microdissection



Contact:
Dr. Torsten Gerike

Joseph-Wild-Str. 20
D-81829 München
Phone: +49 (0) 89 451519-010
Fax: +49 (0) 89 451519-019
E-Mail: info@celgene.de
Internet: www.celgene.de



Contact:
Dr. Joachim Wiest

Karlstr. 96
D-80335 München
Phone: +49 (0) 89 2000110-74
Fax: +49 (0) 89 2000110-76
E-Mail: wiest@cellasys.com
Internet: www.cellasys.com

Carl Zeiss Microscopy GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, Microscopy, Tissue Engineering/Cell Culture

Carl Zeiss Microscopy GmbH offers a broad range of modern and innovative microscope systems and solutions for different fields such as biotechnology, biomedical and clinical research as well as routine and industrial applications. Carl Zeiss MicroImaging employs about 1,750 staff worldwide and has its direct sales force in 130 countries. The company's headquarter is in Jena. At its Munich site Carl Zeiss Microscopy GmbH is focusing on software development, systems for laser microdissection and its application as well as digital slide and automation technology. In addition, in Munich the company is maintaining a unique facility hosting a modern application center and an up-to-date laboratory for biomedical and clinical research, molecular analysis and imaging. Practical courses, workshops and training are held on a regular basis and customer services are offered.

Celgene GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Drug Delivery, Hematology, Small Molecules, Drug Development

Celgene is a globally acting biopharmaceutical company, founded in New Jersey (USA) in 1986. Celgene is mainly active in developing and distributing drugs in hematology, oncology and immunotherapy. Since 2006, Celgene operates a German subsidiary in Munich-Riem. For further information visit: www.celgene.de

cellasys GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Chip/Array Technology, Pharmacokinetics, Drug Development, Tissue Engineering/Cell Culture, Toxicology

cellasys offers system solutions for online analysis of living cells. These include services as research and development, production and maintenance of cell based assays. Furthermore we are consultant for development of applications, data analysis and data interpretation.

CellTool GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Microscopy

CellTool is a company that develops, manufactures and distributes innovative systems for non-contact and marker-free recognition, quantitative characterization and gentle sorting of living cells based on Raman spectroscopy. CellTool systems are especially designed to meet the requirements of biologists and physicians. They are extremely user friendly. Cell handling and cell measurements are highly automated. In combination with innovative microfluidics cells can be characterized in a physiological environment keeping them viable for downstream applications. Capabilities are fast diagnosis, patient-specific drug screening or individual cell therapy.

Centronic GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Medicinal Chemistry, Analytical Chemistry, Clinical Diagnostics

Centronic GmbH is a German manufacturer, with a certified Quality Management System according to EN ISO 9001:2008 and ISO 13485:2003/AC: 2009, and distributor of a big range of high qualitative clinical chemistry reagents in fluid and lyophilised form for the determination of enzymes, electrolytes, substrates, lipids and proteins. The product range is completed by a wide range of immunoturbidimetric reagents and corresponding controls, Latex reagents, controls-calibrators, food chemistry reagents, cleaning solutions for several analysers and our registered additive for waterbaths Prothermal. The products are distributed worldwide. Our team consists of highly engaged scientists from different special fields with an experience of many years in the area of clinical chemistry.

Certara Coöperative U.A.

BIOTECH BIOINFORMATICS

Keywords: Pharmacokinetics, Drug Development, Medicinal Chemistry, Molecular Modelling, Data Management and Biostatistics, Informatics, Data Management

Certara is dedicated to improving human health through a broad spectrum of software products and scientific consulting services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by uniting industry leaders Tripos®, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery; Simcyp™ a research-based company providing predictive pharmacokinetic and pharmacodynamics tools, workshops, and consultancy services, and Pharsight® Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development.



Contact:
Dr. Karin Schütze

Am Neuland 1
D-82347 Bernried
Phone: +49 (0) 8158 9064010
E-Mail: info@celltool.de
Internet: www.celltool.de



Contact:
Dr. Johannes Betz

Am Kleinfeld 11
D-85456 Wartenberg
Phone: +49 (0) 8762 724300
Fax: +49 (0) 8762 724312
E-Mail: info@centronic-gmbh.com
Internet: www.centronic-gmbh.com



Contact:
Dr. Fabian Bös

Martin-Kollar-Str. 17
D-81829 München
Phone: +49 (0) 89 451030-0
Fax: +49 (0) 89 451030-30
E-Mail: fabian.boes@certara.com
Internet: www.certara.com



Oskar Tropitzsch

Contact:
Dipl.-Kfm. Oskar Tropitzsch

Waldershofer Str. 49–51
D–95615 Marktredwitz
Phone: +49 (0) 9231 9619-0
Fax: +49 (0) 9231 9619-60
E-Mail: info@cfmot.de
Internet: www.cfmot.de

CHROMBIOS

Gesellschaft für molekulare Zytogenetik mbH

Contact:
Dr. Andrea Kofler

Hochriesweg 14
D-83131 Nussdorf
Phone: +49 (0) 8035 9849-28
Fax: +49 (0) 8035 9849-30
E-Mail: kofler@chrombios.com
Internet: www.chrombios.com

Cfm Oskar Tropitzsch e.K.

PHARMA & CHEMICAL INDUSTRY

Keywords: Natural Compounds, Drug Development, Pharmacology, Drug Delivery, Agrobiotechnology, Antibiotics, Fine Chemicals/Reagents

Supply for the Pharmaceutical and Biotech-Sector

Latest research substances:

- Cyclopamine, DTT, Ebselen, Geldanamycin, IPTG, LL-Z-1640-2, Mycotoxins, Rapamycin.
- Small scale API manufacturing (cGMP)
- Contract synthesis (GMP)
- Fermentation products (> 700 substances)
- Phytochemicals (> 1000 substances)
- Pharmaceutical raw materials
- Enzymes
- Chemical specialities (Curare, Picric acid incl. DMF)
- NEW: Natural toxins - synthetically produced

ChromBios GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Founded in 1998, ChromBios is focused on the field of Molecular Cytogenetics (fluorescence in situ hybridisation, FISH). The company's aims are to provide service and products for chromosome analysis tailored to the needs of the customers. We offer "FISH service" such as chromosome analysis with "chromosome painting", mapping of clones, characterisation of cancer cell lines and animal models in genome research. We especially focus on multi colour karyotyping human tumour cells and other transformed cell lines (for example for patent applications). Chrombios also offers multi colour chromosome painting of mouse cells to identify translocations in mouse tumours and to characterise mouse ES cells. Apart from human and mouse, we also provide service in the characterization of chromosomes from other animal model species including rat, hamster, cat, and various live stock animals.

ChromoTek GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics, Antibody, Oncology, Clinical Diagnostics

ChromoTek GmbH, founded in 2008, is a biotech company focused on the discovery and development of novel nanoprobe and cell based assays for biomedical research and early drug development. During the last years ChromoTek has developed innovative research tools including the GFP-Trap® and RFP-Trap®, two versatile pull-down reagents for biochemical analysis of fluorescent fusion proteins. In April 2011 ChromoTek successfully introduced its first cell based assay for early drug development, the U2OS Cell Cycle Chromobody®. This real-time High-Content Analysis (HCA) screening assay enables to monitor the complete cell cycle in live cells for the first time. In addition ChromoTek developed the Fluorescent 2-Hybrid (F2H)-Assay to analyze protein-protein interactions in vivo in real time.

Clariant Produkte (Deutschland) GmbH Biotech & Renewables Center

CHEMICAL INDUSTRY & INDUSTRIAL BIOTECHNOLOGY

Keywords: New Materials, Agrobiotechnology

Clariant is an internationally active specialty chemical company based in Muttenz. Clariant focuses on creating value by investing in future profitable and sustainable growth, which is based on four strategic pillars: Improving profitability, innovation as well as research and development, dynamic growth in emerging markets, and optimizing the portfolio through complementary acquisitions or divestments. The main focus of Clariant's Biotech & Renewables Center is on bio-catalysis and bio-refining. The company develops energy-efficient processes for the manufacture of biomass-based chemicals and fuels. Clariant has developed a process which uses enzymatic hydrolysis followed by fermentation to produce cellulosic ethanol from agricultural residues.

Clinical Trial Care GmbH

CRO

Keywords: Dermatology, Metabolic Diseases, Nephrology, Pain, Rheumatoid Arthritis

Clinical Trial Care GmbH founded in 2001 is a CRO located in the southwest of Munich (Krailling) and provides the full scope of clinical and biometric services required for the conduct of clinical trials of phase II-IV, post marketing surveillance as well as non-interventional or epidemiologic studies. The very experienced, flexible and successful team ensures expert support and a responsive commitment. The CRO is headed by Dipl. Psych. Andreas Behr (CEO) with a long standing history of clinical research.



Contact:
Dr. Marion Jung

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 787973-10
Fax: +49 (0) 89 787973-11
E-Mail: info@chromotek.com
Internet: www.chromotek.com



Contact:
Prof. Dr. Andre Koltermann

Staffelseestr. 6
D-81477 München
Phone: +49 (0) 89 710 661-0
Fax: +49 (0) 89 710 661-122
E-Mail: biotech@clariant.com
Internet: www.clariant.com



Contact:
Dr. Christa Sommerburg

Pionierstr. 2
D-82152 Krailling
Phone: +49 (0) 89 8638933-12
Fax: +49 (0) 89 8638933-99
E-Mail: andreas.behr@clinical-trial-care.de
Internet: www.clinical-trial-care.de



Contact:
Birgit Hennecke-Janzer

Landsberger Str. 408
D-81241 München
Phone: +49 (0) 89 9999-7733
Fax: +49 (0) 89 9999-7744
E-Mail: bhennecke-janzer@clinipace.com
Internet: www.clinipace.com



Clinrex GmbH
your clinical research experts

Contact:
Dr. Dagmar Chase

Rosenkavalierplatz 12
D-81925 München
Phone: +49 (0) 89 92 92 87 0
Fax: +49 (0) 89 92 92 87 50
E-Mail: dagmar.chase@clinrex.com
Internet: www.clinrex.com

Clinipace GmbH

CRO

Keywords: Drug Development, Pharmacovigilance, Regulatory Affairs, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Medical Writing

Clinipace Worldwide, a global digital clinical research organization (dCRO), specialized in serving the strategic product and clinical development needs of emerging and mid-tier biopharmaceutical and medical device firms. Our core competencies are

- Concepts for Drug & Medical Device Development
- Regulatory & Medical-Scientific Services
- Clinical Operations
- Data Management & Biostatistics
- QMS Services & Auditing
- TEMPO eClinical Platform

We maintain offices on four continents, including centralized North American, South American, and European hubs. The combination of our service portfolio, our technology-driven approach and our flexible & highly trained teams enables the adaptation to the specific requirements of each project.

Clinrex GmbH

CRO

Keywords: Clinical Trial Management and Monitoring, Consulting and Training, Data Management and Biostatistics

Clinrex was founded in 2004 by Dr. Dagmar Chase to offer consulting services and training in the areas GCP, Quality Management and Project Coordination for clinical trials. The set-up and handling of DSMBs / DMCs is also one of Clinrex' core competencies.

GCP/Quality Management Consulting

- Assessment of systems or studies regarding GCP compliance
- Inspection preparedness
- SOP development/SOP streamlining
- GCP gap analyses
- Interface sponsor/CRO
- Investigator Initiated Trials

Training

- All areas of GCP and project management of clinical trials
- Smart Training® or customised in-house training
- Training for sponsors, CROs, investigators and study nurses

ClinTec GmbH

CRO

Keywords: Medical Writing, Oncology, Drug Development, Regulatory Affairs, Cardiovascular Diseases, Neurology

ClinTec International is a privately owned full service global Clinical Research Organization covering more than 40 developed and emerging countries. It was founded in 1997 by Dr Rabinder Buttar, the company's President & CEO. ClinTec International offers industry best-practice in the following functions: Regulatory Affairs, Clinical Research, Data Management & Biostatistics, Medical Writing, Resourcing, Patient Recruitment and Quality Assurance. We are working seamlessly with our clients, understanding their needs and constraints in order to deliver optimal solutions.

conoGenetix biosciences GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Peptide/Protein, CNS, Pain, Cardiovascular Diseases

conoGenetix is a privately owned biopharmaceutical company focused on the development of new peptide therapeutics for the treatment of autoimmune diseases. conoGenetix was founded in 2002 by Dr. Andreas Klostermann and Dr. Jörg Stockhaus and is located in Martinsried, Germany. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads that modulate ion channel targets causatively involved in the generation of autoimmune diseases.

conoGenetix runs a program targeting severe autoimmune disorders like Multiple Sclerosis (MS), Rheumatoid Arthritis (RA) and Vasculitis. Several peptides called cgtx-peptides within this program are in preclinical development. The leading indication for the cgtx-peptides will be Vasculitis; a fatal disease strongly related to Rheumatoid Arthritis. Vasculitis is a rare disease and will be a market door opener for conoGenetix.



Contact:
Dr. Hans Wolf

Landshuter Allee 8-10
D-80637 München
Phone: +49 (0) 89 5455 8355
Fax: +49 (0) 89 5574 43
E-Mail: germany@clintec.com
Internet: www.clintec.com



Contact:
Dr. Andreas Klostermann

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 3187-2662
Fax: +49 (0) 89 3187-3835
E-Mail: info@conogenetix.de
Internet: www.conogenetix.de



Contact:
Jürgen Schäfer

Neuhauser Str. 47
D-80331 München
Phone: +49 (0) 89 236650-0
Fax: +49 (0) 89 236650-50
E-Mail: schaefer@conreso.com
Internet: www.conreso.com



Contact:
Dr. Michael Kersten

Elisabethstr. 91
D-80797 München
Phone: +49 (0) 89 202 444 9718
Fax: +49 (0) 89 202 444 979
E-Mail: mkersten@corelabpartners.com
Internet: www.corelabpartners.com



Contact:
Dr. Michael Wiggenhorn

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 5424498-0
Fax: +49 (0) 89 5424498-22
E-Mail: contact@coriolis-pharma.com
Internet: www.coriolis-pharma.com

Conreso GmbH

CRO

Keywords: Clinical Trial Management and Monitoring, Data Management and Biostatistics, veterinary clinical trials

Conreso, established in 1990, BVMA member, offers a wide range of medical and clinical research services, from phase II to late phase and epidemiological studies. A particular strength, the Conreso monitoring quality, is considered by its clients to be unrivalled. Conreso shows an impressive record of successful FDA inspections and significant contributions to important new product licenses. Having recruited more than 30.000 patients between 0 and 17 years of age proves the company's unique expertise in pediatric trials. Further areas of particular expertise are oncological and vaccine studies. Quality and service of Conreso are awarded by a constant repeat business rate of 90 %. The Conreso department of veterinary medicine provides all types of veterinary studies.

CoreLab Partners Europe GmbH

CRO

Keywords: Imaging Analytics, clinical trial

CoreLab Partners is an imaging core lab, managing the complete imaging segment of clinical trials for the global pharmaceutical, biotechnology and medical device industries. Our expertise spans Phase I through IV and all major therapeutic areas. We are specialized in oncology trials but also do cardiovascular, musculoskeletal, CNS and medical device studies. Our radiologists, nuclear physicians and medical oncologists interpret data from all major modalities, including CT, MRI, X-ray, SPECT, Ultrasound, PET and PET/CT in a centralized and independent way. We assist in planning, tracking and implementation of studies and provide medical expertise, regulatory know-how and validated technologies. In spring 2013 CoreLab and BioClinica merged and will operate in future under BioClinica name.

Coriolis Pharma

MEDTECH

Keywords: Drug Delivery, Peptide/Protein, Vaccines, Antisense/Nucleotides

Coriolis Pharma is a globally operating independent service provider for research and formulation development of (bio)pharmaceutical drugs (proteins, peptides, monoclonal antibodies, RNA/DNA etc.) and vaccines. An interdisciplinary team of highly qualified scientists with many years of experience in the development of (bio)pharmaceuticals provides cutting-edge service and know-how related to the formulation development of biopharmaceuticals, supported by an expert scientific advisory board. This may involve for example formulation development of (pre-)clinical material through to commercial products, lyophilization processes, stability testing (light obscuration, Micro-Flow imaging and AF4/HF5 under cGMP), supply of pre-clinical material, and analytical services using innovative analytical technologies.

Covance Clinical and Periapproval Services GmbH

CRO

Keywords: Biomarker, Regulatory Affairs, Oncology, CNS, Medical Writing, Pharmacology

About Covance: Covance is one of the world's largest and most comprehensive drug development services companies with more than 11,000 employees in 60 countries. Covance is the market leader in toxicology services, central laboratory services, discovery services, and a top global provider of Phase III clinical trial management services. Through its nonclinical, clinical and commercialization services, Covance has helped pharmaceutical and biotech companies develop one-third of all prescription medicines in the market today. Covance, headquartered in Princeton, New Jersey, has annual revenues greater than \$2 Billion. For more information please visit www.covance.com

CRELUX GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Peptide/Protein, 3D-Structural Analysis, Drug Development, Premium Drug Discovery Service

CRELUX is a leading expert in premium drug discovery solutions for pharma, biotech and research organizations. Our services are highly individualized for our customers – we have been delivering customized solutions in drug discovery, X-ray crystallography, biophysical screening, fragment based screening and protein supply to global pharma and biotech for more than a decade. In a strategic alliance with 4SC Discovery we are offering full services from idea to pharmaceutical development candidate. Our joint i2c platform operates on a seamlessly integrated suite of technologies including virtual high throughput screening, molecular modelling, X-ray crystallography, in vitro and cell based screening medicinal chemistry and pharmacology. Our mission is to enable our clients to perform their work better, faster, more efficiently and more successfully by providing a flexible, expert work force.

CROMSOURCE GmbH

CRO

Keywords: clinical development

CROMSOURCE is an ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions. A well-established full-service CRO, CROMSOURCE is unique in offering an end-to-end guarantee covering trial timelines, enrolment and contract price. This guarantees our clients that their trials are delivered on time and within the contract price with no CRO initiated change orders. CROMSOURCE supports the full spectrum of clinical development via our Pharmaceutical, Medical Device, and Staffing Solutions divisions.



Contact:
Margarete Rudloff

Rosenkavalierplatz 10
D-81925 München
Phone: +49 (0) 89 9210930
Fax: +49 (0) 89 913466
E-Mail: dominika.kasper@covance.com
Internet: www.covance.com



Contact:
Dr. Martin Ried

Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 700760-170
Fax: +49 (0) 89 700760-222
E-Mail: schaeffer@crelux.com
Internet: www.crelux.com



Contact:
Dr. Susanne Gerbl-Rieger

Rüdesheimer Str. 15/1
D-80686 München
Phone: +49 (0) 89 21019101
Fax: +49 (0) 89 21019150
E-Mail: Christine.Wurm@cromsource.com
Internet: www.cromsource.com



Contact:
Eva Hurst

Konrad-Adenauer-Allee 1
D-86150 Augsburg
Phone: +49 (0) 821 450807-4
Fax: +49 (0) 821 450807-6
E-Mail: eva.hurst@crosnt.com
Internet: www.crosnt.com



Contact:
Christina Müller

Henkestr. 91
D-91052 Erlangen
Phone: +49 (0) 9131 4000917
Fax: +49 (0) 9131 4000918
E-Mail: info@curadis.eu
Internet: www.curadis.eu



Contact:
Dr. Silke Ostermann

Trimburgstr. 2
D-81249 München
Phone: +49 (0) 89 20335359
Fax: +49 (0) 89 80919380
E-Mail: info@cso-services.eu
Internet: www.cso-services.eu

CROS DE GmbH

CRO

Keywords: Statistical Consultancy, Pharmacovigilance, Medical Writing, Data Management and Biostatistics

CROS NT is an international Contract Research Organisation (CRO) specialized in clinical data services. Founded in 1992, CROS NT has completed over 800 studies and remains focused on biometrics services including clinical data management, biostatistics (analysis and programming), pharmacovigilance, medical writing and life science technology. CROS NT can also offer expert consultancy services on trial design, CDISC standards, DSMB review and regulatory submissions. With offices in Italy, Germany and the UK, CROS NT has retained 100% of its customers due to advanced internal governance and client relationships built on trust.

Curadis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology

The pharmaceutical start-up company located in Erlangen/Regensburg researches and develops steroidal medicines for breast cancer and benign enlargement of the prostate gland. Curadis GmbH was founded in 2008 in Erlangen and has S-Refit AG of Regensburg as one of its investors. The company is developing a novel substance for breast cancer and a substance for prostate cancer.

CSO Pharma Consulting GmbH

CRO

Keywords: Pharmacovigilance, Compliance, Safety, Organisation Development

CSO Pharma is a customer focused Consulting Company providing Pharmacovigilance and Medical Affairs support combined with Quality Management services as regulatory required and inspected. We offer our services as hands-on partner but also consultant to help especially SMEs and Start-ups to set-up Pharmacovigilance (PV) and GxP processes and develop their own know-how. Our services comprises i.e. development of SOPs and implementation, training, contract development, audits and support of self inspections, complaint management, answering pharm.- and med. enquiries, preparation of Risk Management Plans, PV Master File, Consultant QPPV/Information Officer, update of product information, leaflets and SPCs, announcements in product reference books.

CYTOX, biologische Sicherheitsprüfungen

BIOTECH DEVICES & REAGENTS

Keywords: Tissue Engineering/Cell Culture, Toxicology, ELISA/EIA, Microscopy

CYTOX provides biological testing service for the medical device and pharmaceutical industry by using in vitro toxicological testing procedures according to ISO 10993 as well as FDA-compliant processes. Next to classical 2D cell culture testing systems we use organotypical 3D cell culture systems especially in the area of skin irritation testing and REACH applications.

DAIICHI SANKYO EUROPE GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Antibiotics, Drug Development

Daiichi Sankyo is a global pharmaceutical company that focuses on researching and marketing of innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of more than EUR 8.6 billion in fiscal year 2012, Daiichi Sankyo is one of the world's 20 leading pharmaceutical companies. The company's world headquarters is in Tokyo, and its European base is located in Munich. Daiichi Sankyo has established affiliates in 12 European countries since it set up European production facilities and marketing offices in 1990. The company's research activities focus on the areas of cardiovascular diseases, hematology, diabetes, anti-infectives and cancer.

Dartsch Scientific GmbH Institut für zellbiologische Testsysteme

BIOTECH

Keywords: Cellbiology research support

Scientific core competences: Highly skilled and experienced scientist; interdisciplinary broad knowledge about scientific correlations in the areas of human physiology, biology, chemistry, biochemistry, medicine, toxicology; specific scientific expertise in the areas of cardiovascular diseases, arteriosclerosis, research on various three-dimensional in vitro models and organ cultures, cytoskeleton, human and animal cell cultures, apoptosis, cell volume regulation, protein expression.



Contact:
Dr. Dietmar Scheddin

Gottlieb-Keim-Str. 60
D-95448 Bayreuth
Phone: +49 (0) 921 1511-254
Fax: +49 (0) 921 1511-255
E-Mail: info@cytox.de
Internet: www.cyttox.de



Contact:
Olaf Lamberz

Zielstattstr. 48
D-81379 München
Phone: +49 (0) 89 7808-0
Fax: +49 (0) 89 7808-202
E-Mail: service@daiichi-sankyo.eu
Internet: www.daiichi-sankyo.eu

Dartsch Scientific

Contact:
Prof. Peter Dartsch

Oskar-von-Miller-Straße 10
D-86956 Schongau
Phone: +49 (0) 8861 256-5250
Fax: +49 (0) 8861 256-7162
Internet: www.dartsch-scientific.com



DATA ANALYSIS SOLUTIONS

Contact:
Dr. Jürgen von Frese

Kellersgartenstr. 19
D-86919 Utting am Ammersee
Phone: +49 (0) 8806 9597430
Fax: +49 (0) 8806 9597431
E-Mail: info@da-sol.de
Internet: www.da-sol.de



Contact:
Dr. Michael Davids

Roentgenstr. 3
D-93055 Regensburg
Phone: +49 (0) 941 948228
Fax: +49 (0) 941 9468119
E-Mail: antibodies@dabio.de
Internet: www.davids-bio.de

DEFINIENS®
Understanding Images

Contact:
Florian Fleiß

Bernhard-Wicki-Straße 5
D-80636 München
Phone: +49 (0) 89 231180-0
Fax: +49 (0) 89 231180-90
E-Mail: fleiss@definiens.com
Internet: www.definiens.com

Data Analysis Solutions DA-SOL GmbH

BIOTECH BIOINFORMATICS

Keywords: [Datamining](#)

DA-SOL is a services and consulting company providing advanced multivariate bioinformatics, biostatistics, chemometrics and data mining. Based on extensive experience in large scale industry projects and fostered by proprietary algorithms, DA-SOL develops innovative, tailored data analysis solutions for its clients and provides project support as well as training on all levels. Gene expression, proteomics, metabolomics, spectroscopy, imaging and other data – DA-SOL helps its clients to conduct their studies most efficiently and to harvest the full potential of their data. Focus areas are the analysis of process data, the development of medical diagnostics and the integration of diverse biomedical or pharmaceutical data.

Davids Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Allergy](#), [Immune Therapy](#), [Antibody](#), [Proteomics](#), [ELISA/EIA](#), [Tissue Engineering/Cell Culture](#), [Antibody Production Service](#)

Davids Biotechnologie is a German custom manufacturer for antibodies since 1996. Polyclonal antibodies and monoclonal antibodies. Antibodies and other proteins are produced in HEK and CHO cells after transient transfection as well as in standard E.coli cells. Chromatographic and affinity purification services for purification of protein without a tag and with a tag. Cell based natural killer cell assays for detection of active molecules and for control of human therapies.

Definiens AG

BIOTECH BIOINFORMATICS

Keywords: [Drug Development](#), [Microscopy](#), [Personalized Medicine](#), [Oncology](#), [Toxicology](#), [Biomarker Discovery & Development](#), [Clinical Diagnostics](#)

Definiens is the leading provider of image analysis and data mining solutions for Quantitative Digital Pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans, and allows the correlation of this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy. Definiens' vision is to open new fields of research, to advance personalized medicine and to significantly improve the quality of patients' lives.

DelphiTest GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: RFLP-analysis

The company's core technology capitalizes on the revolutionary development of DNA analysis, DNA sequencing and DNA fragment analysis. Delphitest GmbH focussed on family relationship testing especially for private customers but also for courts, lawyers, medical doctors, youth welfare offices and embassies. We developed new techniques and tests, e.g. paternity tests for dogs, sibling tests etc. In addition, we offer genetic tests for hereditary diseases like Chorea Huntington, Alzheimers Disease or Canavan Syndrome and a genetic blood group test. Delphitest provides its high level of competence in DNA techniques to scientific partners like universities, hospitals or pharmaceutical companies in Europe.

DENK PHARMA GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

Keywords: Manufacturing

DENK PHARMA was founded in Munich, Germany in 1948. We have a strong focus on export markets and presently supply our DENK PHARMA premium medicine to over 50 countries around the world. In Germany our products are sold through co-marketing agreements with other companies. All DENK PHARMA products are: Manufactured in Germany, Registered in Germany, Quality controlled in Germany.

DiaServe Laboratories GmbH

BIOTECH DEVICES & REAGENTS

DiaServe is a primary manufacturer of human and animal blood derived raw materials for diagnostic industry. Based on this raw materials DiaServe also offers tailor-made in vitro controls/calibrators for medical laboratories. The company was established in 1997 with a mission to identify, develop and manufacture in vitro diagnostics mainly on OEM basis for diagnostic manufacturers and clinical laboratories.



Contact:
Dr. Frank Pfannenschmid

Unter den Schwibbögen 23
D-93047 Regensburg
Phone: +49 (0) 941 2986615
Fax: +49 (0) 941 6963846
E-Mail: info@delphitest.de
Internet: www.delphitest.de

DENK PHARMA

Contact:
Stephan Huber

Prinzregentenstr. 79
D-81675 München
Phone: + 49 (0) 89 230029-0
Fax: + 49 (0) 89 230029-480
E-Mail: pharma@denkpharma.de
Internet: www.denkpharma.de



Contact:
Dr. Ulf Henseling

Seeshaupter Str. 27
D-82393 Iffeldorf
Phone: +49 (0) 8856 803605
Fax: +49 (0) 8856 803607
E-Mail: DiaServe@t-online.de
Internet: www.diaserve.de



Contact:
Takatoshi Ezoe

Leopoldstr. 254
D-80807 München
Phone: +49 (0) 89 35404805
Fax: +49 (0) 89 35404806
E-Mail: info@dojindo.eu.com
Internet: www.dojindo.eu.com



Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: info@donatur.de
Internet: www.donatur.de



Contact:
Dr. Reinhard Nibler

Fürstenriederstr. 105
D-80686 München
Phone: +49 (0) 89 56823726
Fax: +49 (0) 89 92185265
E-Mail: mail@dr-nibler.de
Internet: www.dr-nibler.de

Dojindo EU GmbH

REAGENTS

Keywords: [Fine Chemicals/Reagents](#)

Dojindo produces over 500 well-known products used by research organizations over the world. Many of these products were developed jointly between Dojindo staff and outside researchers. Dojindo strives to expand its ability to analyze the future direction of science by maintaining continued interest in new research activities as well as improving its information-gathering network. Dojindo is ready for this shortened product cycle because our creative researchers are working continuously to meet tomorrow's research needs.

DoNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Drug Development](#), [Rheumatoid Arthritis](#)

DoNatur GmbH develops new therapeutics from herbal extracts with traditionally confirmed therapeutic efficiency. The comprehensive analysis of the genuine extracts, the isolation and structural characterization of the active substances and the test of their pharmacological activities constitutes the main competence of the company. Over the last years DoNatur has successfully developed a new immunomodulatory acting natural substance which has been proved highly efficacious for the therapy of rheumatic diseases.

Dr. Nibler & Partner

CRO

Keywords: [Medical Writing](#), [Pharmacology](#), [Devices](#), [Drug Development](#)

Legal requirements for pharmacovigilance are continuously rising. The fulfillment turns out to be a major burden for small and medium sized enterprises. We provide a complete pharmacovigilance full-service solution:

- 24-hours availability for receipt of adverse event reports by phone, fax or e-mail
- Literature screening and -review
- Data entry and MedDRA coding
- Follow-up by medically qualified personnel (MD, RN)
- Scientific assessment by experienced physicians
- Authority reporting either electronically or on paper
- SUSAR reporting
- Preparation of periodic reports: PSUR and ASR
- Preparation and maintenance of risk management plans
- Implementation and optimization of your pharmacovigilance system
- SOP preparation or revision
- Audits and guidance through inspection

Dr. R. Pflieger GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Dermatology, Antibiotics, Pharmacokinetics, Pharmacology, Drug Delivery

Dr. R. Pflieger GmbH is a medium sized German pharmaceutical company located in Bamberg (Bavaria) with a staff of 300 employees. Established in 1945 as a private company, it is nowadays exclusively owned by the Doktor Robert Pflieger Foundation, which aims are the exclusive sponsoring of charitable and social projects and the support of medical research. The company is currently selling about 35 medicinal products with emphasis in urology, gynaecology and dermatology and has GMP approved production facilities. The international business is focused on the antimuscarinic drug trospium chloride which was developed by the Dr. R. Pflieger and is approved for treatment of overactive bladder.

Dynamic Biosensors GmbH

BIOTECH DNA & PROTEIN ANALYTICS

Keywords: Antibody, Proteomics, Small Molecules, Peptide/Protein, Chip/Array Technology, Drug Development, Devices

Dynamic Biosensors offers a superior new analysis system for molecular interaction. Based on the revolutionary label-free switchSENSE technology, we allow researchers to determine affinity and kinetics of molecular interactions with unrivaled sensitivity in real time. As a total novelty in label-free analysis, switchSENSE allows to determine molecular size (e.g. formation of aggregates) and conformational changes as well. While switchSENSE is an extremely versatile technology, our current focus lies on protein interaction analysis (antibodies and transcription factors), protein folding and post-translational modifications.



Contact:
Dr. Peter Topfmeier

Dr.-Robert-Pflieger-Str. 12
D-96045 Bamberg
Phone: +49 (0) 951 6043-0
Fax: +49 (0) 951 6043-29
E-Mail: info@dr-pfleger.de
Internet: www.dr-pfleger.de



Contact:
Dr. Dirk Scholl

Lichtenbergstr. 4
D-85748 Garching
Phone: +49 (0) 89 289-11490
Fax: +49 (0) 89 289-12704
E-Mail: info@dynamic-biosensors.com
Internet: www.dynamic-biosensors.com



Contact:
Ahmed Abdelaziz

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 3187 4584
E-Mail: ahmed@eadmet.com
Internet: www.eadmet.com



Contact:
PD Dr. Hans-Peter Klenk

Poeckinger Fussweg 7a
D-82340 Feldafing
Phone: +49 (0) 8157 9963-164
Fax: +49 (0) 8157 9963-162
E-Mail: info@egene-biotech.de
Internet: www.egene-biotech.de



Contact:
Iris Heigl

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 70939316
Fax: +49 (0) 89 70939440
E-Mail: info@ellabiotech.com
Internet: www.ellabiotech.com

eADMET GmbH

BIOTECH BIOINFORMATICS

eADMET GmbH develops and markets innovative IT solutions for the prediction of important properties of chemicals and drugs, especially physical and ("drug-like") characteristics. The term "eADMET" stands for "early&electronic ADMET" - computational models designed to predict the ADMET (absorption, distribution, metabolism, excretion and toxicity) of molecules. We are an enterprise solution provider committed to long-term partnerships with our customers. For the full range of small to large business organizations, we offer business consulting and IT infrastructure solutions that enable our clients to exploit the potential of an up-to date in-silico property prediction infrastructure with minimum effort. The central product of eADMET is OCHEM, a web-based database system that links the molecular structures of chemical substances to their physical and ADME /Tox characteristics. Based on a comprehensive data collection and excellent algorithms, the properties of new substances can be estimated accurately. .

e.gene Biotechnologie GmbH

BIOTECH BIOINFORMATICS

Keywords: Pharmacogenomics, Genomics

e.gene Biotechnologie GmbH is a service provider in microbial genomics and pharmacogenomics. We perform for our academic and industrial customers complete microbial genome analyses from genome sequencing to annotation and pathway reconstruction.

ELLA Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, PCR, Chip/Array Technology, RNAi & Antisense, Genomics, Antisense/Nucleotides

Our focus is the synthesis of special oligoribonucleotides for selected projects in diagnostics, chip technologies, genesynthesis and further topics – following quality standards which you would appreciate and expect in your own lab. The guidelines for the synthesis standards can be defined by our customers themselves. Through our validated technology platform, our experienced interdisciplinary team and our resolute attitude towards the highest quality in our products we offer tangible advantages to our customers and partners.

Emergent Product Development Germany GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Vaccines, Infectious Diseases

Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders.



Contact:
Isabelle Erdelji

Walter-Gropius-Str. 17
D-80807 München
Phone: +49 (0) 89 5506988-0
Fax: +49 (0) 89 5506988-88
E-Mail: erdeljii@ebsi.com
Internet: www.emergentbiosolutions.com

EMFRET Analytics GmbH & CoKG

BIOTECH ANALYTICS&DIAGNOSTICS

emfret Analytics GmbH (founded 2002) is focussing on production, characterization, derivatization and supply of monoclonal antibodies in biomedical research, namely vascular biology.

EMFRET Analytics

Contact:
Susanne Nieswandt

Am Morgenroth 6
D-97246 Eibelstadt
Phone: +49 (0) 9303 984964
Fax: +49 (0) 700 36 37 38 00
E-Mail: service@emfret.com
Internet: www.emfret.com

EMP Genetech

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Drug Development, Clinical Diagnostics, Peptide/Protein, Biomarker Discovery & Development

EMP Genetech Recombinant Proteins from Human Cells, Improving your Research Activities, EMP Genetech provides non-GMP services in recombinant protein production and the development of stable high producer cell lines. Protein purification to customer given purity is also conducted, as well as cell banking. We work with industrial and academical clients. Since 2000 the company has developed several dozen recombinant biomolecules.

Genetech Services:

- Gene Cloning
- Development of Stable High Producer Cell Lines
- Recombinant Protein Production
- Process Development
- Generation of Cell Banks
- Protein Purification
- Experience since 2000

EMP Genetech
RECOMBINANT PROTEIN EXPRESSION

Contact:
Dr. Franz X. Welser

Hebbelstr. 61
D-85055 Ingolstadt
Phone: +49 (0) 841 3796013
Fax: +49 (0) 841 8817185
E-Mail: info@empgenetech.com
Internet: www.empgenetech.com



Contact:
Markus Fischer

Industriestr. 1
D-93077 Bad Abbach
Phone: +49 (0) 9405 96999-10
Fax: +49 (0) 9405 96999-28
E-Mail: info@entelechon.com
Internet: www.entelechon.com

...EPICEPT GmbH

Contact:
Uschi Lang

Goethestr. 4
D-80336 München
Phone: +49 (0) 89 680872-0
Fax: +49 (0) 89 680872-20
E-Mail: info@epicept.de
Internet: www.epicept.com

EPIGENE

Contact:
Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.epigen.de

Entelechon GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics, Antibody Production Service, Genomics, PCR, Chip/Array Technology

Entelechon is a globally operating service provider specialized in advanced genomics and proteomics projects. Success factor: Leveraging full potential of gene and protein synthesis platforms as well as synergy of biochemistry, molecular biology and bioinformatics for implementation of complex projects. Services: Gene optimization and synthesis, protein expression in various systems, protein analysis and quantification, design and synthesis of gene mutant libraries, bioinformatics software development. Applications: Preclinical stage drug discovery, protein engineering and production, development of therapeutic proteins, antibodies, vaccines, industrial enzymes, downstream biotech services, multiple profile research projects.

EpiCept GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Immune Therapy, Hematology, Drug Development

EpiCept GmbH is a subsidiary of EpiCept Corp. (Tarrytown, NY) which is a specialty pharmaceutical company that focuses on fulfilling unmet medical needs in cancer treatment and pain management. The Company possesses an approved cancer product and a deep and balanced pipeline of nine clinical product candidates. EpiCept Corp. is listed on both the NASDAQ National Market and the OM Stockholm Exchange, under the symbol "EPCT".

EpiGene GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiGene GmbH, founded in 1999, is a genomics-based research and development company focusing on applications in plant protection. The core competences comprise the molecular characterization of plant-pathogen interactions and the development of high throughput systems for molecular diagnostics of involved genetic factors. In addition, research efforts include investigations of the mode of action of plant protective agents at the molecular level and the identification of mutations or differentially expressed genes in pathogens as potential new targets.

EpiLogic GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Genomics, Agrobiotechnology

EpiLogic is a European wide operating company involved in product development based on genomic analysis of fungal pathogens propagated by wind in agricultural crops (at present: cereals and vine). Pathogen analysis of virulence and fungicide sensitivity are used as decision support for breeding, choice of cultivar and fungicide management to ensure sustainable agriculture. A genotype bank of several pathogens is currently being set up to offer high quality inoculum for selection in laboratory, greenhouse and field. Additionally, methods are under development for analysing and culturing new pathogens.

ethris GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Dermatology, Bone/Joint Diseases, Gene Therapy, Gene Transfer, Tissue Engineering/Cell Culture, Drug Development

With stabilized, non-immunogenic messenger RNA ("SNIM[®]RNA"), ethris GmbH possesses an enabling platform for Transcript Therapies. SNIM[®]RNA is a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM[®]RNAs encode therapeutic proteins to be produced in the patient's body and overcome short duration effects of recombinant proteins. SNIM[®]RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, life style- or age-related, rare or frequent. ethris develops transcript therapeutics with a focus on regenerative medicine.

eticur) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

eticur) is headquartered in the IZB in Martinsried and cooperates with the Department of Transfusion Medicine and Haemostaseology of the University Hospital of Erlangen. Based on the idea that umbilical cord blood contains multipotent adult stem cells, the cord blood is prepared and stored for potential later use. These cells might in future play an important role in therapies including regenerative medicine. Our priority is to grant the most secure storage, highest quality and extensive testing by highly qualified personnel. eticur) grants the storage of stem cells following the highest quality-standards of the Federal Board of Physicians and the Institute for Sera and Vaccine (Paul-Ehrlich-Institute).



Contact:
Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.EpiLogic.de



Contact:
PD Dr. Carsten Rudolph

Lochamer Str. 11
D-82152 Martinsried
Phone: +49 (0) 89 8955788-0
Fax: +49 (0) 89 8955788-18
E-Mail: info@ethris.com
Internet: www.ethris.com



Contact:
Felix Raslag

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 125981-0
Fax: +49 (0) 89 125981-19
E-Mail: info@eticur.de
Internet: www.eticur.de



Contact:
Dr. Brigitte Obermaier

Anzinger Str. 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-200
Fax: +49 (0) 8092 8289-201
E-Mail: info@medigenomix.de
Internet: www.medigenomix.de



Contact:
Dr. Jutta Huber

Anzinger Str. 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-0
Fax: +49 (0) 8092 21084
E-Mail: info-eu@eurofins.com
Internet: www.eurofinsgenomics.com

Eurofins Medigenomix GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Pharmacogenomics, Clinical Diagnostics, Pharmacogenetics, Genomics, Agrobiotechnology

Since foundation in 1998 Eurofins Medigenomix has evolved into a recognized reliable outsourcing partner for the biopharmaceutical industry and academic institutions for high fidelity DNA sequencing incl. GLP sequencing and molecular biological techniques. It expanded successfully with services for DNA forensics, animal and plant breeding, food authenticity testing and for Pharmacogenomics/Pharmacogenetics, e.g. genotyping, DNA/RNA preparation, polymorphism screening, biomarker analysis, expression analysis, residual DNA testing, assay development & validation, exclusive marker set for the general identification of responder/non-responder in the scope of clinical studies. Medigenomix is certified according to ISO 9001 and ISO 17025 and audited by pharmaceutical clients for GxP.

Eurofins MWG Operon

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, NGS, PCR, Antisense/Nucleotides

Eurofins MWG Operon was founded in 1990 and is part of the Eurofins Scientific Group, a Life Science Company with laboratories in 33 countries and over 13,000 employees. We are an international provider of genomic services around the core business lines next generation sequencing, custom DNA sequencing, oligonucleotides, siRNA and gene synthesis. We operate worldwide through a network of more than 500 talented employees positioned to serve both the emerging and established markets. Our whole team works tirelessly to establish new standards in the world of the four bases. If you want to know more about Eurofins MWG Operon, we invite you to enter our world of genomic research at www.eurofinsgenomics.com.

Evotec Munich GmbH

BIOTECH DRUG DISCOVERY

Keywords: Small Molecule Drug Discovery and Development Solutions, Proteomics, Genomics, CNS, Metabolic Disease, Oncology, Pharmaceuticals, Biomarkers

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Medimmune/Astra Zeneca, Novartis, Ono Pharmaceutical and Roche. The Company's headquarters are located in Hamburg. Additional major technology and research facilities are based in Göttingen (former DeveloGen AG) and Martinsried (former Kinaxo Biotechnologies GmbH), Abingdon, UK, Thane, India and San Francisco, USA. Evotec has more than 600 employees worldwide. For additional information please visit www.evotec.com

EXCELLA GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Medicinal Chemistry, Analytical Chemistry, Small Molecules, Oncology

Excella GmbH has been serving the pharmaceutical industry for more than 35 years with high quality API's and finished dosage forms. Recent investments have directed our focus towards high containment products (including OEB5) and a one-stop-shopping approach. Excella supplies products to the generic industry but although manufactures for big pharma life cycle end products and develops processes for innovative API's and novel solid dosage forms. Services offered range from early product development through registration support to state-of-the-art manufacturing. Excella's Feucht site has an excellent track record with the FDA and other regulatory agencies since 1983 and is Safebridge certified.



Contact:
Dr. Dirk Ullmann

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 4524465-0
Fax: +49 (0) 89 4524465-20
E-Mail: info@evotec.com
Internet: www.evotec.com



Contact:
Dr. Johann Peter Mörsdorf

Nürnberg Str. 12
D-90537 Feucht
Phone: +49 (0) 9128 4045-38
Fax: +49 (0) 9128 4045-81
E-Mail: pmoersdorf.excella@fareva.com
Internet: www.excella-pharma-source.de



Contact:
Dr. Mikkel Noerholm

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 416172-70
Fax: +49 (0) 89 416172-69
E-Mail: munich@exosomedx.com
Internet: www.exosomedx.com



Contact:
Kurt Heiberger

Neumeyerstr. 48
D-90411 Nürnberg
Phone: +49 (0) 911 801 98409
Fax: +49 (0) 911 801 98400
E-Mail: k.heiberger@eyesight-vision.de
Internet: www.eyesight-vision.com

Exosome Diagnostics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Metabolic Diseases](#), [Diabetics](#), [CNS](#), [PCR](#), [Genomics](#), [Clinical Diagnostics](#)

Exosome Diagnostics is developing biofluid based molecular diagnostic tests for use in personalized medicine applications. Exosomes and other microvesicles are shed into all biofluids, including blood, urine, and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. The Company is commercializing in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of disease. The Company is located in New York, USA and Munich, Germany and is backed by an international consortium of leading VCs.

Eyesight & Vision GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Devices](#), [Automation](#), [Ophthalmology](#)

Eyesight & Vision is focused on intraoperative real-time laser diagnostics for refractive eye-surgery. Our goal is to become the global leader in intraoperative real-time diagnostics for the growing number of patients which desire perfect vision. Our team of experts in ophthalmic devices works closely with eye doctors, clinical specialists and partners to advance the wavefront guided cataract surgery. We provide innovative solutions and utilize our advanced technology, to be the first to introduce intraoperative real-time wavefront diagnostics, so that surgeons are able to decide during the cataract surgery which intraocular lens is best to achieve postoperative perfect vision.

FermCom Bio-VNT – Biologische Verfahrenstechnik und Netzwerk-Technologie

BIOTECH DEVICES & REAGENTS

Keywords: Devices

FermCom Bio – VNT is a research and development company focused on biotechnology and network applications. FermCom Bio – VNT is in development of an innovative in-situ online-analysis system by using a high-technology bioreactor. With the help of the device for classification of biomolecules in liquid there will be new technologies brought together to a new biosensor system "Multisensor-MiniLab". The use of bio-chips allows to miniaturize online real-time-analysis. In cooperation with appropriate high-tech partner companies FermCom Bio – VNT creates a national / international network via Internet / Intranet for data tele-transfer. International patent-applications (PCT) are the cornerstone of the company's strategy. FermCom's field of activity is to develop a new compact system for non-invasive process-monitoring in the area of biotechnology, fermentation- and environment-analytics.

FGK Clinical Research GmbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Regulatory Affairs, Clinical Trial Management and Monitoring, CRO/CMO, Drug Development

FGK Clinical Research is a European CRO with headquarters in München offering all services for phase II to IV clinical trials. Our more than 80 highly qualified medical, scientific and regulatory experts can guide you through the clinical trial process, from planning and approval to the final report. FGK has subsidiaries in the UK, Hungary, Poland and Czech Republic. Our international client base includes biotechnology, medical device, and pharmaceutical companies. With our "all services through one company" philosophy we are able to offer tailored approach to meet the specific requirements of each sponsor. FGK has extensive experience in all major therapeutic areas allowing it to effectively design, manage, and analyze development programs and clinical trials.



Contact:
Albert Stumpf

Finkenstr. 27a
D-82166 Gräfelfing
Phone: +49 (0) 89 895300-24
Fax: +49 (0) 89 895300-25
E-Mail: info@fermcom.de
Internet: www.fermcom.de



Contact:
Martin Krauss

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893119-0
Fax: +49 (0) 89 893119-20
E-Mail: martin.krauss@fgk-cro.com
Internet: www.fgk-cro.com



Contact:
Dr. Edgar J. Fenzl

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893119 22
Fax: +49 (0) 89 893119 20
E-Mail: edgar.fenzl@fgk-rs.com
Internet: www.fgk-rs.com



Contact:
Iris Margraf

Fraunhoferstr. 15
D-82152 Martinsried
Phone: 49 (0) 89 864667-367
E-Mail: service@formycon.com
Internet: http://dev.formycon.com/



Contact:
Dr. Elisabeth Schulze

Frankfurter Ring 193a
D-80807 München
Phone: +49 (0) 89 306593-0
Fax: +49 (0) 89 306593-292
E-Mail: info@fresenius-biotech.com
Internet: www.fresenius-biotech.com

FGK Representative Service GmbH

CRO

Keywords: Drug Development

FGK Representative Service GmbH was founded in order to meet legal requirements of sponsor companies which do not have a subsidiary within the European Union and Switzerland, for the purpose of performing clinical research projects in this region. Such a "legal representative" for clinical drug trials or "authorized representative" for medical device trials fulfills the obligation that the sponsor companies must be established or represented in the European Union according to Clinical Trials Directive 2001/20/EC. FGK represents in all member states of the EU for drug and medical device trials to enable submissions of regulatory applications to the European authorities and ethics committees. FGK also represents for all applications in drug authorizations and orphan drug designations.

Formycon GmbH

PRECLINICAL SERVICES

Keywords: Formulation

Formycon GmbH is more than a regular CRO that provides formulation and analytical services to the biopharmaceutical industry. The complete analytical development chain – starting from protein characterization and comparability studies up to GMP Quality Control and stability testing of clinical study and market medication. The Formulation one-stop shop – Formycon covers pre-formulation, development of systemic and local, liquid, freeze-dried and sustained release drug product formulations, supply of pre-clinical studies and development of the manufacturing process.

Fresenius Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Gene Therapy, Cell Therapy, Antibody, Immune Therapy, Hematology, Drug Development

Fresenius Biotech GmbH is a globally operating company dedicated to delivering biopharmaceutical treatment options in oncology and transplantation medicine. A focal point of activity is the development and commercialization of immunologically active biopharmaceutical therapeutics based on innovative antibody technologies. The company currently has two drugs on the market: Removab in Oncology and ATG Fresenius-S in solid organ and stem cell transplantation. Fresenius Biotech GmbH is a subsidiary of the Fresenius SE healthcare group. For further details please visit www.fresenius-biotech.com. further Keywordlist: Antibody Therapy, Oncology, Malignant Ascites, Transplantation, GvHD, Stem cell, Immune Therapy, Biopharmaceutical Therapy.

FRIZ Biochem Gesellschaft für Bioanalytik mbH

BIOTECH DEVICES & REAGENTS

Keywords: Chip/Array Technology, Infectious Diseases, Devices, Clinical Diagnostics

FRIZ Biochem develops and produces highly reliable user-friendly and inexpensive biochip systems for applications in medical diagnostics, food testing and pharmaceutical research. Key products are DNA-chips with direct electrical read-out where SNPs (single nucleotide polymorphism) can unambiguously be detected and time-consuming labeling of the target-DNA is no longer necessary. This enables a broad range of simple and fast analyses making the system ideal for biological medical studies. The company's proprietary combination of micro arrays, electrical detection and semiconductor technology opens the way to compact multiplex analyses directly at a PC without the expensive instrumentation commonly needed.

GE Healthcare Europe GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Fine Chemicals/Reagents, Devices, Analytical Chemistry, Genomics, Proteomics

GE Healthcare Life Sciences provides a broad range of products and services for biomolecule separations at all scales.

Chief products include:

- ÄKTAdesign™ chromatography systems and BioProcess™ media
- Filtration systems and devices
- Wave Bioreactor™ and mixers
- Cell separation for isolating and purifying cells, viruses, and sub-cellular particles
- FastTrak™ BioPharma Services.

Our products are used in the manufacture of the majority of all FDA-approved biopharmaceuticals on the market. GE Healthcare Life Sciences is a part of GE Healthcare, a General Electric company with more than 42,000 employees, providing transformational medical technologies that are shaping a new age of patient care.



Contact:
Thomas Kratzmüller

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 72 44 09-0
Fax: +49 (0) 89 72 44 09-10
E-Mail: info@frizbiochem.de
Internet: www.frizbiochem.de



GE imagination at work

Contact:
Michael Kaleja

Oskar-Schlemmer-Str. 11
D-80807 München
Phone: +49 (0) 89 96281-0
Fax: +49 (0) 89 96281-679
E-Mail: michael.kaleja@ge.com
Internet: www.gelifesciences.com



Contact:
Bernd Merkl

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 94276-0
Fax: +49 (0) 941 94276-711
E-Mail: geneart.info@lifetech.com
Internet: www.lifetechnologies.com



Contact:
Dr. Peter Haberl

Lena-Christ-Str. 50
D-82152 Martinsried
Phone: +49 (0) 89 4581901-0
Fax: +49 (0) 89 4581901-5
E-Mail: peter.haberl@genedata.com
Internet: www.genedata.com



Contact:
Dr. Hildegard Haas

Schwanthalerstr. 60
D-80336 München
Phone: +49 (0) 89 543448-0
Fax: +49 (0) 89 543448-20
E-Mail: info@genedia.de
Internet: www.genedia.de

GeneArt AG

BIOTECH

Keywords: Genomics, Combinatorics, Synthetic Biology

Since entering the Gene Synthesis market in 2000 GeneArt has established as the global market leader. GeneArt provides key technologies for Synthetic Biology projects for example for the construction of bacteria which produce complex biopolymers such as biofuels or organisms which degrade environmental toxins. Furthermore the company contributes key technologies necessary to develop and produce new therapeutics and vaccines. Customers also rely on GeneArt services to improve enzymes, such as the ones used as additives in detergents. GeneArt was awarded the worldwide largest gene synthesis contract for the completion of the "Mammalian Gene Collection (MGC) Program" by the U.S. National Institutes of Health (NIH). In addition, GeneArt produced subgenomic elements for the construction of the first synthetic bacterial genome by the J. Craig Venter Institute. Since December 2010 GeneArt AG is a 100% subsidiary of the U.S.-American Life Technologies Corporation.

Genedata Bioinformatik GmbH

BIOTECH BIOINFORMATICS

Genedata is a bioinformatics company that specializes in developing software systems for the comprehensive analysis of genomes, transcriptomes, proteomes, metabolomes, and biochemical compounds. By working closely with key partners, the company combines its extensive product portfolio with expert scientific consulting services to offer tailor-made solutions for specific applications and multiple therapeutic areas. The company's solutions are key for moving the focus of life science research from high-throughput data acquisition to high-content data interpretation. Founded in 1997 as a spin-off from Novartis, the company is headquartered in Basel (Switzerland) with branch offices in Munich (Germany), San Francisco (USA), Boston (USA), and Tokyo (Japan).

Genedia AG

BIOTECH SERVICES AND PRODUCTS

Keywords: Biotech DNA/Protein Analytics, Medicinal Chemistry, Genomics, Antisense/Nucleotides

Genedia AG Biotec Services and Products is a provider of DNA testing services including private DNA paternity testing, legal DNA paternity testing as well as other relationship testing services (full or half sibling testing, grandparents testing, aunt or uncle testing, 1st cousin testing, maternity testing as well as twin testing). An other area is DNA genealogy and antropology, which includes ancestral origin DNA population test, Y-Chromosome Analysis, mt-DNA analysis. The forensic area includes DNA identification and banking services forensic testing services especially stain analysis. DNA molecular testing of diseases (Factor V and II, MTHFR, CFTR-Mutation). DNA testing of animals.

Genelux GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Immune Therapy, Drug Delivery, Clinical Diagnostics, Drug Development

Genelux Corporation, San Diego, CA (www.genelux.com) has been founded in 2001. Its focus is the exploration of the potentials of innovative recombinant oncolytic Vaccinia Viruses for therapeutic and diagnostic applications, opening a new area of anti-cancer strategies. A first product is in clinical trials in the UK, in Germany and in the USA. Genelux GmbH, Bernried, Germany, has been founded mid 2004. Its focus is process development and manufacturing of the viruses and the development of in process and quality control assays and companion diagnostics.

Genetic ID (Europe) AG Labor für gentechnische Analysen

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: ELISA/EIA, Genomics, PCR, , Laboratory, Transgenic Plants, Agrobiotechnology

Genetic ID is a global leader in testing for the presence of genetically modified organisms (GMOs) in food and agricultural products. In addition Genetic ID also offers Allergen screening. Founded in 1996, Genetic ID Inc. maintains global headquarters in USA, as well as premier testing laboratories in Japan and Germany, offices in Brazil, and the Global Laboratory Alliance of affiliated laboratories and representatives spanning five continents. We develop technologies that address all aspects of the GMO-testing segment and provide all clients with the technology, services and information they need to operate in the increasingly high-tech global marketplace.

GeneWake GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Genomics, Oncology, Clinical Diagnostics, Pharmacogenomics

GeneWake is a pharmacogenomics company focussed on biomarker analysis for the field of oncology. Proprietary bioinformatical algorithms based on the company's thorough knowledge in oncology pathways enable high quality detection of new biomarkers. GeneWake realizes a personalized cancer treatment by offering targeted expression analyses of relevant biomarker panels or single biomarkers in tumor tissue and circulating tumor cells for patient stratification or therapy tracking. Additionally, GeneWake provides the development of innovative diagnostic kits or molecular techniques and services like next generation sequencing, mutation detection, SNP genotyping, multiplex PCR and immunohistology.



Contact:
Dr. Albert Röder

Am Neuland 1
D-82347 Bernried
Phone: +49 (0) 8158 9223-0
Fax: +49 (0) 8158 9223-35
E-Mail: a.roeder@genelux.de
Internet: www.genelux.de



Contact:
Dr. Elke Müller

Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 747 76-30
Fax: +49 (0) 821 747 76-39
E-Mail: info-europe@genetic-id.com
Internet: www.genetic-id.de



Contact:
Dr. Robert Löwe

Floriensbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 74419-166
Fax: +49 (0) 89 74419-164
E-Mail: info@genewake.com
Internet: www.genewake.com



Contact:
Dr. Korbinian Grote

Bayerstr. 85a
D-80335 München
Phone: +49 (0) 89 599766-0
Fax: +49 (0) 89 599766-55
E-Mail: info@genomatix.de
Internet: www.genomatix.de



Contact:
Jennifer Neugebauer

Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 89 899890-0
Fax: +49 (0) 89 899890-90
E-Mail: info@gilead-sciences.de
Internet: www.gilead.com



Contact:
PD Dr. Henning Gieseler

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 907056-78
Fax: +49 (0) 931 907056-79
E-Mail: info@gilyos.com
Internet: www.gilyos.com

Genomatix Software GmbH

BIOTECH BIOINFORMATICS

Keywords: Genomics, Devices, NGS, Informatics, Data Management and Biostatistics

Genomatix is one of the world's leading suppliers of technologies to analyze and interpret genomic data. As well as laying the groundwork for microarray experiments and NGS data sequencing analyses, our hardware, software & service solutions help answer the typical questions posed by systems biology. Our approach: combine multiple lines of evidence to perform an integrated meta-analysis. Instead of looking at single strands of information separately, we access an exceptionally large pool of data from different sources. This wealth of data is continually expanding, so it is continually up to date. This meta-analysis leads to more relevant results, more precise scientific knowledge and a better chance of understanding the molecular contexts of gene regulation and expression. Genomatix was finalist in CLARITY-contest 2012.

Gilead Sciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Gilead Sciences is dedicated to providing accelerated solutions for patients and the people who care for them. The evolution of Gilead - from a promising biopharmaceutical company to a leader in the international development and commercialisation of medicines for life-threatening infectious diseases (viral, fungal and bacterial infections) - is testament to what the company has achieved through disciplined science, visionary thinking and diversified planning. Gilead's headquarter is based in Foster City, California with additional operations in San Dimas, California. Sales and marketing organisations are located in the following cities: Athens, Greece; Cambridge, UK; Lisbon, Portugal; Madrid, Spain; Istanbul, Turkey; Munich, Germany; Paris, France; Dublin, Ireland; Milano, Italy.

GILYOS GmbH

CRO

Keywords: Small Molecules, Peptide/Protein, Antibody, Nanobiotechnology, Drug Development

GILYOS is a research-oriented, highly specialized contract service partner in the field of pharmaceutical freeze-drying. Services include, but are not limited to, formulation development for pharmaceuticals (protein, peptide), freeze-drying cycle development, optimization of processes including Quality-by-Design and scale-up from laboratory to production. GILYOS offers a variety of analytical methods to fully characterize drug formulations (liquid and solid state), with special focus on the examination of the physicochemical properties of materials. Moreover, the company offers a full range of consulting services, including technical support for freeze-dryers and sales of equipment.

gimbio mbH Gesellschaft für Informationsmanagement in der Biotechnologie

BIOTECH BIOINFORMATICS

Keywords: Food Analytics

Since 2003 GIMBIO, Freising in the north of Munich, is successful in implementing and developing expert systems for optimization and monitoring of production processes. Our specific expertise helps global breweries to optimize production processes, i.e. filtration. We provide non-invasive analytics for large production fermenter.

GKM Gesellschaft für Therapieforschung mbH

CRO

Keywords: Clinical Trial Management, Statistical Planning, Medical Writing, Regulatory Services, Pharmacovigilance, Data Management, Study Conception, Site Recruitment

GKM Gesellschaft für Therapieforschung mbH is a privately owned full service Contract Research Organisation for planning and conducting clinical trials phase II-IV as well as for post-marketing-surveillances. Since 1981, GKM is a reliable partner for pharmaceutical, biotech and medical device companies. GKM provides flexible services with expert knowledge and dedication to your projects in accordance with ICH-GCP and other applicable national and international guidelines. More than 30 years experience: cost-effective quality combined with the latest standards and technologies.

GlaxoSmithKline GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

Keywords: Antibiotics, Vaccines, CNS, Dermatology, Oncology, Respiratory Diseases

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies with biotech developments in the area of vaccines and biopharmaceuticals.



Contact:
Markus Fellner

Lise-Meitner-Str. 30
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 986 4480
Fax: +49 (0) 8161 986 5661
E-Mail: info@gimbio.de
Internet: www.gimbio.de



Contact:
Dr. Christian Hautmann

Lessingstr. 14
D-80336 München
Phone: +49 (0) 89 209 120-0
Fax: +49 (0) 89 209 120-30
E-Mail: c.hautmann@gkm-therapieforschung.de
Internet: www.gkm-therapieforschung.de



Contact:
Claudia Kubacki

Prinzregentenplatz 9
D-81675 München
Phone: +49 (0) 89 360 440
Fax: +49 (0) 89 360 448000
E-Mail: service.info@gsk.com
Internet: www.glaxosmithkline.de



Contact:
Dipl.-Ing. Robert Grafina

Mühlfeld 9
D-83324 Ruhpolding
Phone: +49 (0) 8663 41800-0
Fax: +49 (0) 8663 41800-99
E-Mail: info@glucometrix.de
Internet: www.glucometrix.de



Contact:
Dr. Lars Ullerich

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 998 207 180
Fax: +49 (0) 89 998 207 188
E-Mail: info@gna-bio.de
Internet: www.gna-bio.de

Glucometrix Pharma Vertriebs- und Verwaltungsgesellschaft

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Chip/Array Technology, Devices, Drug
Development, Diabetics

KEY FIGURES

- GlucoMetrix AG was founded in 2001. It has 3 major subsidiaries that concentrate on different aspects of enhancing the quality of life for people suffering from diabetes.
- GlucoMetrix NIB GmbH develops medical devices for measuring blood sugar non-invasively, i.e. without puncturing the skin.
- GlucoMetrix PVS GmbH develops a new production method for insulin which promises a purer insulin with less side effects.
- GlucoMetrix Pharma VV GmbH develops, manufactures and markets medicinal products related to wound healing. These are particularly suited for diabetic wounds.

PRODUCTS AND TECHNOLOGIES

- Development of expression platforms for biomedical products and
- Development of downstream purification methods.
- BIOSept line of wound treatment products

MAJOR R&D TOPICS

- Opto-acoustical device to measure blood sugar non-invasively (in collaboration with ETH Zurich)
- Immunological assay to determine glycosylated serum proteins (POC-assay; in collaboration with FHI BMT)
- Genetic predisposition for diabetes mellitus
- Cost-effective production methods for human insulin

GNA Biosolutions GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Analytical Chemistry, Devices, Clinical Diagnostics,
Nanobiotechnology

GNA Biosolutions is a spin-off from the Institute for Photonics and Optoelectronics at the University of Munich, and was incorporated in 2010. Founders and managing directors of GNA are Dr. Joachim Stehr (head of research), Dr. Federico Bürgens (finances and hardware development), and Dr. Lars Ullerich, MBR (biotechnology and business development).

Harrison Clinical Research Deutschland GmbH

CRO

Keywords: Pain, Oncology, Nephrology, Metabolic Diseases, CNS, Cardiovascular Diseases

Harrison Clinical Research is an independent ISO 9001 certified CRO founded in 1987 in Munich with offices in UK, Belgium, Israel, Spain, Italy, France, Austria, Poland, Ukraine, Russia, USA and partners in Asia and Australia. Our team comprises more than 300 research professionals. We offer all services required for the clinical development and registration of new pharmaceutical products/medical devices: International project management, monitoring, data management, statistics, medical writing, auditing, training and outsourcing. Apart from conduct of standard Phase I studies, our Phase I/IIa clinic is specialised on proof-of-concept studies in special patient populations and efficacy studies in various indications. For more information please visit www.harrisonclinical.com. In 2013 HCR has merged with Synteract to build SynteractHCR, refer to: <http://www.synteracthcr.com>

Haupt Pharma AG

CMO

Keywords: Full service contract development and manufacturing, clinical trial supply services, cytotoxics, hormones, lyophilization, high-potency APIs

With nine production sites in Germany, France, Italy and Japan and a representative office in the USA, Haupt Pharma is one of the leading contract developers and manufacturers in Europe. With our full service, which covers pharmaceutical development, materials procurement, commercial production, packaging and distribution, we will manage important sections of your value chain.

Haupt Pharma provides a technology that covers most pharmaceutical dosage forms, with a special expertise in sterile products and lyophilized formulations. In addition to conventional APIs, we handle cytostatics, hormones, beta-lactam antibiotics and controlled drugs.

Apart from pharmaceuticals (ethical and OTC), our portfolio includes veterinary medicinal products, dietary supplements and cosmetics. We serve regulated markets worldwide, with a particular focus on Europe, USA and Japan.

More than 200 customers, among them many global players, rely on Haupt Pharma's manufacturing, development and clinical trial supply services.

Haupt Pharma Amareg GmbH in Regensburg/Bavaria is the production site for solid dosage. This location is also successful development partner for many international companies.

Harrison
Clinical
Research

Harrison

Contact:
Herbert Schwab

Albrechtstr. 14
D-80636 München
Phone: +49 (0) 89 126680-0
Fax: +49 (0) 89 126680-2444
E-Mail: Herbert.Schwab@synteracthcr.com
Internet: www.harrisonclinical.com



Contact:
Christian Schmitt

Pfaffenrieder Str. 5-7
D-82515 Wolfratshausen
Phone: +49 (0) 8171 414 150
Fax: +49 (0) 8171 414 109
E-Mail:
Christian.Schmitt@haupt-pharma.de
Internet: www.haupt-pharma.de



Contact:
Dr. Dr. Stefan Bertsch

Professor-Messerschmitt-Str. 3
D-85579 Neubiberg
Phone: +49 (0) 89 6008761-0
Fax: +49 (0) 89 6008761-24
E-Mail: bertsch@hematris.de
Internet: www.hematris.de



Contact:
PD Dr. Bernhard Kreymann

Agnes-Pockels-Bogen 1
D-80992 München
Phone: +49 (0) 89 4111842-0
Fax: +49 (0) 89 4111842-09
E-Mail: info@hepawash.com
Internet: www.hepawash.com



Contact:
Kurt Martin

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 89 95001711
Fax: +49 (0) 89 9612087
E-Mail: Kurt.Martin@hepacult.de
Internet: www.hepacult.de

Hematris Wound Care GmbH

MEDTECH

Keywords: Devices

Hematris Wound Care GmbH develops, manufactures and markets products in the area of wound care. Our major initial focus is the marketing of hemostatic products to control bleeding. We are experts in the field of hemostasis and wound healing. Our vision is to build up an attractive company together with our investors in this business area.

Hepa Wash GmbH

MEDTECH

Keywords: Hepatology, Devices

Hepa Wash GmbH is a medical device company dedicated to the development, production and marketing of a new liver and/or kidney support device for the treatment of patients with life-threatening liver and/or kidney disease. Main features of the Hepa Wash® extracorporeal technology are its highly efficient albumin dialysis and its innovative albumin regeneration circuit. The technology proves to be several times more effective than currently available alternatives and has the potential to significantly increase the survival rates in liver patients. The company has established an ISO 13485 certified quality management system regarding the development, production and marketing of the device and the necessary fluids. The CE-certificate of the device and the MDD Annex II.3 certificate of the company are expected in May 2013. Hepa Wash plans its European market introduction for the middle of 2013.

hepacult GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Analytical Chemistry, Drug Development, Tissue Engineering/Cell Culture, Toxicology

hepacult develops and markets cell culture technology based on human liver cells and other human organs. The cell culture technology is used to prognose the metabolism of novel drugs and for the in vitro simulation of liver dysfunctions. With their cutting edge cell and tissue products hepacult provides to the scientific community and pharmaceutical industry an outstanding in vitro test system coming close to the human in vivo conditions. Animal experiments can be replaced to a large extent. Results gained during the preclinical stage with hepatocytes show a better prognostic value. Partially even the cost-intensive clinical experiments on humans and related risks to humans can be reduced.

Hexal AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Peptide/Protein, Pharmacokinetics, 3D-Structural Analysis

HEXAL is the leading German generic manufacturer and belongs to the worldwide Sandoz Group with its headquarters in Holzkirchen, Bavaria. HEXAL brings biosimilars to the German market. Biosimilars are highly-differentiated products, based on very complex biological molecules. Biologics, or biopharmaceuticals, are medicines produced from living organisms using biotechnology techniques. Many biologics are recombinant proteins and are manufactured using "recombinant DNA" technology, a process that involves inserting a specific gene into a host cell to produce a particular protein. These complex state-of-the-art molecules represent a distinct regulatory class of medicine compared to "traditional", chemically synthesized medicines. In Germany HEXAL employs more than 4.000 people at six sites. The company was founded in 1986 and merged with Sandoz in 2006.

HolsboerMaschmeyer NeuroChemie GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Biomarker Discovery & Development, Laboratory, Personalized Medicine, Medicinal Chemistry, Drug Development

HolsboerMaschmeyer NeuroChemie GmbH is a Munich-based biotech company specialised in research and development of new drugs against depression and anxiety disorders, that was founded in December 2010. The company utilizes research results for the development of new chemical structures which then become specifically acting drugs. Laboratory tests developed by HolsboerMaschmeyer NeuroChemie GmbH identify the specific disease mechanism of the affected patient and thus allow an individual therapy. The combined application of laboratory tests and specific drugs improves the quality of the therapy: duration of disease is shortened for the benefit of patients and the savings for the health care system are considerable.



Contact:
Helmut Fabry

Industriestr. 18
D-83607 Holzkirchen
Phone: +49 (0) 8024 908-0
Fax: +49 (0) 8024 908-1290
E-Mail: service@hexal.com
Internet: www.hexal.de



Contact:
Prof. Dr. Dr. Dr. h.c. Florian Holsboer

Maximilianstr. 13
D-80539 München
Phone: +49 (0) 89 30 622 455
Fax: +49 (0) 89 30 622 483
E-Mail: info@hmnc.de
Internet: www.hmnc.de



Contact:
Ditte Heimberg

Am Forst 6
D-85560 Ebersberg
Phone: +49 (0) 8092 2092-0
Fax: +49 (0) 8092 2092-28
E-Mail: info@hti-bio-x.com
Internet: www.hti-bio-x.com



Contact:
Karolina Heed

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9060-0
Fax: +49 (0) 8158 9060-210
E-Mail: info@hyglos.de
Internet: www.hyglos.de

Hyperthermics

Contact:
Prof. Dr. Michael Thomm

Josef-Engert-Str. 9
D-93053 Regensburg
E-Mail: michael.thomm@biologie.uni-regensburg.de
Internet: www.hyperthermics.com

HTI bio-X GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Devices](#), [Automation](#)

HTI bio-X GmbH is an engineering supplier for products and technical service. We are developing customized solutions of instruments and automations. Our product portfolio covers e.g. consumables and instruments for DNA-synthesis. The biomagnetic workstation X-Tract facilitates magnetic beads applications. The main focus is a system of instruments and modules for the automation of laboratory processes. The X-TubeProcessor is based on the X-Capper for capping and of screw cap tubes. This device is expandable with many modules e.g. for labelling, barcode reading, filling reagents or powder into individual tubes or dispensing of reagents into all tubes. The X-TubeProcessor is usable for a wide range of tubes. The system will be combined with modules regarding to the market requirements.

Hyglos GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Clinical Diagnostics](#), [Peptide/Protein](#), [Infectious Diseases](#), [Proteomics](#)

Hyglos' core competency is to exploit the principles of bacteriophage biology and the expert use of the proprietary phage-protein technology for diagnostics, antimicrobial and research applications. Hyglos' products and services are supplied to well known pharmaceutical and biotech companies as well as research institutes. Hyglos product portfolio includes the endotoxin detection assays EndoLISA® & EndoZyme®, EndoTrap®, EndoGrade®, reagents for food diagnostics, Bacteria Capture Kits. Furthermore, Hyglos offers customized services using state-of-the-art technology; Endotoxin Detection Service, Endotoxin removal Service, From Gene to Protein Service. Hyglos GmbH is certified according to ISO 9001:2008 and ISO 13485:2003 + AC:2007.

Hyperthermics Regensburg GmbH

BIOTECH

Keywords: [Industrial Applications](#)

Hyperthermics Regensburg GmbH is a biotechnology company developing applications of hyperthermophilic organisms in renewable energy solutions and in industrial processes. In these applications hyperthermophilic micro-organisms are the "software". In the initial phase we are focusing on developing applications together with international industrial partners. In an operational phase we will focus our research activities towards "software development and update".

i.DRAS GmbH international Drug Regulatory Affairs Services

CONSULTANTS

Keywords: Drug Development, Analytical Chemistry, Medical Writing, Pharmacology, Toxicology, Regulatory Affairs, Devices

i.DRAS is a service provider for international drug regulatory affairs. i.DRAS offers support and services for human and veterinary medicinal products from the preclinical/early clinical development stages to the first submission of the MA dossier throughout post marketing activities, covering the whole product life cycle. Services provided cover CTAs and MAAs and all respective documentations to be filed (IB, IMPD, CTD, NtA) for new and established drug substances and the corresponding drug products, including herbal and biological/biotechnological medicinal products. If requested i.DRAS takes over the project management for complex projects with further partners who may be assigned through us or our clients. The same applies to border-line medicinal devices and such incorporating an ancillary drug substance.

I.M.N. International MED Network GmbH

CRO

Keywords: Regulatory affairs

I.M.N. is a leading internationally operating CRO with unmatched expertise and extensive experience in drug development and study management. I.M.N. provides end to end solutions for drug development including services of phase I to IV, regulatory affairs, consulting for drug development, medical writing, data management and statistics, quality assurance and pharmacovigilance.

ibidi GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Chip/Array Technology, Tissue Engineering/Cell Culture, Nanobiotechnology, Devices

ibidi develops, produces and distributes cell-culture biochips (μ -Slides) and devices for functional cell-based assays. An extensive line of μ -Slides and μ -Dishes offers solutions for immunofluorescence and basic cell culture, plus the following complex assays: angiogenesis, chemotaxis, wound healing, shear stress and flow. The company also specializes in instruments such as heating and incubation units, and a unique perfusion system that provides continuous flow for the simulation of blood vessels. The high optical quality of the μ -Slides allows microscopic cell investigations, using phase contrast or DIC, fluorescence and also confocal microscopy. The new F-actin marker LifeAct makes it possible to keep track of the development and movement of F-actin structures in living cells. All of the products are offered world-wide through a variety of distributors.



Contact:
Prof. Dr. Markus Veit

Fraunhoferstr. 18B
D-82152 Martinsried
Phone: +49 (0) 89 856536-50
Fax: +49 (0) 89 856536-66
E-Mail: info@i-dras.com
Internet: www.i-dras.com



Contact:
Cornelia Beier

Kopernikusstr. 9
D-81679 München
Phone: +49 (0) 89 41 42 48 89-99
Fax: +49 (0) 89 41 42 48 89-88
E-Mail: info@imn-network.com
Internet: www.imn-network.com



Contact:
Dr. Susanne Seifert

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 5204617-0
Fax: +49 (0) 89 5204617-59
E-Mail: sherzog@ibidi.de
Internet: www.ibidi.de



Contact:
Dr. Merold Müller

Lise-Meitner-Str. 30
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 2010301
Fax: +49 (0) 8161 9363876
E-Mail: info@ikinowo.com
Internet: www.ikinowo.com



Contact:
Christine Kraft

Bayerstr. 21
D-80335 München
Phone: +49 (0) 89 548844-0
Fax: +49 (0) 89 548844-143
E-Mail: ikkf@ikkf.de
Internet: www.ikkf.de



Contact:
Dr. Ralph Oehlmann

Lochhamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 89 8955784-0
Fax: +49 (0) 89 8955784-1
E-Mail: info@imgm.com
Internet: www.imgm.com

IKINOWO GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Chip/Array Technology, Aptamer Technology, Analytical Chemistry, Clinical Diagnostics, Oncology, Proteomics

The main goal of the *IKINOWO GmbH* is to develop diagnostic tools for human diseases and cell profiling concerned with ribonuclease, expression defects and codon usage. *IKINOWO GmbH* has been funded by the german government: Federal Ministry of Education and Research (BMBF) in the framework of the program "EXIST SEED" promoting business start ups from university research.

IKKF GmbH

CRO

Keywords: Devices, Data Management and Biostatistics, Cardiovascular Diseases, Clinical Trial Management and Monitoring

Specialist for Cardio-Vascular Research and e-Trial Management – Professional Research Services for: ■ Commercial sponsors (pharma industry & device companies) ■ Universities & academic hospitals (investigator sponsored trials) ■ Medical societies & public sponsors (health economic research, public research) ■ Health insurance companies (health economic projects)
Our Fokus: ■ Cardiovascular research ■ Medical device companies ■ Electronic Trial Management ■ Research networking
We offer: ■ Research services for controlled clinical trials of phase III + IV and for clinical registries ■ Project management Data management ■ Site management ■ Clinical monitoring ■ E-trial management system ■ Statistics and biometry ■ Tele-ECG services

IMG M Laboratories GmbH – your outsourcing partner for genomic services

BIOTECH

Keywords: PCR, Laboratory, Genomics, Chip/Array Technology, Pharmacogenetics

Munich based IMG M Laboratories offers advanced genomic services to customers from pharma, academia and biotech. IMG M is accredited according to DIN EN ISO/IEC 17025 and is a Certified Service Provider for Agilent (Microarrays), Ion Torrent (PGM) and Affymetrix (DMET Plus). IMG M offers first-class NGS services based on Roche 454, Ion Torrent and Illumina sequencing platforms. Metagenomics, HLA typing, pharmacogenetics, sequence detection and gene analysis expression are core components of our service portfolio. At IMG M, we combine state-of-the-art technology with complex data analysis to deliver meaningful results in an easy-to-understand format. For more information, please visit [www.imgm.com].

immatics biotechnologies GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Genomics, Proteomics, Peptide/Protein, Vaccines, Immune Therapy, Oncology

immatics biotechnologies is a clinical-stage biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer. immatics' lead product, IMA901 for renal cell carcinoma, completed Phase III patient recruitment in Nov. 2012. immatics' pipeline also includes IMA910, in Phase II for colorectal cancer, and IMA950 which is being developed for glioma. immatics' technology platform rapidly generates defined therapeutic cancer vaccines which are based on multiple tumour-associated peptides (TUMAPs) with the ability to specifically stimulate the immune system against cancer cells. These vaccines – comprising multiple peptides confirmed to be naturally presented by real tumour tissue - offer the prospect of greater effectiveness than existing cancer vaccine approaches. immatics' products are 'drug like' with stable, off-the-shelf formulations and robust easily scalable manufacturing. immatics is based in Tuebingen and Munich, Germany, and has raised EUR 108 million (US\$ 140 million) in private equity in three financing rounds.

Immumed GmbH Gesellschaft für angewandte Immunologie

BIOTECH PRECLINICAL SERVICES

Keywords: Laboratory, Inflammation, ELISA/EIA, Clinical Diagnostics

Applied Immunology – Testing Services

We offer testing services for human, mouse or rat samples:

- Analysis of cytokines, chemokines and phosphoproteins
- Cell-characterization
- Cell-separation
- Cytotoxicity

Our team is specialized in measuring multiplex-parameter analysis with Luminex-Technology in various samples like serum, cell cultures, saliva, urine. We perform every application for flow-cytometry analysis, for example cell phenotyping, intracellular cytokine detection or cytotoxicity assays as well as positive or negative selection of cells with magnetic-bead technology.



i m m a t i c s

Contact:
Dr. Carsten Reinhardt

Fraunhoferstr. 18 b
D-82152 Martinsried
Phone: +49 (0) 89 540415-0
Fax: +49 (0) 89 540415-905
E-Mail: info@immatics.com
Internet: www.immatics.com



Contact:
Wolfgang Mayer

Karlstr. 46
D-80333 München
Phone: +49 (0) 89 5432177-89
Fax: +49 (0) 89 5432177-92
E-Mail: info@immumed.de
Internet: www.immumed.de



Contact:
Dr. Matthias Reinhard

Rudolf-Diesel-Str. 8A
D-97267 Himmelstadt
Phone: +49 (0) 9364 810-610
Fax: +49 (0) 9364 810-613
E-Mail: info@immunoglobe.com
Internet: www.immunoglobe.com



Contact:
Erika von der Decken

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 8932811105
E-Mail: vonderdecken@immunoqure.com
Internet: www.immunoqure.com



Contact:
Martin Sahiri

Schatzbogen 52
D-81829 München
Phone: +49 (0) 89 7263718-0
Fax: +49 (0) 89 7263718-51
E-Mail: info@implen.de
Internet: www.implen.de

immunoGlobe Antikörpertechnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Antibody Production Service, Antibody

immunoGlobe® GmbH is a privately owned company, established in 1997.

Core competences are:

- Manufacturing of novel research antibodies,
- Full service custom antibody production and purification,
- Marketing of own and licensed antibodies through a global network of OEM partners, wholesalers, and distributors.

Specializations:

Through sophisticated schemes of immunization, affinity purification & depletion on multiple proteins or peptides immunoGlobe® has specialized in the generation of highly specific antibodies against:

- any combination of (de)phosphorylation states of neighboring double-phosphorylation sites
- neo-epitopes (e.g. cleavage sites)
- isoforms, variants, and point mutations

Epitope mapping services with single amino acid precision complete the service catalog.

ImmunoQure AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

ImmunoQure AG – rare natural antibodies derived from patients for patients. ImmunoQure AG is a young biotech company spearheading the research and development of human-derived antibodies (HD-MABs) for the treatment of human diseases. Through our unique access to rare patient populations, we are able to identify patients harboring naturally optimized antibodies against key drug targets that are involved in preventing a number of human diseases.

Implen GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Nanobiotechnology, Genomics, Chip/Array Technology, Automation, Devices

Implen is a privately held corporation that is a leading supplier for spectroscopy instruments and consumables for the non-destructive analysis of ultra low volume samples. The company focuses on biological, chemical, and pharmaceutical laboratories in industry and research.

Inamed GmbH

CRO

Keywords: Drug Delivery, Medical Writing, Respiratory Diseases

Inamed GmbH – "THE Respiratory CRO"

INAMED was founded in 1998 and is an experienced, independent, privately owned and managed CRO with its headquarters located at the periphery of Munich, and with its roots in basic research and clinical medicine.

We are an international contract research organization with true respiratory expertise. Complementing our solid experience in conducting clinical trials, INAMED's team of inhalation and clinical experts provides our sponsors with a unique spectrum of services. Besides our clinical trial operations at all phases of development and our fully staffed, in-house Phase I-IIa unit with twenty beds, INAMED performs in-vitro studies in our own labs and is the only CRO in continental Europe able and approved to perform radio-labeling studies. Our studies deliver the highest quality data and can enhance your clinical trials and development projects for drugs and inhalation devices. INAMED offers an opportunity for sponsors to get their products to market more successfully.

INC Research GmbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Vaccines, Inflammation, CNS, Oncology, Pharmacovigilance

INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The company's Trusted Process® methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. For more information, please visit www.incresearch.com.



Contact:

Patrick McManus

Robert-Koch-Allee 29

D-82131 Gauting

Phone: +49 (0) 89 89 35 69 0

Fax: +49 (0) 89 89 35 69 22

E-Mail: request@inamed-cro.com

Internet: www.inamed-cro.com



Contact:

Birgit Pöckl

Stefan-George-Ring 6

D-81929 München

Phone: +49 (0) 89 993913-0

Fax: +49 (0) 89 993913-160

E-Mail: muc.info@incresearch.com

Internet: www.incresearch.com



Contact:
Hedi Sperling

Dachauer Str. 6
D-85254 Einsbach
Phone: +49 (0) 8135 8333
Fax: +49 (0) 8135 8320
E-Mail: infors.de@infors-ht.com
Internet: www.infors-ht.com



Contact:
Prof. Toni Lindl

Balanstr. 6
D-81669 München
Phone: +49 (0) 89 48777-4
Fax: +49 (0) 89 48777-2
E-Mail: info@I-A-Z-zellkultur.de
Internet: www.I-A-Z-zellkultur.de

Infors GmbH

BIOTECH DEVICES & REAGENTS

INFORS HT is your specialist for bioreactors, incubation shakers and bioprocess control software. You benefit from sophisticated systems, in which your cell lines or microorganisms develop their full potential in a reproducible way, thus contributing to your success. For your applications, we offer the right solutions:

- Fermentation of microorganisms (bacteria, fungi and yeasts)
- Cell culture (mammalian cells, insect cells, plant cells and algae)
- Biofuel (biodiesel and bioethanol)
- Parallel bioprocesses
- Custom-made bioreactors and incubation shakers
- Bioprocess control software
- Qualification of bioreactors and incubation shakers

Closeness to the customer, high quality, innovation and flexibility are our greatest strengths.

Institut für angewandte Zellkultur Dr. Toni Lindl GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Antibody Production Service](#), [Tissue Engineering/Cell Culture](#)

The Institut für angewandte Zellkultur Dr. Toni Lindl offers services in the area of cell culture and tissue culture, training in cell culture work, distribution of cell lines, consulting in cell culture, molecular biology, genetic engineering and development of monoclonal antibodies and in vitro processes. The core competences cover cell culture services and genetic engineering with a product range of recombinant human interleukin-2 and human monoclonal antibodies against rabies. Partnerships are sought with university research institutes in immunology and virology, where know-how in cell culture and in vitro technologies can be transferred.

Institut Virion\Serion GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Automation, Respiratory Diseases, Infectious Diseases, Autoimmune Diseases, ELISA/EIA, Clinical Diagnostics

Institut Virion\Serion GmbH is a German in-vitro diagnostic company with more than 30 years of experience in the international market. The extensive high-quality product portfolio for the diagnosis of infectious diseases contains SERION ELISA classic tests recommended for quantified antibody detection in human serum, plasma, and, if necessary, in cerebrospinal fluid, against various viral, bacterial, fungal and parasitic infections. SERION ELISA antigen tests enable a direct antigen detection of pathogens. Our Complement Fixation Tests are featuring more than 50 different antigens. The latest developments of our particle-based SERION Multianalyt™ products allow simultaneous antibody detection against multiple antigens using flow cytometry. Parallel to immunoassays we have introduced the Immunomat™ for automated processing and analysis of SERION ELISA classic and SERION ELISA antigen tests.

Intana Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Microscopy, Antibody, Peptide/Protein, Small Molecules

Intana Bioscience GmbH, founded 2008, is a privately owned service provider company. Understanding the selectivity profile and the binding characteristics of a candidate drug has been shown to be essential for downstream optimization. Intana Bioscience GmbH offers interaction analysis based on a single molecule sensitive spectroscopic approach called fluorescence cross correlation spectroscopy (FCCS). FCCS can be applied in cellular lysates to determine the binding and rate constants of biomolecular interaction and represents a highly efficient approach to develop selective inhibitors for targeted therapies. Customers benefit from short assay development time, in depth interaction analysis and assay conditions that mimic the natural environment of a drug.



virion\serion

Contact:
Saba Goytom

Friedrich-Bergius-Ring 19
D-97076 Würzburg
Phone: +49 (0) 931 3045-0
Fax: +49 (0) 931 3045-100
E-Mail: dialog@virion-serion.de
Internet: www.virion-serion.de



Contact:
Dr. Frank Becker

Lochhamer Str. 29 a
D-82152 Martinsried
Phone: +49 (0) 89 895572-80
Fax: +49 (0) 89 895572-81
E-Mail: info@intana.de
Internet: www.intana-bioscience.de

INTERLAB

central lab services – worldwide

Contact:

Dr. Hermann Schulz

Bayerstr. 53

D-80335 München

Phone: +49 (0) 89 741393-0

Fax: +49 (0) 89 741393-39

E-Mail: info@INTERLAB.de

Internet: www.INTERLAB.de



Contact:

Dr. Thomas Bruckdorfer

Waldershofener Str. 49–51

D-95615 Marktredwitz

Phone: +49 (0) 9231 9619-73

Fax: +49 (0) 9231 9619-99

E-Mail: info@iris-biotech.de

Internet: www.iris-biotech.de



Contact:

Christian Wiest

Ingolstädter Landstr. 1

D-85764 Neuherberg

Phone: +49 (0) 89 3187-3973

Fax: +49 (0) 89 3187-4170

E-Mail: christian.wiest@ithera-medical.com

Internet: www.ithera-medical.com

INTERLAB GmbH

central lab services – worldwide

CRO

Keywords: ELISA/EIA, PCR, Logistics, Clinical Diagnostics, Analytical Chemistry, Drug Development

INTERLAB is an independent central laboratory supporting clinical trials for pharmaceutical and biotechnology companies covering Europe, North and South America, Australia, Africa and Asia. The international head office is in Munich, Germany. INTERLAB performs routine and esoteric testing on a daily basis: over 15.000 samples daily: clinical chemistry, hematology, endocrinology, genetics, PCR, microbiology, virology, immunology, serology, histopathology, cytology, toxicology, drug assays, incl. LC-MS/MS. Additional services: professional project managers, flexible data management and transfer, cost-effective shipment logistics worldwide, extended sample storage at -20°C, -70 or 80°C, rental or sale of centrifuges and freezers. EN 45,000, ISO 9001 and EC/ISO/EN 15189 (17025).

Iris Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Peptide/Protein, Drug Development, Drug Delivery, Medicinal Chemistry, Combinatorial Chemistry, Natural Compounds

1. Starting materials for peptide synthesis, peptidomimetic and medicinal chemistry: protected amino acids, coupling reagents, linkers and resins, natural and unusual amino acids and natural compounds with physiological properties.
2. Technologies for Drug Delivery: more than 900 different carriers used in polymer therapeutics products (PEGylating reagents, PASylation, PGA Poly(glutamic acid) and multi-functional dendrimers).
3. Reagents for Life Sciences and Diagnostics: substrates, inhibitors, cross-linker, immunologic tools, carbohydrates, dyes and fluorescent labels.
4. We carry out custom synthesis in all areas above. Our strengths are compounds with one or several chiral centers.

iThera Medical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Drug Development, Devices, Cardiovascular Diseases, Inflammation, Oncology

iThera Medical develops and markets a novel in-vivo biomedical imaging technology, "MSOT" = multi-spectral opto-acoustic tomography. MSOT utilizes the photo-acoustic effect to visualize and quantify anatomical, functional and molecular information of living tissue. Today, MSOT allows the early and reliable validation of new substance efficacy in drug discovery (e.g., for oncology, neurology and cardiovascular problems). For the future, MSOT also promises to become a valuable tool for clinical diagnostics.

ITM Isotopen Technologien München AG

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Chip/Array Technology, Automation, Devices, New Materials, Drug Delivery, Drug Development

The ITM Group is a leading pharmaceutical company for the development, production and worldwide distribution of highly effective radionuclides for diagnostics (soon to be GMP-certified) and therapy (GMP-certified since 12/2011). Its commitment to bringing exclusive next-generation radionuclide concepts and advanced medical devices to patients, has been successfully achieved in the treatment of neuroendocrine tumors, skin cancer and end-ovascular therapy. Strengthening its portfolio with the development of targeted radiodiagnostics and radiotherapy, while at the same time further expanding the esteemed network of strategic partnerships, investigating small peptidic binding molecules for co-development into clinical phase, is ITM's number one priority in order to remain the provider of choice in radionuclide technology. Headquartered on the premises of the elite Technical University of Munich TUM and next door to the novel FRM II – one of the most modern neutron source in the world – this high-tech environment provides the ITM Group with the ideal setup to drive forth radionuclide technologies. A state of the art GMP Labeling Platform and sophisticated radiopharmaceutical supply chain management contribute to the success. The ITM AG and its subsidiaries ITG GmbH, ITM OncoBeta GmbH and ITM RP Munich GmbH are renowned for their excellence and precision in R&D and production, as well as their unprecedented reliability and flexibility in terms of offering global logistic services and customer care, 365 days a year.

Kantar Health GmbH Clinical Research

CRO

Keywords: Regulatory Affairs, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Medical Writing, Oncology, Pharmacovigilance, Logistics

Kantar Health GmbH Clinical Research conducts phase I-IV clinical trials, retrospective and prospective non-interventional studies, patient reported outcomes and pharmacoeconomic studies. Our operations span local agencies in over 45 countries worldwide. Kantar Health combines more than 30 years of CRO expertise in drug research including development of innovative web-based applications (InTrial® and InDrugs®). Our services include: protocol and CRF design, eCRF solutions, feasibility and site selection, investigators training, handling of legal and ethical requirements, monitoring and site management, project management, implementation of risk management programs, data management, medical coding, pharmacovigilance, quality assurance, statistical planning and analysis, medical writing.



Contact:
Dr. Richard Henkelmann

Lichtenbergstr. 1
D-85748 Garching
Phone: +49 (0) 89 289-13908
Fax: +49 (0) 89 289-13929
E-Mail: info@itm.ag
Internet: www.itm.ag

KANTAR HEALTH

Contact:
Susanne Faber

Landsberger Str. 284
D-80687 München
Phone: +49 (0) 89 5600-1280
Fax: +49 (0) 89 5600-1590
E-Mail:
mercedes.apecechea@kantarhealth.com
Internet: www.kantarhealth.com



Contact:
Dr. Klaus Hellmann

Geyerspergerstr. 27
D-80689 München
Phone: +49 (0) 89 580082-0
Fax: +49 (0) 89 580082-77 77
E-Mail: info@klifovet.com
Internet: www.klifovet.com



Contact:
Dr. Michael Miller

Ferdinand-Zwack-Str. 39
D-85354 Freising
Phone: +49 (0) 08161 205957
E-Mail: info@kmbioservices.de
Internet: www.kmbioservices.de



Contact:
Dr. Elisabeth Müller

Steubenstr. 4
D-97688 Bad Kissingen
Phone: +49 (0) 971 7202-0
Fax: +49 (0) 971 68546
E-Mail: mueller@laboklin.de
Internet: www.laboklin.com

KLIFOVET AG

CRO

Keywords: Regulatory Affairs, Medical Writing, Clinical Trial Management and Monitoring, Data Management, Pharmacovigilance, veterinary clinical trials

KLIFOVET is the provider of high quality services for the Animal Health and Animal Nutrition Industry regarding the registration and marketing of all kind of veterinary products. Full business and product development management, regulatory affairs including dossier writing, compilation and submission, full CRO services for safety and efficacy studies in all animal species is our business. We handle EU, US or other projects with our dedicated partners. 15 years of experience, well organized logistics, a highly motivated team, a comprehensive net of co-operators and skilled investigators throughout Europe, North America and other continents. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA or FDA standards.

kmbs

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, PCR

kmbs is your service partner for organismic studies e. g. in Conservation Biology, Zoology, Phylogeny, Taxonomy, and Molecular Biology to clear up specimens' identities by means of molecular/genetic analyses (Sample preparation, PCR, DNA sequencing, Gene Fragment analysis) for purposes like resolving species relationships, detecting sibling species, delimiting species boundaries, investigating population structure and integrity, a.s.o. In addition, we are experienced in making microscopic preparations, carrying out outdoor services like mapping species inventories or searching for special organisms within a given habitat including the collection of organisms on demand, and acting as project manager and consultants.

Laboklin GmbH & Co KG – Unternehmensbereich Labogen

BIOTECH THERAPEUTICS & DIAGNOSTICS

Our laboratory provides a complete testing service for veterinary surgeons to meet the diagnostic needs of your practice. You can find all important information and our laboratory profiles and screens (microbiology, haematology, allergy, pathology and genetic testing). Furthermore you can download submission forms or order sample collection material. If you are registered you are able to locate your samples, the stage of investigation and much more.

Labor Friedle GmbH

BIOTECH ANALYTICS & DIAGNOSTICS

Our modern service center is located in Tegernheim, South Germany. The employees of our lab are dedicated to provide you with information and quality results. Our wide array of laboratory services include food testing, pesticide residue analysis, microbiology, indoor air diagnostics and environmental testing. We provide a wide spectrum of analytical services for the German and international market. A solid and reliable service, attention to timely delivery of test results, flexibility towards your needs, and trustworthy customer relations are the basis of our company ethics.

Labor L+S AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Medicinal Chemistry, Allergy, Clinical Diagnostics, Laboratory, Analytical Chemistry

Labor L+S AG is a service provider who understands the language of the future: Achievement, service, quality. With L+S AG there is no separation from advisors and practitioners. More than 900 customers from the pharmaceutical, cosmetics, food and feed industry trust our know-how. Our range of services: Microbiological, molecular-biological, biological, chemical and physicochemical tests of pharmaceuticals, medicinal products, food and feed, cosmetics as well as related raw materials and intermediate goods, Industrial hygiene, Clinical-microbiological diagnostic as well as diagnostic of food intolerances and allergies. In our state of the art laboratory (5100 sqm) 350 employees carefully handle more than 240.000 samples/year.

LabPMM GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

LabPMM GmbH is an ISO 15189 compliant reference laboratory based in the South of Munich, Germany focused on Personalized Molecular Medicine and Personalized Molecular Diagnostics for customers throughout Europe. LabPMM is the only reference laboratory licensed to perform testing for FLT3 and NPM1 mutations – these are the most important prognostic biomarkers for karyotype normal AML. Current WHO guidelines include assessment of FLT3 mutation status as a "standard of care" in treatment of acute myeloid leukemia.



Contact:
Albrecht Friedle

Im Gewerbebark D22
D-93059 Regensburg
Phone: +49 (0) 941 2086590
Fax: +49 (0) 941 20865920
E-Mail: info@labor-friedle.de
Internet: www.labor-friedle.de



Contact:
Dr. Frank Böttcher

Mangelsfeld 4, 5, 6
D-97708 Bad Bocklet-Großenbrach
Phone: +49 (0) 9708 9100-520
Fax: +49 (0) 9708 9100-36
E-Mail: timo.krebsbach@labor-ls.de
Internet: www.labor-ls.de

LabPMM

Contact:
Niels Adams

Bunsenstr. 7a
D-82152 Martinsried
Phone: +49 (0) 89 899480780
E-Mail: nadams@labpmm.de
Internet: www.labpmm.de



Contact:
Dr. Franz Kelnhofer

Am Haag 4
D-82166 Gräfelfing
Phone: +49 (0) 89 858967-0
Fax: +49 (0) 89 858967-111
E-Mail: info@lat-gmbh.de
Internet: www.lat-gmbh.de

leon-nanodrugs
leading edge nanodrugs®

Contact:
Dr. Wolfgang Beier

Kopernikusstr. 9
D-81679 München
Phone: +49 (0) 89 41 42 48 89-0
Fax: +49 (0) 89 41 42 48 89-88
E-Mail: w.beier@leon-nanodrugs.com
Internet: www.leon-nanodrugs.com

LAT GmbH Dr. Tittel Institut für Pharma-Analytik

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Laboratory, Analytical Chemistry, Small Molecules

LAT is a well equipped, state-of-the art service provider with 35 years of experience in the pharmaceutical industry. Main analytical focus of the company is gas and liquid chromatography, mass spectrometry and capillary electrophoresis as well as development of tests for in-vitro in-vivo correlation. All analytical work is embedded in a long-term experience of all aspects of regulatory affairs (CTD, eCTD, IMPD, ASMF/US-DMF).

leon-nanodrugs GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Small Molecules, Peptide/Protein, Antisense/Nucleotides, Antibody, Nanobiotechnology, Drug Delivery, Drug Development

leon-nanodrugs is a specialized contract drug development company providing its clients with nanotechnology-based reformulations of established oral and parenteral drugs. More than 70% of all marketed drugs are poorly soluble in water and often show a low membrane permeability in parallel, limiting their oral bioavailability. These problems can be solved by using our innovative, proprietary and patented MJR-Technology. By "downsizing" the APIs into the "nanoscale" we increase the solubility and the dissolution rate of the given API without violating the chemical integrity of the API, which is very important for regulatory reasons (no toxicology!).

With the MJR-Technology we can process small molecules, peptides, hormones and proteins. Our approval strategy meets the requirements of an ANDA, NDA (505) b (2) (FDA) or hybrid approval (EMA). From concept to submission for approval we execute our projects within an average time of 36 to 48 months. Based on our "network of expertise" we are able to provide a 360 degree service range – from concept to market launch incl. GMP-manufacturing any size. Each of our reformulation projects is covered by an API-specific formulation patent. After drug approval, the complete IP is transferred to the client, whereas leon-nanodrugs gets royalties after approval.

LEUKOCARE AG

BIOTECH DEVICES & REAGENTS

Keywords: Stabilization and Protection of Biologicals, Formulation Technologies, Proteins, Vaccines, Combination Devices

LEUKOCARE provides proprietary formulation technologies and related development services for stabilization and protection of biologics. LEUKOCARE technologies are employed in collaborations with partners in the field of vaccines, therapeutic proteins, and biologic device combination products. LEUKOCARE provides development services based on fee for service during implementation of its technologies. LEUKOCARE's technologies provide manifold benefits:

- Improved shelf-life / stability / quality
- Terminal sterilization of biologics
- Significant production cost savings.

LISANDO GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Lysando is a manufacturer of medical devices. Lysando AG and the R&D centre Lisando GmbH are owned by the TGI Group, which is specialised in environmentally supportive technologies and manufacturing. In 2010 our team received the Food Safety Innovation Award for a novel method to detect bacterial contamination in food. In October 2012 LYSANDO AG has been rated with the best rating possible by Dun&Bradstreet. Lysando cooperates with various Universities and Institutes in Europe, Thailand, Japan and United States of America.

LivImplant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Inflammation, Bone/Joint Diseases, Cell Therapy, Tissue Engineering/Cell Culture

LivImplant GmbH develops and sells innovative cell based therapies for lesions and diseases of tendons, joints, cartilage and bones, focusing on stimulating the self-healing powers of the body by applying stem cells and growth factors. As a spin off from the Experimental Surgery and regenerative Medicine department of the Ludwig-Maximilians-University of Munich (www.experimed.de) and a close collaboration with the Veterinary Clinic of the University of Giessen LivImplant benefits from the latest scientific proceedings. First applications are available for curing lameness with horses and dogs.



Contact:
Michael Scholl

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7801665-0
Fax: +49 (0) 89 7801665-11
E-Mail: info@leukocare.com
Internet: www.leukocare.com



Contact:
Dr. Stefan Miller

Josef-Engert-Str. 13
D-93053 Regensburg
Phone: +49 (0) 941 28096208
Fax: +49 (0) 941 28096940
E-Mail: info@lisando.com
Internet: www.lisando.com



Contact:
Prof. Dr. Matthias Schieker

Truhenseeweg 8
D-82319 Starnberg
Phone: +49 (0) 8151 5590291
Fax: +49 (0) 8151 917922
E-Mail: info@livimplant.de
Internet: www.livimplant.de

LOEWE®

Contact:
Dr. Caroline Freye-Minks

Mühlweg 2 a
D-82054 Sauerlach
Phone: +49 (0) 8104 616-20
Fax: +49 (0) 8104 616-48
E-Mail: service@loewe-info.com
Internet: www.loewe-info.com

lophius biosciences

Contact:
Dr. Michael Lutz

Josef-Engert-Str. 13
D-93053 Regensburg
Phone: +49 (0) 941 6309197-0
Fax: +49 (0) 941 6309197-9
E-Mail: info@lophius.de
Internet: www.lophius.de



Contact:
Dr. Stephan Fischer

Forstenrieder Str. 8-14
D-82061 Neuried
Phone: +49 (0) 89 990178-0
Fax: +49 (0) 89 990178-199
E-Mail: info@mabdiscovery.com
Internet: www.mabdiscovery.com

Loewe® Biochemica GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Agrobiotechnology](#), [ELISA/EIA](#)

LOEWE is committed to the development and production of high quality reagents for the detection of plant diseases caused by bacteria, fungi, nematodes, and viruses. Furthermore we offer contract testing services for all kinds of crops and ornamentals (ELISA techniques, Immuno Fluorescence Antibody Assays, Blotting, and PCR).

Lophius Biosciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Infectious Diseases](#), [Immune Therapy](#), [Clinical Diagnostics](#)

Lophius Biosciences GmbH is a leading developer and provider of novel, innovative T-cell-based diagnostic test systems. With a recently closed financing round, investors have strongly validated the successful product developments for the CE-marked T-Track® CMV and EBV-Tests as well as a novel T-Track® TB Test (Tuberculosis) as well as the underlying patented technology platforms. Clinical studies are ongoing to prove the full clinical value of T-Track® CMV and EBV in modern transplantation medicine to properly steer immunosuppression and antiviral treatment to the patients' benefit. T-Track® TB has been designed and is currently being clinically evaluated regarding its potential to distinguish between latent infection and active disease with a major impact on the treatment and clinical outcome. Beyond tracking the patients' T cell responses in immunosuppressed transplant patients and TB infected individuals, Lophius' proprietary platform technologies provide significant diagnostic and clinical value to patients and physicians in a number of medical indications including but not limited to autoimmune diseases. Lophius' current focus is on the rounding off and launch of the product portfolio and thus become a fully integrated player in the new field of T-cell based diagnostics.

MAB Discovery GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Drug Development](#), [Antibody](#)

MAB Discovery, based in Munich, Germany, is a provider of high quality IND ready monoclonal antibodies derived from rabbits and rats. Relying on the natural immune response and state of the art B cell cloning techniques, we produce monoclonals with unprecedented epitope coverage and potency, so much so that further time consuming affinity maturation is not required. The diversity of the immune responses also ensures success against targets heretofore considered intractable. Backed by a strong investor, PPD Inc., we have chosen to keep our business terms simple and straightforward, eschewing the traditional IP license approach. Current partners include Boehringer Ingelheim and an undisclosed US biotech company.

medicomp GmbH

CRO

medicomp GmbH was founded in 1985 and has developed ever since into a full service CRO. We offer a wide range of services for phase I-IV trials, PMS and medical devices: medical and biometrical planning, protocol and CRF design, project management, data management, monitoring, statistical analysis and medical writing. medicomp is a member of the Bundesverband Medizinischer Auftragsinstitute (BVMA), which implies regular independent system audits. Furthermore, medicomp is a founding member of Pharmaceutical Service Network (PSN), a network of independent European CROs, which allows us to offer services for studies conducted on a European scope in collaboration with our partners.

Medigene AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Dermatology, Autoimmune Diseases, Oncology, Drug Development

Medigene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene was the first German biotech company to have revenues from marketed products, which are distributed by partner companies. It has two drug candidates in clinical trials and is developing an innovative vaccine technology.

Medpace Germany GmbH

CRO

Keywords: Oncology, Metabolic Diseases, Cardiovascular Diseases

Medpace, established in 1992, is a full-service Contract Research Organization (CRO), who partners with leading pharmaceutical and biotech organizations to bring promising new drugs to market. Medpace combines comprehensive regulatory consulting with efficient clinical trial management to provide sponsors with exceptional support in drug development. Proven leaders in medical and scientific research monitor every project. Medpace physicians have first-hand experience working with regulatory agencies to successfully guide projects through the complexities of the regulatory process. The medical expertise and regulatory guidance provided by Medpace leads to reduced costs and increased efficiencies for our valued customers.



Contact:
Dr. med. vet. Michael Gierend

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 895286-0
Fax: +49 (0) 89 895286-66
E-Mail: medicomp@medicomp-cro.de
Internet: www.medicomp-cro.de



Contact:
Julia Hofmann

Lochhamer Str. 11
D-82152 Martinsried
Phone: +49 (0) 89 20 00 33-0
Fax: +49 (0) 89 20 00 33-20
E-Mail: medigene@medigene.com
Internet: www.medigene.com



Contact:
Dr. Alfred Fraunhofer

Theresienhöhe 30
D-80339 München
Phone: +49 (0) 89 8955718-0
Fax: +49 (0) 89 8955718-100
E-Mail: A.Fraunhofer@medpace.com
Internet: www.medpace.de



Contact:
Dr. Horst H. Langenbahn

Olschewskibogen 7
D-80935 München
Phone: +49 (0) 89 354 998-0
Fax: +49 (0) 89 354 998-199
E-Mail: office1@MedPharmTec.de
Internet: www.MedPharmTec.de



Contact:
Dr. Bernhard Ladstetter

Am Feld 32
D-85567 Grafing
Phone: +49 (0) 8092 7008-0
Fax: +49 (0) 8092 7008-99
E-Mail: hannelore.lechner@merck.de
Internet: www.merck.de

MedPharmTec-Services

CRO

Keywords: Regulatory Affairs, Data Management and Biostatistics, Medical Writing

MedPharmTec-Services is a Pharmaceutical Contract Service Organisation providing expert assistance in drug development, clinical research (phase II through IV), medical information, regulatory affairs and drug safety to pharmaceutical and biotechnology companies. Our clinical research services range from protocol planning, CRF design, trial management, monitoring and auditing up to data management, biometrics and report writing. Further areas of MedPharmTec-Services' activities include medical information, i.e. medical and scientific translations, proof-reading, writing/designing of brochures, publications and scientific literature searches as well as consulting and services in terms of regulatory affairs and drug safety.

Merck KGaA – Institute of Drug Metabolism and Pharmacokinetics

PHARMA & CHEMICAL INDUSTRY

Keywords: Small Molecules, Antibody, Pharmacokinetics, ELISA/EIA, Drug Development

The Institute of Drug Metabolism and Pharmacokinetics (DMPK) is located in Grafing near Munich and is part of Global Research of Merck Serono, Geneva. The institute was established in 1969 and has grown considerably over the years. Currently 80 people are working at Grafing. The scope of the Institute of DMPK includes ADME studies of NCEs and NBEs in laboratory animals during drug discovery and development phases. Support is given to toxicology (toxicokinetics) and to clinical R&D by providing bioanalytical data and information about the metabolism in humans. The institute is equipped with state of the art instruments (e.g. LC-MS/MS, NMR, biacore, phosphor-imaging systems) and laboratories for radiolabelling of drugs with various radioisotopes (e.g. C-14, H-3, J-125).

metabion international AG

BIOTECH DEVICES & REAGENTS

Keywords: Genomics, Proteomics, NGS, Other Diagnostics, Antibody Production Service, Antisense/Nucleotides, PCR

metaBIO is one of the globally leading suppliers of custom nucleic acids renowned for its focus on reliable supplies of consistently high quality products and services. Founded in 1997 in Munich/Martinsried, metabion keeps on expanding its product portfolio from the production of a wide range of synthetic DNA and RNA oligonucleotides according to customers' needs to the supply of standard life science products. Successfully translating highest quality standards into daily practice is the core of metabion's business philosophy and key to its popularity at the same time. Careful evaluation and implementation of new and promising technologies and products are complementing metabion's progressive and innovative approach within a healthy and sound business setup.

Metronomia Clinical Research GmbH

CRO

Keywords: Logistics, Medical Writing, Drug Development, Oncology

Metronomia Clinical Research is a mid-size European CRO, providing full- or tailored services in clinical trials phase I - IV and NIS, with special focus on e-clinical, data management and biostatistics. Metronomia's mission statement is to improve and accelerate drug development by bringing together cutting-edge e-clinical technologies, well accepted study designs and pronounced customer orientation. Since more than 20 years our customers particularly esteem the high-quality and reliability of our data, our commitment to best service and outstanding flexibility, our stable project teams and the competitive cost-benefit ratio. Metronomia has a proven track record in all major therapeutic areas (core indications: oncology, dermatology, transplantation, nephrology and pulmonary diseases).



Contact:
Dr. Regina Bichlmaier

Lena-Christ-Str. 44
D-82152 Martinsried
Phone: +49 (0) 89 899363-0
Fax: +49 (0) 89 899363-11
E-Mail: metabion@metabion.com
Internet: www.metabion.com



Contact:
Dieter Meyer

Paul-Gerhardt-Allee 42
D-81245 München
Phone: +49 (0) 89 829265-100
Fax: +49 (0) 89 829265-099
E-Mail: info@metronomia.net
Internet: www.metronomia.net



Contact:
Emma Kick

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9981-0
Fax: +49 (0) 8158 9981-10
E-Mail: info@microcoat.de
Internet: www.microcoat-biotechnologie.de



Contact:
Dr. Bernd W. Krämer

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 54801-0
Fax: +49 (0) 89 54801-100
E-Mail: mikrogen@mikrogen.de
Internet: www.mikrogen.de

MicroCoat Biotechnologie GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Analytical Chemistry, PCR, ELISA/EIA, Clinical Diagnostics

Founded in 1992, MicroCoat is a biotechnology company focused on the field of Immune- and Nucleic acid-Diagnostics.

The major work areas are

- Coating of various biological reagents (Streptavidin; antibodies; nucleic acids; and others) on solid phases (e.g. micro plates, micro particles, tubes, chips)
- Development and manufacturing of diagnostic assays, especially for pharma testing (biologicals, ADA-, Nab-testing)
- Service in the field of Immune and Nucleic acid-Diagnostics like: measurement of samples, also for preclinical and clinical trials; method comparison of assays; configuration and handling of "sample panels"; system verification and validation.

MicroCoat has been certified for EN ISO 13485:2003 (9001/EN 46001).
GLP-Certified since April 2009.

MIKROGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Chip/Array Technology, Autoimmune Diseases, Automation, Infectious Diseases, ELISA/EIA, Clinical Diagnostics, PCR

Founded in 1989 MIKROGEN GmbH offers innovative solutions for medical laboratories. The company's scope is the development and production of clinical diagnostic test systems based on recombinant antigens, with the focus on bacterial, viral, parasitic and autoimmune diseases. MIKROGEN's core competencies covers genetic engineering and the scientific quality of research and development, which is reflected in various patent applications and publications in international journals. The key success factors of the company are consistent customer orientation, the strong product competence and highly skilled employees. MIKROGEN meets ongoing market demands by emphasising its activities on automation and standardisation in the in-vitro diagnostics, to improve processes in medical laboratories.

MINITÜB GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Artificial Reproduction Technologies, Drug Development, Transgenic Animals, Cardiovascular, Diabetics, Respiratory

Minitüb is an international established system supplier for assisted reproduction of domestic animals, notably in the areas of A.I., cryobiology and E.T. Through its participation in MWM Biomodels GmbH, a spin-off company of the LMU Munich, Minitüb is also engaged in the development and characterization of transgenic large animal models for biomedical research. Current projects are focused on genetically modified pigs for xenotransplantation as well as transgenic pig models of diabetes mellitus, muscular dystrophy and immunodeficiency. Customer support starts as early as from the design of a project, the development of expression and targeting vectors, the generation of genetically modified large animals, their phenotypic characterization, and the performance of preclinical studies.

MLL Münchner Leukämie Labor GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Chip/Array Technology, Genomics, PCR, Hematology, Oncology

MLL Munich Leukemia Laboratory is working as a reference laboratory for the diagnosis of hematologic malignancies focussing on leukemia and lymphoma. All 132 coworkers (physicians, molecular biologists, biostatisticians, and technicians) have outstanding reputation in the field of comprehensive diagnostics. In parallel, cytomorphology, cytochemistry, immunophenotyping, cytogenetics, FISH, and molecular genetic techniques such as PCR as well as new techniques such as next-generation sequencing are performed. The seven day available work-flow is orientated to the clinical needs of patients and physicians. MLL serves as a reference laboratory for German and European leukemia studies and is a SME-member in the European Leukemia Network (ELN). Education programmes are provided for physicians and technicians.



Contact:
Dr. Christian Simmet

Hauptstr. 41
D-84184 Tiefenbach
Phone: +49 (0) 8709 9229-664
Fax: +49 (0) 8709 9229-82664
E-Mail: adler@minitube.de
Internet: www.minitube.de



Contact:
PD Dr. Wolfgang Kern

Max-Lebsche-Platz 31
D-81377 München
Phone: +49 (0) 89 99017-0
Fax: +49 (0) 89 99017-111
E-Mail: info@mll.com
Internet: www.mll.com



Molecular Networks
Inspiring Chemical Discovery

Contact:
Dr. Oliver Sacher

Medical Valley Center, Henkestr. 91
D-91052 Erlangen
Phone: +49 (0) 9131 8156-68
Fax: +49 (0) 9131 8156-69
E-Mail: info@molecular-networks.com
Internet: www.molecular-networks.com



Contact:
Alena Haas

Karl-Weinmair-Str. 5
D-80807 München
Phone: +49 (0) 89 360 900 900
Fax: +49 (0) 89 360 900 901
E-Mail: dinfo@molekula.com
Internet: www.molekula.com



Contact:
Dr. Claudia Gutjahr-Löser

Lena-Christ-Str. 48
D-82152 Martinsried
Phone: +49 (0) 89 89927-0
Fax: +49 (0) 89 89927-222
E-Mail: info@morphosys.com
Internet: www.morphosys.com

Molecular Networks GmbH

BIOTECH BIOINFORMATICS

Keywords: [Chemoinformatics](#), [Molecular Modelling](#), [Small Molecules](#)

Molecular Networks offers innovative chemoinformatics software products, consulting, development and research services to increase the quality and productivity of discoveries in chemical, pharmaceutical and biotechnology R&D. Founded in 1997, the company established international business relationships and Molecular Networks' technology is utilized in major industrial and academic discovery laboratories worldwide to design and optimize chemical products and processes. Molecular Networks' product portfolio comprises a variety of software tools, databases and decision support applications for the design and the synthesis of chemical compounds, the prediction of their chemical, physical and biological properties, their chemical reactivity and metabolic or environmental fate.

Molekula GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: [Drug Development](#), [Fine Chemicals/Reagents](#), [Peptide/Protein](#), [Medicinal Chemistry](#), [New Materials](#), [Analytical Chemistry](#), [Antibiotics](#)

Molekula is a leading supplier of fine chemicals and biochemicals and stands at the forefront of this constantly changing industry. Molekula is different – we specialise in hard-to-source chemicals using production laboratories across the world with a diligence and tenacity that sets us apart from any other chemical supply company. Having started in a rented facility just over ten years ago, Molekula now boasts sales locations all over Europe. We are constantly expanding, having recently developed our operations in the UK and Germany. Our catalogue, which was initially comprised of just 500 research chemicals, now holds over 8000 ex-stock products and our ability to source high-quality compounds quickly and easily means our product list is growing all the time.

MorphoSys AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [CNS](#), [Oncology](#), [Infectious Diseases](#), [Antibody](#), [Drug Development](#), [Inflammation](#), [Rheumatoid Arthritis](#)

MorphoSys is an independent biotechnology company that develops novel antibodies, mainly for therapeutic applications. By successfully applying HuCAL® and other proprietary technologies, MorphoSys has become a leader in the field of fully human therapeutic antibodies. With Ylanthia®, MorphoSys's next-generation antibody technology has been launched in 2011. Through its alliances with some of the world's largest pharmaceutical companies, MorphoSys has created a pipeline of more than 70 drug candidates of which 20 are in clinical studies. In addition, the company develops a portfolio of proprietary therapeutic antibody candidates in the area of inflammation and oncology.

MSD SHARP & DOHME GMBH

PHARMA & CHEMICAL INDUSTRY

Keywords: Hepatology, Cardiovascular Diseases, Dermatology, Diabetics, Oncology, Ophthalmology, Immunology

MSD SHARP & DOHME GMBH is the German subsidiary of Merck & Co., Inc., a research-driven, worldwide acting pharmaceutical company based in the US, which develops, produces and distributes medicines and vaccines in different therapeutic fields. MSD wants to contribute to medical care in order to guarantee and improve access to urgently needed medicines worldwide. Thus, MSD supports numerous poor countries with donations of pharmaceuticals. For more than 100 years MSD publishes the renowned "MSD-Manual", a standard publication for physicians and pharmacists (www.msd.de/msdmanual/). Medical knowledge and advice for the public is published in the "MSD-Manual Handbuch Gesundheit". MSD Germany has 1.455 employees. The company is situated in Haar near Munich.

multi service monitoring

CRO, BIOTECH DEVICES & REAGENTS

Keywords: Oncology, Clinical Trial Management and Monitoring, Autoimmune Diseases, Devices, Regulatory Affairs, Drug Development

multi-service-monitoring (in the BioPark, founded in 2003, 5 employees) is a clinical research organisation (CRO) that is specialised in monitoring of non-commercial clinical trials and medical clinical trials with devices. All tasks are carried out in accordance with the appropriate national regulations and the international guidelines ICH/GCP and "DIN ISO 14155".

multimmune GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Antibody, Cell Therapy, Vaccines, Oncology

multimmune is a biopharmaceutical company dedicated to the discovery and development of new products for the treatment of cancer. The company focuses on the development of drug candidates to treat heat shock protein 70 (Hsp70) positive tumors, as surface-bound Hsp70 is a tumor-specific marker expressed on about 50-75% of various cancer entities, e.g. lung, breast, colon, pancreas. Currently, four approaches are being explored to destroy cancer cells: (1) by extracorporeal activation of Natural Killer (NK) cells with a synthetic peptide (ready to go into phase II), (2) by using an antibody against Hsp70 (preclinical), (3) by inducing tumor specific apoptosis with a recombinant human serine protease (preclinical), (4) by direct infusion of an Hsp70 peptide (preclinical).



Contact:
Eva-Maria Recker

Lindenplatz 1
D-85540 Haar
Phone: +49 (0) 89 4561-1130
Fax: +49 (0) 89 4561-1329
E-Mail: eva.maria.recker@msd.de
Internet: www.msd.de



multi-service-monitoring

Contact:
Dr. Josef Reisinger

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 3782498
Fax: +49 (0) 941 6308648
E-Mail: info@multi-service-monitoring.de
Internet: www.multi-service-monitoring.de



Contact:
Dr. Claus Botzler

Arnulfstr. 197
D-80634 München
Phone: +49 (0) 89 4520-7707
Fax: +49 (0) 89 4140-4299
E-Mail: info@multimmune.de
Internet: www.multimmune.de



Contact:
Dr. Christian Simmet

Hauptstr. 41
D-84184 Tiefenbach
Phone: +49 (0) 8709 9229-664
Fax: +49 (0) 8709 9229-82664
E-Mail: csimmet@minitube.de
Internet: www.minitube.de



MYRIAD®

Contact:
Dr. med. Heinz Jörg Oehl

Bunsenstr. 7
D-82152 Martinsried
Phone: +49 (0) 89 87 57 81 89
Fax: +49 (0) 89 87 57 81 70
E-Mail: hoehl@myriad.com
Internet: www.myriad.com

MWM Biomodels GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Pharmacokinetics, Transgenic Animals, Cardiovascular Diseases, Diabetics, Respiratory Diseases

MWM Biomodels GmbH is a spin-off company of the LMU Munich and Minitube, specialized in the development and characterization of transgenic large animal models for biomedical research. Current projects are focused on genetically modified pigs for xenotransplantation as well as transgenic pig models of diabetes mellitus, muscular dystrophy and immunodeficiency. MWM Biomodels offers support starting from the design of a project, the development of expression and targeting vectors, the generation of genetically modified large animals, their phenotypic characterization and the performance of preclinical studies.

Myriad GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Molecular Diagnostics, Biomarker Discovery & Development, Genomics, Personalized Medicine, Oncology

Myriad is a leading molecular diagnostic company based in Salt Lake City, Utah. Myriad's key focus is to personalize cancer therapy by the discovery and commercialization of targeted tests to assess a person's risk of developing disease, guiding treatment decisions and assessing risk of disease progression and recurrence. Originally founded in 1991, Myriad has spent more than twenty years to help patients and care givers to better understand the role genes play in hereditary cancers, such as breast, colon, endometrial, ovarian, pancreatic, and skin cancers. Since 2011/2012 Myriad is building onto its strong tradition and extending the geographic footprint in Europe.

The central European laboratory of Myriad GmbH has opened in Martinsried/Munich in March 2012. The Company provides caregivers access to the technology of its BRACAnalysis® test for genetic predisposition to hereditary breast and ovarian cancer, Prolaris® – a test to assess prostate cancer aggressiveness to predict disease outcome, Colaris® – a test for genetic predisposition to colon and endometrial cancer, and Colaris AP® – a test for genetic predisposition to polyposis colon cancer. In addition to the laboratory in Munich, Myriad operates its European headquarters in Zurich, Switzerland and regional offices in Paris, France, Madrid, Spain, and Milan, Italy.

Nanion Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology

Nanion Technologies is a spin-off from the Center for Nanoscience (CeNS) of the Ludwig-Maximilians-University of Munich (LMU). Nanion combines bio- and microtechnology in a company serving the life sciences industry by offering products and services which will dramatically increase the speed and efficiency of the drug discovery process in an important segment of the pharmaceutical market. Nanion bases its business on a proprietary chip technology and will design and develop High Throughput Screening (HTS) systems for ion channel active drugs (ICADs). Ion channels are prime targets for innovative medicines aimed at many important diseases.

NanoScape AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Nanobiotechnology, Drug Delivery, New Materials, Peptide/Protein, Small Molecules, Vaccines, Fine Chemicals/Reagents

NanoScape is a developer and producer of porous, nanoscale materials for the pharmaceuticals, environment (e.g. water purification membranes) and electronics (e.g. gas sensors; anti-reflection-coatings) sectors. Its NanoZeolite materials are cage-like structures with very high loading capacity which, through modification of the particle size and pore diameter, functionalisation of the surface chemistry or binding of ligands, can be adapted to meet the requirements of the individual customer, allowing a wide range of pharmaceutical, biochemical, electrical and optical properties to be realised. Using such materials intelligent drug-delivery systems for APIs (small molecules, biopharmaceuticals) and diagnostic sensors can be developed, and applications in the area of proteomics supported.

The logo for nan]i[on features the company name in a white, lowercase, sans-serif font. The characters are contained within a solid black rectangular box.

Contact:
Dr. Niels Fertig

Gabrielenstr. 9
D-80636 München
Phone: +49 (0) 89 218997972
Fax: +49 (0) 89 218997960
E-Mail: info@nanion.de
Internet: www.nanion.de

The NanoScape logo consists of a stylized blue triangle above the company name. The triangle is composed of three smaller triangles meeting at a central point, with the top triangle being a lighter shade of blue than the two base triangles. The name "NanoScape" is written in a blue, sans-serif font.

Contact:
Dr. Andreas Kohl

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 46133443-10
Fax: +49 (0) 89 46133443-30
E-Mail: info@nanoscape.de
Internet: www.nanoscape.de



Contact:

Dr. Philipp Baaske

Flößergasse 4

D-81369 München

Phone: +49 (0) 89 45 22 895 0

Fax: +49 (0) 89 45 22 895 60

E-Mail: info@nanotemper.de

Internet: www.nanotemper.de



Contact:

Dr. Rainer Paffenholz

Weihenstephaner Str. 28

D-81673 München

Phone: +49 (0) 89 3585-4000

Fax: +49 (0) 89 3585-4010

E-Mail: munich@ndareg.com

Internet: www.ndareg.com



Contact:

Dr. Stefan Schiefer

Bunsenstr. 5

D-82152 Martinsried

Phone: +49 (0) 89 787939-78

Fax: +49 (0) 89 787939-79

E-Mail: info@neaspec.com

Internet: www.neaspec.com

NanoTemper Technologies GmbH

BIOTECH DEVICES & CONSUMABLES

Keywords: Nanobiotechnology, , Peptide/Protein, Small Molecules

NanoTemper Technologies GmbH develops, produces and markets innovative, high quality instruments for bio-medical research. The products are based on NanoTemper's unique and proprietary technology termed Microscale Thermophoresis (MST). Microscale Thermophoresis allows to measure all kinds of biomolecule interactions ranging from protein-ion, protein-compound/fragment to protein-macromolecular complex interactions (e.g. ribosomes and liposomes). Worldwide NanoTemper is the only provider of this patented technology, which has major advantages over existing technologies and provides an important add-on for academic and biopharmaceutical research.

NDA Regulatory Service GmbH

CRO

Keywords: Regulatory Affairs, Pharmacovigilance, Drug Development

NDA Group is one of the leading Regulatory Affairs consultancies in Europe. With ~85 employees and offices in Sweden, UK and Germany, NDA has successfully provided Regulatory Support throughout Europe for over 15 years. NDA Regulatory Service GmbH in Munich was founded by a core group of regulatory experts from the European headquarter of an international pharmaceutical company. Our consultants are experienced professionals who offer expert knowledge and understanding of European regulations, guidelines and procedures. They are proficient in all regulatory activities associated with small molecules, biologicals and advanced therapies. We are dedicated to guide our clients smoothly through product development and registration in Europe.

Neaspec GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Analytical Chemistry, Microscopy, Nanobiotechnology

Neaspec is dedicated to delivering innovative solutions for nanoscale optical imaging & spectroscopy for research laboratories in industry and academic institutions. After 15 years of R&D, Neaspec now introduces the NeaSNOM microscopy platform - the only commercially available microscope that enables optical imaging and spectroscopy with a lateral resolution of better than 20 nm within the material fingerprint region in the infrared, visible and terahertz spectral region. As the ultimate nanoanalytic tool for material research and photonics, NeaSNOM has a high application potential in many disciplines such as Semiconductor Technology, Chemistry, Photonics, Polymer Science and Life-Sciences.

NeuroProfile GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

NeuroProfile is committed to the discovery and development of novel therapeutics for the treatment of Central Nervous System (CNS) diseases. The main objective is the identification and commercialization of novel neuronal drug targets (disease-related genes or proteins) for the most important neurodegenerative diseases Alzheimer and Parkinson and for psychiatric disorders such as schizophrenia and depression. Our targets will be the basics for forthcoming drug generations with new mechanisms of action that not only ameliorate the disease symptoms, but potentially prevent or block progression of the disease. Several patent pending target candidates are run in pre-clinical validation projects.

nexttec GmbH

BIOTECH DNA/PROTEIN ANALYTICS

The nexttec™ 1-Step technology is a reversal of the usual, known DNA purification systems on a silica or magnetic bead base. Proteins, detergents and low molecular weight compounds are retained by the nexttec™ sorbent. DNA passes through the nexttec™ cleanColumn during a short, one-step purification procedure (4 minutes). The obtained DNA is suitable for all common enzymatic reactions (restriction digests, real-time PCR, PCR, genotyping etc.).

NIGU Chemie GmbH

PHARMA & CHEMICAL INDUSTRY

Nigu offers a full range of high-purity guanidine salts for biotechnological applications, which meet the supreme quality standards set by the biopharmaceutical industry. The product group includes several grades of guanidine hydrochloride for separation and purification of recombinant proteins and antibodies. Guanidine thiocyanate for nucleic acid based diagnostics is another integral part of the portfolio. A typical example is to provide guanidine-salts and recycling of used solutions as a complete package to the biopharmaceutical industry.



Contact:
Dr. Thomas Rohrmeier

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 7853690
Fax: +49 (0) 941 7853699
E-Mail: info@neuroprofile.com
Internet: www.neuroprofile.com



Contact:
Uwe Luksch

Thalmanndorf 25
D-86567 Hilgertshausen
Phone: +49 (0) 214 869-1515
Fax: +49 (0) 214 869-1528
E-Mail: service@nexttec.biz
Internet: www.nexttec.biz

NIGU

AlzChem Group

Contact:
Dr. Frank Fleischer

Beuthener Str. 2
D-84478 Waldkraiburg
Phone: +49 (0) 8638 962-0
Fax: +49 (0) 8638 962-287
E-Mail: info@nigu.de
Internet: www.nigu.de



Contact:
Frank Hauerken

Zielstattstr. 40
D-81379 München
Phone: +49 (0) 89 7877-0
Fax: +49 (0) 89 7877-444
E-Mail:
communications.munich_de@novartis.com
Internet: www.novartis-consumerhealth.de



Contact:
Dr. Christian Fritsch

Roonstr. 25
D-90429 Nürnberg
Phone: +49 (0) 911 273-0
Fax: +49 (0) 911 273-12653
E-Mail:
novartis.kommunikation@novartis.com
Internet: www.novartis.de

Novartis Consumer Health Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Novartis Consumer Health, located in Munich, merchandises and distributes OTC and prescription drugs for self-medication. Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet the following needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 128,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit <http://www.novartis.com>.

Novartis Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet the following needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 128,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit <http://www.novartis.com>.

Novartis Vaccines and Diagnostics

PHARMA & CHEMICAL INDUSTRY

Novartis Vaccines and Diagnostics is a division of Novartis, which focuses on the development of preventive treatments. The division has two businesses: Novartis Vaccines and Novartis Diagnostics. Novartis Vaccines is the world's fifth-largest vaccines manufacturer and second-largest supplier of flu vaccines in the U.S.A. The products of the division also include meningococcal, pediatric and travel vaccines. Novartis Diagnostics develops and sells innovative technologies for the early detection of pathogens to protect the world's blood supply and prevent the spread of infectious diseases. Novartis Vaccines Deutschland is made up of the production site Novartis Vaccines and Diagnostics GmbH and Novartis Vaccines Vertriebs GmbH. The production company has a more than 100-year tradition, which goes back to the founder Emil von Behring, the first winner of the Nobel Prize for Medicine. The product portfolio in Germany includes vaccines for Influenza, TBE - Tick-Borne Encephalitis, Rabies, Tetanus, Diphtheria, Pertussis, Meningococcal C and Meningococcal A, C, W, Y, Japanese Encephalitis, Cholera, Hepatitis A and Typhoid. Novartis Vaccines is a strong and vibrant combination of tradition and the future: The tradition is based on the company's founder, Emil von Behring, the first winner of the Nobel Prize for Medicine (1901). Novartis also stands for an innovative future-oriented global company that is committed to maintaining the health of people throughout the world. An example of the innovative power of the vaccines division is the first commercial cell culture influenza vaccine, which was developed in Marburg. Another example is the product pipeline, e.g. vaccines against meningococcal disease, which is unique on a worldwide basis.

numares GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Agrobiotechnology, Analysis, Plant Breeding, Renewable Energies, Fine Chemicals/Reagents, Pharmacokinetics, Metabolic Diseases, Nephrology, Clinical Diagnostics

numares GROUP is specialized in developing diagnostic and analytical tests based on NMR in three businesses. numares HEALTH develops and sells diagnostic products for the healthcare sector and medical research in the therapeutic areas of cardiology, oncology and nephrology. Specific tests for the early detection of renal graft rejection and cardiovascular risk assessment are currently in development. numares PLANTS supports plant breeders and the plant processing industry in optimizing output traits and answering complex issues such as seed identification. numares ENERGY develops systems and provides information for controlling biogas plants and assessing raw materials for their use as substrates. numares is certified to EN ISO 13485:2003 and ISO 9001:2000 and has been issued the State - ment of GMP Compliance.



Rudolf-Diesel-Ring 27
D-83607 Holzkirchen
Internet: www.novartis-vaccines.de



Contact:
Dr. Fritz Huber

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 698 091-00
Fax: +49 (0) 941 698 091-01
E-Mail: info@numares.com
Internet: www.numares.com



Contact:
Dr. Karl Michaelis

Wegenerstr. 13
D-89231 Neu-Ulm
Phone: +49 (0) 731 9840-0
Fax: +49 (0) 731 9840-280
E-Mail: karl.michaelis@nuvisan.com
Internet: www.nuvisan.com



Omegamatrix GmbH

Contact:
Adrian Passow

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 55063007
Fax: +49 (0) 89 55063008
E-Mail: info@omegamatrix.eu
Internet: www.omegamatrix.eu



Contact:
Dr. Igor Ivanov

Zugspitzstr. 5
D-85757 München-Karlsfeld
Phone: +49 (0) 8131 2748047
Fax: +49 (0) 89 380122159
E-Mail: request4more@oncolead.com
Internet: www.oncolead.com

Nuvisan GmbH

CRO

Keywords: Oncology, Small Molecules, Peptide/Protein, Pharmacokinetics, PCR, ELISA/EIA

Nuvisan Pharma Services is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. We deliver services ranging from a single test to fully integrated drug development programs. Together with Focus we are pleased to offer our sponsors the complete spectrum of drug development services and assist the sponsor in bringing safe and effective pharmaceutical products to market.

Omegamatrix GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Prof. W.S. Harris, Sanford University - USA, and Prof. C. von Schacky, University of Munich, invented and defined the HS-Omega-3 Index in 2004. Then, in 2006 Schacky founded Omegamatrix GmbH, as a Laboratory, to deal with the ever growing number of research projects, applications and samples. Initially proposed as a risk factor for sudden cardiac death, it now indicates cardiovascular risk as well. First studies have shown its association to life expectancy in general. Other applications, still in development, range from psychiatric diseases to pregnancy and lactation.

OncoLead GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Clinical Diagnostics, Drug Development, Translational Research, Cell Culture

Oncolead, is a privately owned service provider company. We offer a unique cellular screening of anticancer agents in a panel of 80-200 cancer cell lines. Routine operation and highly standardized processes guarantee our customers the results within 2-4 weeks with outstanding reproducibility for cellular screening. Customers will further benefit from a comprehensive data analysis including correlation of activity profile with mutation status and with activity profile of thousands of known anticancer agents. We provide complementary tests using a complete 80+ cell line panel: an in vitro combination of more than 500 combination pairs, development of drug tolerance or test of different drug schedules using a longer (3-4 weeks) drug treatment. All these data are requested in translational research and clinical development and help our customers to increase confidence in making drug development decisions.

origenis GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Combinatorial Chemistry, Medicinal Chemistry, Automation, Combinatorics, Molecular Modelling, Small Molecules

Origenis is a leader in small molecule drug discovery with over 14 years of experience in the field. Origenis is a privately owned company based in Martinsried, Germany. Origenis runs its own patented Drug Discovery platform MOREsystem®. The unique platform combines state-of-the-art drug design, patent analysis, chemical synthesis and biological characterization performed in an integrated manner on 20.000 square feet of integrated lab space. Origenis runs research alliances as well as active in-house programs. Origenis is currently focusing on anti-inflammatory and CNS drugs. Origenis is offering a variety of out-licensing opportunities. Origenis offers access to its proprietary patent database Cippix® – www.cippix.com.

Otsuka Novel Products GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Infectious Diseases, Antibiotics, Clinical Diagnostics, Drug Development

Otsuka Novel Products GmbH (ONPG) was founded in 2011 in Munich, as an Otsuka group company. With an international network of 145 subsidiaries and 39,000 employees in 23 countries, and regions across Europe, Asia-pacific, America and the Middle East, Otsuka researches, develops, manufactures and markets innovative and original products with a focus on pharmaceutical products for the treatment of diseases. ONPG will initially focus on infectious diseases, working in collaboration with other group companies to develop improved diagnostic tools and novel products for the treatment of tuberculosis.

Oxford BioLabs Ltd.

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Oxford BioLabs Ltd. is a science-based company tackling Androgenetic Alopecia (AGA). A small group is located in Regensburg, BioPark. Our goal is to create a new standard of care for the treatment of AGA. Oxford BioLabs is developing novel therapies for the treatment of androgenetic alopecia (AGA), which is commonly known as male and female pattern baldness. Available therapies include drugs or hair transplant surgery, which treat acute symptoms but lead to side effects, hospitalization and unsatisfactory patient outcome. Currently there is no cure against AGA and new treatment options are urgently needed.

origenis

Contact:
Michael Almstetter

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 7801676-0
Fax: +49 (0) 89 7801676-777
E-Mail: info@origenis.de
Internet: www.origenis.de



Otsuka Novel Products GmbH

Contact:
Dr. Katharina Thiele

Erika-Mann-Str. 21
D-80636 München
Phone: +49 (0) 89 2060205 20
Fax: +49 (0) 89 2060205 55
E-Mail: kthiele@otsuka.de
Internet: www.otsuka.de



Contact:
Dr. Thomas Whitfield

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +44 (0) 1865 60 0355
Fax: +44 (0) 1865 41 2355
E-Mail: contact@oxbiolabs.com
Internet: www.oxbiolabs.com



Contact:
Dr. Axel F. Wenzel

Kreillerstr. 65
D-81673 München
Phone: +49 (0) 89 92 20 03-0
Fax: +49 (0) 89 92 20 03-90
E-Mail: office@p-ss-t.de
Internet: www.p-ss-t.de



Contact:
Dr. Josef Hofer

Dachauer Str. 44a
D-80335 München
Phone: +49 (0) 89 55 15 53 50
Fax: +49 (0) 89 55 15 53 51
E-Mail: info@paediacro.de
Internet: www.paediacro.eu



Contact:
Prof. Dr. Michael Wiechmann

Gewerbepark 13
D-94501 Aidenbach
Phone: +49 (0) 8543 601630
Fax: +49 (0) 8543 601649
E-Mail: info@pan-biotech.de
Internet: www.pan-biotech.de

P.S.S.T Pharma Scientific Services Team

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Devices, Nutraceuticals, Antibiotics

P.S.S.T is a small international consultancy and service provider for pharmaceutical and related industries. We accompany your drug / medical device development projects with advise and services in:

- regulatory affairs (from Clinical trials to Marketing authorisation filings, strategies+services including e.g. eCTD, User testing for PILs)
- drug dev. project management organisation+services, quality management
- clinical dev. (incl. scientific writing, protocol development, EUDRACT filings, IMPD etc.)
- general services and consultancy
- training and information provision

P.S.S.T's range includes scientific services for all sections of pharmaceutical, medical and healthcare industry. For support in other countries we established partnerships with local CROs and consultant.

PaediaCRO GmbH

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Medical Writing

PaediaCRO – your specialised CRO for your product development in paediatric use. Founded in 2007 by Prof. Dr. med., Dr. rer. nat., Dr. h. c. mult. Dieter Adam, Dr. rer. nat. Josef Hofer and Dipl.-Math. Jürgen Wyen, PaediaCRO will support you in the development of solutions for your products in paediatric use. A smile of a healthy child is our vision. To achieve this, PaediaCRO develops with its partners medicinal products to save children's life and improve their quality.

PAN Biotech GmbH

BIOTECH DEVICES & REAGENTS

PAN-Biotech GmbH is a modern and innovative company with its headquarters in Aidenbach/Germany. PAN-Biotech was founded in 1988 and is today a major producer of biotechnological products which are worldwide distributed and used in research and industry. The product range includes new serum- and proteinfree media, sera (FCS) from different countries of origin including important special variants and a broad variety of media for cell culture. Important new product areas are our automated cell culture systems for research and industry as well as new services all around the cell culture and cell processing. As a specialist for cell culture we can offer you nearly the complete range of products and services that you need for your successful cell culture.

PANACEA BIOTEC GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2011), as well as among the top 50 pharmaceutical companies (as per ORG IMS March 2010) of India. Panacea Biotec Germany GmbH is located in Munich and delivers and markets products in transplantation, immunosuppression and anti-infection.

PARI Pharma GmbH

PHARMA & CHEMICAL INDUSTRY, MEDTECH

Keywords: Drug Development, Drug Delivery, Analytical Chemistry, Liposomes, Antibiotics, Infectious Diseases, Respiratory Diseases

PARI Pharma focuses on the development of aerosol delivery devices and comprehensive inhalation drug development to advance aerosol therapies where drug and device can be optimized together. Based on PARI's 100-year history working with aerosols, PARI Pharma develops treatments for pulmonary and nasal administration customized with advanced delivery platforms, such as eFlow (lower respiratory) and Vibrent (upper respiratory) Technologies. PARI Pharma partners with pharmaceutical companies to develop new or improved therapies. PARI Pharma has several clinical development programs ongoing, either partnered or on its own, for cystic fibrosis, asthma, COPD, respiratory syncytial virus (RSV) infection, and treatments for lung transplant patients among other indications. PARI Pharma, a PARI Medical Holding company, is located near Munich, Germany with a major presence in the United States.

Patrys GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS


Keywords: Drug Development, Antibody, Infectious Diseases, Oncology

Biotech therapeutics for cancer treatment: Patrys – the natural human antibody based company. Patrys GmbH is a subsidiary of Patrys Limited (ASX: PAB), an Australian public company committed to the development of novel treatments for cancer and the commercialization of a unique natural human antibody based therapies for the treatment of multiple myeloma, melanoma, lung, gastric and colon cancers. The company has the world-wide and exclusive rights to technologies that have been developed over 25 collective years of research and development and which uniquely allow for the capture, development and production of natural human antibodies for potential therapeutic applications. The technologies, and resulting deep product pipeline, have achieved positive results in animal studies in the treatment of human lung, pancreatic, gastric and colon cancers. Currently a phase I clinical trial in refractory multiple myeloma patients is ongoing at the University clinic Würzburg. Patrys' commercial strategy is to blend the internal development of lead product candidates while simultaneously benefiting from partnerships and collaborations aimed at developing additional product candidates from the company's deep product pipeline.

PANACEA BIOTEC

Contact:
Dr. Wolfgang Klotz

Landshuter Allee 8–10
D-80637 München
Phone: +49 (0) 89 5455 8350
E-Mail: info-de@panaceabiotec.com
Internet: www.panaceabiotec.de



Contact:
Michael Hahn

Lochhamer Schlag 21
D-82166 Gräfelfing
Phone: +49 (0) 89 742846-831
Fax: +49 (0) 8151 279-6331
E-Mail: m.hahn@pari.de
Internet: www.paripharma.com



Contact:
Dr. Frank Hensel

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 230795-0
Fax: +49 (0) 931 230795-19
E-Mail: fhensel@patrys.com
Internet: www.patrys.com



Contact:
Peter Frost

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 517 286 59-0
Fax: +49 (0) 89 517 286 59-88
E-Mail: info@pelobiotech.com
Internet: www.pelobiotech.com



Contact:
Reinhold Mischau

Carl-Thiersch-Str. 2B
D-91052 Erlangen
Phone: +49 (0) 91 31-61 07 020
Fax: +49 (0) 91 31-61 07 099
E-Mail: info@peqlab.de
Internet: www.peqlab.de



Contact:
Susanne Müller

Heinrich-Mack-Str. 35
D-89257 Illertissen
Phone: +49 (0) 7303 12-0
Fax: +49 (0) 7303 12-387
E-Mail: peter.remiger@pfizer.com
Internet: www.pfizer.com

Pelo Biotech GmbH

BIOTECH DEVICES & REAGENTS

FROST LIFESCIENCE and Steeb Handelsvertretung merged to offer an excellent product portfolio and a one shop solution for 2D as well as 3D cell culture products. Together we have more than 30 years of experience producing and selling primary cells & stem cells, media and further cell culture products.

PEQLAB Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

PEQLAB is a leading supplier of products for Life Science Research. The German biotech company develops, manufactures and supplies reagents, consumables and instruments of impeccable quality to molecular and cell biology laboratories worldwide. PEQLABs purpose is to provide excellent products at a fair price and to support their customers with a dedicated and experienced staff. It was founded 1996 in Erlangen, Germany by Reinhold Mischau and employs now more than 100 people. PEQLAB operates in Germany/Austria, UK and USA and is represented globally by distributors.

Pfizer Manufacturing Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Infectious Diseases, CNS, Cardiovascular Diseases, Automation

Pfizer is a leading pharmaceutical company with headquarters in the US which develops, produces and distributes medicines and vaccines in different therapeutic fields. The product portfolio of the Pfizer Illertissen manufacturing site is specialized in solid dosage forms sold globally. We stand for a high degree of automation, system integration and innovation with an excellent supply performance. We provide innovative concepts and services in Containment Manufacturing and Wallet Packaging with a proven high quality and high service level at competitive costs. The unique expertise is proven by renowned awards achieved: Overall "Facility of the Year Award" from "International Society for Pharmaceutical Engineering" (ISPE) in 2008 for the fully automated containment manufacturing facility and "Healthcare Compliance Packaging Council" (HCPC)-Columbus Award 2011" for innovative compliance packaging solutions realized with wallet cards.

Pharma Stulln GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Ophthalmology, Respiratory Diseases

Experience in manufacturing eye drops in bottles and single-dose-units for more than 30 years. Pharma Stulln fulfills international standards in modern production of sterile preparations. Pharma Stulln has approximately fifty well established pharmaceutical customers in Germany, Europe and international countries such as Australia, China, Canada etc. Pharma Stulln is specialist in manufacturing: Eye drops, Nasal sprays, Respiratory solutions, Lens care products. In our production building in seven separate rooms high-performance bottelpack®-filling machines are placed for manufacturing individual products. A modern zone concept fulfills European and international standards for the production of sterile fluid pharmaceuticals. Advanced water treatment and ventilation technology combined with continuous monitoring ensure a continuous high level of quality production.

Pharmalog – Institut für klinische Forschung GmbH

CRO

Pharmalog Institut für klinische Forschung GmbH acts as an European full service CRO with an excellent reputation in clinical trials phase I - IV since 1983. Our staff of 42 colleagues in our office plus further central field based monitors conducts clinical and non-interventional trials. We operate in Germany and all EU/EEU-countries, using our large pool of motivated investigators in clinics/ practices. Our local monitors are native speakers.

We work

- transparent for our clients
- accurate in planning, realization and evaluation of clinical trials
- flexible focusing the needs of our customer
- friendly to assure a long lasting and strong collaboration with our clients

We have performed more than 400 clinical trials in all medical indications for medical products/-devices/biotechnology products according to ICH-GCP and FDA-standards for more than 50 nat./internat. pharmaceutical companies. We offer full service or modular approach (e.g. monitoring, data management/ statistics), reasonable pricing due to short contact ways and low overhead costs. Pharmalog is TÜV – certified and member of the BVMA.

pharma **STULLN**

Contact:
Karin Irlbacher

Werksstr. 3
D-92551 Stulln
Phone: +49 (0) 9435 3008-0
Fax: +49 (0) 9435 3008-99
E-Mail: info@pharmastulln.de
Internet: www.pharmastulln.de



Contact:
Kristin Hakansson

Neumarkter Str. 18
D-81673 München
Phone: +49 (0) 89 544637-0
Fax: +49 (0) 89 544637-50
E-Mail: pharmalog@pharmalog.com
Internet: www.pharmalog.com

PharmaZell

Contact:
Dr. Wolfgang Burger

Rosenheimer Str. 43
D-83064 Raubling
Phone: +49 (0) 8035 88-0
Fax: +49 (0) 8035 88-143
E-Mail: info@pharmazell.com
Internet: www.pharmazell.com



Contact:
Dr. Peter Sonner

Ingolstädter Str. 20
D-80807 München
Phone: +49 (0) 89 375 0899-0
Fax: +49 (0) 89 375 0899-20
E-Mail: GermanOffice@pharm-olam.com
Internet: www.pharm-olam.com



Contact:
Dr. Thomas W. Becker

Am Klopferspitz 19 (im IZB)
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 444 899 41
Fax: +49 (0) 89 444 899 43
E-Mail: info@phatocon.com
Internet: www.phatocon.com

PharmaZell GmbH

PHARMA & CHEMICAL INDUSTRY

The in-house development and production of various multi-customer active pharmaceutical ingredients is one pillar of PharmaZell's API business model. A product list of currently offered generic APIs is available and information about new products under development and/or evaluation can be provided upon request. The development and production of different single-customer (exclusive) active pharmaceutical ingredients is the other pillar of our API business model. PharmaZell draws upon a long history of successful custom synthesis projects, performed on a proprietary basis for innovation driven pharmaceutical companies worldwide. The company is also diversified into finished dosage form development. Formulation and analytical development labs as well as pilot/pivotal facilities are available at its Indian site in Vizag. The site develops entire dossiers and modular services to customers.

Pharm-Olam International Deutschland GmbH

CRO

Pharm-Olam International is a global, full service, Phase I-IV CRO with offices across Europe, North America, Latin America, South Africa, and India. In Germany, we have conducted trials since 1999 and have a local office in Munich along with regional staff. Our staff are highly experienced and can provide a range of services including Marketing Surveillance (AMG § 67.6) - from protocol writing to delivery of final report, auditing, monitoring and regulatory. Our Munich office also supports neighboring Austria and Switzerland. Let us evaluate your protocol at several of the largest centers in Germany and worldwide to determine projected enrollment by contacting german.office@pharm-olam.com

PhaToCon (Pharm/Tox Concept)

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Drug Development, Regulatory Affairs

You think about Quality-Management (QM) to improve efficiency, data reliability and comparability? However, you work at full capacity and additional resources are not available? We offer individually tailored QM-Concepts in Research and Development as well as preclinical Study-Management with regard to regulatory requirements in Pharmacology / Toxicology (in vitro / in vivo). Our support is customized based on international standards like GLP/GMP, ISO, We operate from a scientific point of view and with our "hands-on" mentality we have strong execution skills. With our network of competence and capabilities we guide your project to success. Benefit from our know-how and our network of experienced partners: selected experts, toxicologists and more than 40 accredited testing laboratories.

Phenoquest AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: CNS, Pharmacology, Drug Development, Antibody, Small Molecules

Phenoquest is a recently founded biopharmaceutical company dedicated to the development of innovative medications for the treatment of psychiatric diseases. The lead project focuses on the development of antibody-based therapeutics for depressive disorders. Scientists at Phenoquest combine profound knowledge in the fields of neurobiology and behavioural pharmacology with substantial experience in drug-development processes in industry. Making use of this combination, Phenoquest offers services ranging from the performance of basic experiments to a multi-faceted evaluation of drug candidates.

Phytochem Referenzsubstanzen GbRmbH

BIOTECH DNA/PROTEIN ANALYTICS

Phytochem develops, produces and markets high purified substances for the pharmaceutical industry, research, analytics and authorities (main focus over 3,000 Natural Compounds). Phytochem synthesizes or isolates also Degradation products and Impurities in remedies or other rare drugs especially for customers needs with best equipment and experience. Lot specific testing is guaranteed. Phytochem products were used as Reference Standards for research and development: (Identity standard Data File: IDF) also for quality control as Primary Standards (Reference Substance Masterfile: RMF) and full documented Method Validation. Additional products and consulting services in the fields of Functional Foods, Dietary Supplements, Food Additional and Cosmetics are new focuses from Phytochem.

Pieris AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Drug Development

Pieris AG is a biopharmaceutical company engaged in the discovery and development of Anticalins® for the diagnosis and treatment of life-threatening human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of its Anticalin® candidates. Recognizing the enormous market potential of protein-based drugs, Pieris is committed to becoming an integrated drug discovery and development company.



Contact:
Dr. Inge Sillaber

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 4161 47979
Fax: +49 (0) 89 4161 47970
E-Mail: service@phenoquest.com
Internet: www.phenoquest.com



Contact:
Hans Rausch

Krumbacherstr. 9
D-89335 Ichenhausen
Phone: +49 (0) 731 97205-45
Fax: +49 (0) 731 97205-46
E-Mail: phytochem@t-online.de
Internet: www.phytochem-standards.de



Contact:
Rita Fischer

Lise-Meitner-Str. 30
D-85354 Freising-Weißenstephan
Phone: +49 (0) 8161 1411400
Fax: +49 (0) 8161 1411444
E-Mail: info@pieris-ag.com
Internet: www.pieris-ag.com



Contact:
Dr. Gudrun Vogeser

Hohenwarter Str. 100
D-85276 Pfaffenhofen
Phone: +49 (0) 8441 87948-30
Fax: +49 (0) 8441 87948-31
E-Mail: info@pika-weihenstephan.de
Internet: www.pika-weihenstephan.de



Contact:
Markus Fischer

Industriestr. 1
D-93077 Bad Abbach
Phone: +49 (0) 9405 96 999 10
Fax: +49 (0) 9405 96 999 28
E-Mail: info@polyquant.com
Internet: www.polyquant.com



Contact:
Dr. Thorsten Klein

Max-Planck-Str. 14
D-86899 Landsberg a. L.
Phone: +49 (0) 8191 985 688 0
Fax: +49 (0) 8191 985 688 99
E-Mail: info@postnova.com
Internet: www.postnova.com

PIKA Weihenstephan GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: PCR, Analytical Chemistry, New Materials, Agrobiotechnology

PIKA Weihenstephan was founded in 2000 as a spin-off from the Technical University of Munich-Weihenstephan. Our focus is the fast detection and identification of microorganisms which may occur as spoilers during the production process of beer and beverages, but also in a diversity of other applications. Besides offering analyses for customers, PIKA Weihenstephan is producing and selling enrichment media and kits to be used for fast and specific process control. We are specialists in microbiology, both in conventional and in DNA analyses, especially PCR based methods. All processes at PIKA Weihenstephan are certified according to DIN EN ISO 9001:2008.

PolyQuant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, ELISA/EIA, Clinical Diagnostics, Proteomics

PolyQuant is a service provider commercializing technology of multiplex protein quantification QconCAT.

- Technology: QconCAT allows absolute quantification of multiple (5 to 100) proteins simultaneously. Method is based on gene synthesis and mass spectrometry platforms; it is a highly sensitive and cost-efficient assay applicable to samples of any nature.
- Applications: Protein biomarker research and validation; compound screening and toxicology evaluation; elucidation of the stoichiometry of protein complexes; quality control of expressed proteins; research and analysis of biological pathways.
- Products and services: Full service of protein quantification based on particular project requirements as well as the ready kits (isotope labeled control mixtures) for MS quantification.

Postnova Analytics GmbH

BIOTECH DNA/PROTEIN ANALYTICS DEVICES

Postnova Analytics provides complete analytical solutions for the characterization of proteins, biopolymers, macromolecules and nanoparticles (1000 Da - 10E12 Da, 10 nm - 100 µm). Postnova's products are used by all major global companies and institutions in the field of biotechnology, pharma, polymer and environmental research, e.g. DOW, BASF, Roche, MIT, TUM. Postnova's product portfolio includes systems, supplies and services based on its proprietary patented FFF technology for protein-virus, aggregate characterization, polymer-rubber characterization, nanoparticle characterization and preparative micron particle separation. Postnova has two locations in Landsberg, Germany (headquarters) and Salt Lake City, Utah, USA.

PPD Germany GmbH & Co. KG Branch office

CRO

Keywords: Drug Development, Devices, Logistics, Medical Writing

PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

PreSens Precision Sensing GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Drug Development, Tissue Engineering/Cell Culture, Analytical Chemistry

PreSens is a world leader in the field of chemical-optical sensors. It develops, manufactures and distributes sensor systems for Biotech & Pharma, Food & Beverage, Scientific Applications and Medical Devices. PreSens focuses on parameters which are essential for life: oxygen, pH and carbon dioxide. Over the last 15 years, we have delivered our special microsensors and our non-invasive systems for various applications such as respirometry, biology, or medical research. We also offer imaging Solutions: 2D-sensing of oxygen-, pH- and CO₂-distributions. PreSens is certified EN ISO 13485:2003 + AC:2007 and ISO 9001:2008. Together with its partners it offers full service in Europe, USA and Asia.

Priaxon AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Peptide/Protein, Oncology, Proteomics, Small Molecules, Drug Delivery, Drug Development

Priaxon is an emerging pharmaceutical company building a pipeline of novel drug candidates in different therapeutic fields, but mainly focusing on protein-protein interactions in oncology and other diseases. The goal is to discover and develop candidates for validated but hard-to-drug targets using two orthogonal drug discovery platforms. In January 2009 a collaboration agreement for the development of mdm2/p53-inhibitors with Boehringer Ingelheim was signed. We open up a new dimension in drug discovery by a unique combination of proprietary chemoinformatic tools with innovative synthetic chemistries. As a result Priaxon rationalizes and accelerates the whole drug discovery process.



Contact:
Dr. Peter Oberosler

Hansastr. 32
D-80686 München
Phone: +49 (0) 89 57877-0
Fax: +49 (0) 89 57877-400
E-Mail: genl.info@ppdi.com
Internet: www.ppdi.com



PreSens
PRECISION SENSING
www.PreSens.de

Contact:
Achim Stangelmayer

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 94272-100
Fax: +49 (0) 941 94272-111
E-Mail: info@presens.de
Internet: www.presens.de



priaxon

Contact:
Dr. Christoph Burdack

Gmunder Str. 37-37a
D-81379 München
Phone: +49 (0) 89 4521308-0
Fax: +49 (0) 89 4521308-22
E-Mail: contact@priaxon.com
Internet: www.priaxon.com



Contact:
Esther Gleede

Hans-Urmiller-Ring 17a
D-82515 Wolfratshausen
Phone: +49 (0) 8171 99747-0
Fax: +49 (0) 8171 99747-19
E-Mail: info@prionics.de
Internet: www.prionics.de



Contact:
Renate Ficker

Fraunhoferstr. 22
D-82152 Martinsried
Phone: +49 (0) 89 452289-700
Fax: +49 (0) 89 452289-717
E-Mail: info@project-pharmaceutics.com
Internet: www.project-pharmaceutics.com

PRIONICS DEUTSCHLAND GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Clinical Diagnostics, Agrobiotechnology, ELISA/EIA, Infectious Diseases

PRIONICS DEUTSCHLAND GmbH, founded in September 2005, is responsible for the marketing, sales and technical support of innovative tests for the early detection of important zoonotic diseases of production animals. The company provides its customers in Germany and Austria with a portfolio of more than 50 diagnostic kits, accessories and biochemicals. PRIONICS offers diagnostic solutions for all major animal disease areas including TSE, BVDV, FMD, TB, ParaTB, CSF, Salmonella, Trichinella and Blue Tongue. PRIONICS is also the distributor for all Ingenasa products. The parent company Prionics AG, Switzerland, is one of the world's leading providers of farm animal diagnostics and a recognized centre of expertise in BSE and prion diseases.

ProJect Pharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cytotoxic drugs, Antibody drug conjugates, Small Molecules, Peptide/Protein, Antibody, Liposomes, Drug Delivery, Drug and Lyophilization Development

ProJect Pharmaceuticals, based in Martinsried/Munich, Germany, transforms proteins, peptides and cytotoxic molecules into pioneering drugs. ProJect Pharmaceuticals adds value to client's bio-pharmaceutical products by applying innovative concepts of pharmaceutical development.

We offer:

- predictive formulation analytics
- formulation development including in-depth protein analytics
- lyophilization process development and optimization
- processing of Arte's Lyo Dual Chamber Prefillable™ syringe
- development of liposomal formulations and manufacturing processes
- manufacturing of preclinical study material
- technology-transfer including scale-up to GMP-manufacturing

www.project-pharmaceutics.com

Proteros biostructures GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Oncology, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Small Molecules, Fine Chemicals/Reagents, 3D-Structural Analysis

Proteros is Europe's largest and most experienced biotechnology company in the field of X-ray protein structure analysis and a leading partner for fully integrated lead discovery. Successful in business since 1998, Proteros collaborates with more than 80 international pharma, biotech and agricultural companies. Proteros services delivers protein crystallography, profiling and screening and tailor-made proteins. Lead discovery combines these unique technologies and medicinal chemistry to generate novel lead compounds for a variety of therapeutically relevant target proteins. Flexible business models, makes Proteros an ideal partner to the Pharmaceutical and Biotech Industry.

quattro research GmbH

BIOTECH BIOINFORMATICS

quattro research addresses the needs of life science and chemical industry by providing state-of-the-art solutions to manage all scientific data produced in research projects. Our applications help scientists to optimise the value of their research data, e.g. the electronic lab notebook quattro/LJ or the compound management solution quattro/CM. quattro research offers software and consulting services to build and integrate heterogeneous data sources and applications, such as compound registration, HTS, LIMS or SAP, into efficient and user friendly data management platforms.

QUINTILES GmbH

CRO

Keywords: Clinical Trial Management and Monitoring

Quintiles is the world's leading biopharmaceutical service provider. With a network of more than 27,000 professionals working in more than 80 countries, we have helped develop or commercialize all of the top 50 best selling drugs on the market. With extensive therapeutic, scientific and analytics expertise, we help biopharmaceutical and health sciences customers navigate the increasingly complex landscape with more predictability to enable better outcomes. For more information visit the company's Website at www.quintiles.com.



Contact:
Dr. Torsten Neufeind

Bunsenstr. 7a
D-82152 Martinsried
Phone: +49 (0) 89 700761-0
Fax: +49 (0) 89 700761-15
E-Mail: business@proteros.com
Internet: www.proteros.com



Contact:
Dr. Bernhard Schirm

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 990 16 29-0
Fax: +49 (0) 89 990 16 29-99
E-Mail: weisser@quattro-research.com
Internet: www.quattro-research.com



Contact:
Beatrice Ebner

Mühlweg 2
D-82054 Sauerlach
Phone: +49 (0) 8104 8980 42
Fax: +49 (0) 8104 8980 99
E-Mail: beatrice.ebner@quintiles.com
Internet: www.quintiles.de



Biopharmaceuticals

Contact:
Dr. Wolfgang Richter

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 70 07 64 90
Fax: +49 (0) 89 70 07 64 99
E-Mail: wolfgang.richter@rdbiopharma.de
Internet: www.rdbiopharma.de



Contact:
Sabine Herr

Kettelerstr. 3-11
D-97222 Rimpar
Phone: +49 (0) 9365 8826-0
Fax: +49 (0) 9365 8826-99
E-Mail: info@rapidbiomed.de
Internet: www.rapidbiomed.de



Contact:
Dr. Albrecht Pfahler

Münchner Freiheit 18
D-80802 München
Phone: +49 (0) 89 33039921-0
Fax: +49 (0) 89 33039221-30
E-Mail: info@remark-pharma.de
Internet: www.remark-pharma.de

R&D Biopharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Small Molecules, Natural Compounds, Drug Development

R&D-Biopharmaceuticals is a biopharmaceutical company focusing on the pre-clinical and clinical development of unique small molecules deriving from natural products for diseases with unmet medical need. The Company has exclusive access to the natural product class of the Tubulysins discovered by Prof. Höfle and Prof. Reichenbach from the Gesellschaft für Biotechnologische Forschung in Braunschweig and to proprietary second generation Epothilones, a highly promising new drug class for the treatment of cancer. The Company is pursuing an active partnering strategy for further development of these compound classes. They are suited especially for conjugation and targeting approaches.

RAPID Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Oncology, CNS, Cardiovascular Diseases, Bone/Joint Diseases, Devices

RAPID Biomedical GmbH is specialised in RF coils for MRI and NMR spectroscopy. The company collaborates with research institutes, hospitals and MR system manufacturers worldwide. Our products include 1H MR resonators for clinical studies at all magnetic field strengths and for all organs. We also supply multi-nuclear (e.g. 1H / 31P) MR-coils for combined MRI and MRS in clinical and basic science investigations. We offer custom made MR probeheads for routine animal research and various accessory devices. Our recent work concentrates on dual tuned coils and multi array coils for parallel MRI both for human as well as for animal studies. Our sister company RAPID MR International, LLC (www.rapidmri.com), situated in Columbus, Ohio, is contact partner for customers from the United States, Canada and South America.

REMARK GmbH Pharmaservices & Consulting

CRO

Keywords: Drug Development, Medical Writing

REMARK is a privately owned pharma services and consulting company founded in 1999. Quality and speed are the decisive factors in the success of a company involved in the healthcare market. To reach your goals our business unit Clinical Research offers the following services:

- Strategic Consulting
- Project Management
- Quality Assurance
- Pharmacovigilance Services
- Training/Coaching
- Medical Writing
- Due Diligence

Together with our unit Pharma Marketing, REMARK bridges the gap between development and marketing. For more information visit our website at www.remark-pharma.com

Ritter GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Pharmacogenetics, PCR, Genomics, ELISA/EIA, Automation, Devices

As a very productive brand-supplier, Ritter provides over 40 years of know-how in developing and producing fine high-precision plastic parts. Ritter produces in accordance to the local quality standards only in own production plants. The company is DIN ISO 9001:2000 certified and works according the DIN EN ISO 13485:2003. The 200 employees are engaged to provide packaging solution for construction chemicals (cartridges), laboratory and medical products (liquid handling systems, products for dialysis and robotic systems).

Roche Diagnostics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Antibody, PCR, ELISA/EIA, Automation, Clinical Diagnostics, Drug Development

Roche Diagnostics GmbH is part of Roche, Switzerland. Roche is a world leader in in-vitro diagnostics, medicines for cancer, transplantation and a market leader in virology. At Penzberg, Roche operates one of the largest biotechnology facilities in Europe for research, development and production of biotechnology based diagnostics and active pharmaceutical ingredients. The portfolio comprises test systems for the life science market, diagnosis, patient stratification and therapy monitoring. Pharma specializes in therapeutic human proteins with focus on monoclonal antibodies and biomarkers for oncology.

Sandoz International GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Peptide/Protein, Pharmacokinetics, 3D-Structural Analysis, Drug Development

Sandoz, the generic pharmaceuticals division of Novartis, is a worldwide leader in generics. Sandoz is also the pioneer and global leader in the rapidly emerging market for biosimilars, also known as follow-on biologics (or biopharmaceuticals). Sandoz developed and launched both, the first-ever biosimilar product in the EU (recombinant human growth hormone in 2006) and the first complex - glycosylated - biosimilar (recombinant human erythropoietin alfa) a year later. With the EU approval and launch in 2009 of biosimilar G-CSF (filgrastim), Sandoz is the only company with three products on the market in Europe. Sandoz currently employs more than 25,000 people in over 140 countries across the globe. The company's global headquarters is based in Holzkirchen/Bavaria, in the south of Munich.



Contact:
Kerstin Lenke

Kaufbeurer Str. 55
D-86830 Schwabmünchen
Phone: +49 (0) 8232 5003-0
Fax: +49 (0) 8232 5003-48
E-Mail: michael.fuchs@ritter-online.de
Internet: www.ritter-medical.de



Contact:
Barbara Jopp-Heins

Nonnenwald 2
D-82377 Penzberg
Phone: +49 (0) 8856 60-0
Fax: +49 (0) 8856 60-3896
E-Mail: barbara.jopp-heins@roche.com
Internet: www.roche.de



Contact:
Ameet Mallik

Industriestr. 25
D-83607 Holzkirchen
Phone: +49 (0) 8024 476-0
Fax: +49 (0) 8024 476-599
E-Mail: info.sandoz@sandoz.com
Internet: www.sandoz-biosimilars.com

Securetec

Contact:

Dr. Karl Kugelbrey

Lilienthalstr. 7

D-85579 Neubiberg

Phone: +49 (0) 89 2030801651

Fax: +49 (0) 89 2030801652

E-Mail: info@securetec.net

Internet: www.securetec.net



Biologische Detektions- und
Schnelltestsysteme

Contact:

Andrea Grethen

Provinstr. 52, Gebäude B14

D-86153 Augsburg

Phone: +49 (0) 821 455799-0

Fax: +49 (0) 821 455799-22

E-Mail: info@sension.eu

Internet: www.sension.eu



Contact:

Dr. Willi Metzger

Joh.-Seb.-Bach-Str. 7

D-85591 Vaterstetten

Phone: +49 (0) 8106 8887

Fax: +49 (0) 8106 301565

E-Mail: service@sequiserve.de

Internet: www.sequiserve.de

Securetec Detektions-Systeme AG

BIOTECH ANALYTICS & DIAGNOSTICS

Established in 1995, Securetec Detektions-Systeme AG provides leading edge technologies to facilitate detection of drugs, explosives, and other hazardous substances. By close cooperation with its customers Securetec understands the specific demands of traffic safety, customs, and drug enforcement authorities across the globe. Securetec's competencies cover tailor-made development and production of immunological test solutions reflecting in highly reliable products for day-to-day use. The specific technologies are successfully employed across a multitude of rapid identification applications of drugs and hazardous substances. We detect to protect - Securetec is proud to play a part in making today's world a safer one.

Sension GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Clinical Diagnostics](#), [ELISA/EIA](#), [Autoimmune Diseases](#), [Antibody](#)

Sension develops immunoassays and rapid test systems for on-site analysis. The tests find broad applications in the fields of food analysis, environmental analysis, medical diagnostics, reproductive management in agriculture, and in the monitoring of samples for mold. Also technologies for label production to prevent products from counterfeiting are realized. Sension is realizing own product developments, but also performs R&D developments for partners and customers and specifically focus on the specific needs required.

SequiServe GmbH

BIOTECH DNA/PROTEIN ANALYTICS

SequiServe offers the following custom services in molecular biology: DNA-sequencing (plasmids, PCR-products, BACs, PACs, primer-walking), purification of PCR products.

SERVIER Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Bone/Joint Diseases, Cardiovascular Diseases, CNS, Diabetics

Following its international success, SERVIER Deutschland GmbH has established an independent branch in Munich since 1996. SERVIER is one of the very dynamic pharmaceutical companies in Germany, experiencing a growth-rate in double figures on average. The reason for this is not only the approved and merchandised drugs but also new, innovative products. The success of the new drugs is supported by the SERVIER Forschung und Pharma-Entwicklung GmbH (also in Munich), which manages many different projects throughout the German-speaking region.

Sigma-Aldrich Chemie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Antibody, Genomics, CNS, Small Molecules, Knock Out, PCR

Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 36 countries and has over 7,600 employees providing excellent service worldwide.

SiNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Diabetics

SiNatur owns the patent rights for the structure, preparation and medicinal applications Sub-Nano-Silicic Acid (SNSA). This recently discovered SNSA is the first biologically active form of silicic acid and of silicon generally. The substance is a potent inhibitor of P-type ATPases and of certain Protein-Phosphatases with IC50 in the nanomolar range. Due to the ubiquitous presence of Si in living organisms the discovery of the first biological active form of this element will have a broad scientific and practical impact. SiNatur is developing medicinal applications of SNSA first of all in the therapy of diabetes and of gastric hyperacidity.



Contact:
Horst Stemmer

Elsenheimerstr. 53
D-80687 München
Phone: +49 (0) 89 57095-01
Fax: +49 (0) 89 57095-126
E-Mail: info@de.netgrs.com
Internet: www.servier.de

SIGMA-ALDRICH®

Contact:
Dr. Udo Sticher

Eschenstr. 5
D-82024 Taufkirchen
Phone: +49 (0) 89 6513-1504
Fax: +49 (0) 89 6513-1399
E-Mail: udo.sticher@sial.com
Internet: www.sigma-aldrich.com



Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: kerek@sinatur.net
Internet: www.sinatur.net



Contact:
Dr. Christian Thirion

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700961-999
Fax: +49 (0) 89 700961-998
E-Mail: info@sirion-biotech.de
Internet: www.sirion-biotech.com

Smartec IngenieurBüro

Contact:
Dipl. Ing. Ulrich Schubert

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 854665-13
Fax: +49 (0) 89 854665-15
E-Mail: ulrichschubert@smartecbio.de
Internet: www.smartecbio.de

SIRION BIOTECH GmbH

BIOTECH DEVICES & REAGENTS

Keywords: RNAi & Antisense, Knock Out, Drug Delivery, Drug Development, Gene Transfer

SIRION Biotech was founded in 2006 in Munich and maintains offices in Tokyo and New Hampshire. It stands for sophisticated cell modeling and viral vector platforms. These enable much improved target identification and compound screening in the drug, the food & cosmetic industries. Its technology has over the years been validated in more than 250 commercial projects with more than 70 academic and industrial organizations worldwide. As a result, primary cell immortalizations are being technically advanced, so are the recombinant construction of adenovirus serotype vectors serving for gene therapy applications and novel vaccines. Specifically, SIRION Biotech is offering a satisfaction guarantee on gene knockdowns of nearly 100% (RNAiONE®), cell lines with built-in reporter genes (SenCELL®), next generation cell models with high on-target knockdowns. VariCHECK® represents an inducible expression system for the functional analysis of protein variants. Ready-to-use-kits offer up to 50 fold transduction enhancement (AdenoBOOST®) or convenient and reliable vector cloning & purification within just 4 weeks (AdenoONE®).

Commercial arrangements range from fee-for-service over exclusive rights on single clones all the way to milestone & licensing arrangements. The latter are suited for longer term complex product developments in the areas of gene therapy and vaccines. Molecular biologists experienced in the field stand ready for project discussions in Europe, Japan and USA.

SMARTEC IngenieurBüro

BIOTECH DEVICES & INSTRUMENTS

Keywords: Tissue Engineering/Cell Culture, PCR, Chip/Array Technology, Automation, Devices

Smartec IngenieurBüro is your competent partner for individual system approaches and instrument development in the biological laboratory. Smartec IngenieurBüro convinces with know-how within the ranges biotechnology, analytics, genetic engineering, micro technology as well as micro fluidic. Smartec IngenieurBüro solves tasks of instrumentation for molecular and immunological process engineering. Smartec IngenieurBüro supports you from the idea to all stages of the product. Smartec IngenieurBüro offers complete solutions, consisting of mechanics, optics, electronics, as well as firm- and software of a hand. Smartec IngenieurBüro consists of engineers and physicists which are predominantly settled in the ranges Research and Development (R&D) of bioanalytic systems.

SpheroTec GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Tissue Engineering/Cell Culture

SpheroTec is a biotech company using 3D cell-culture systems that have similar properties to microtumors in cancer patients. On this basis, SpheroTec offers pharmaceutical and biotech companies the opportunity to conduct functional tests of drug candidates for oncology in close to real conditions. This permits the early identification of promising substances and gives a broad profile of the effects of substances. The process also allows the definition of the kinds of tumors for which a substance or a combination of substances has the best clinical efficacy.

SSS International Clinical Research GmbH

CRO

Keywords: Medical Writing, Respiratory Diseases, Oncology, Cardiovascular Diseases, Hematology

SSS International Clinical Research is a Functional Service Provider for the pharmaceutical, biotechnological and medical device industry since 1993, with headquarter in Germany and subsidiaries in Romania, Poland and UK. We provide cost-effective, high quality, comprehensive and internationally integrated Clinical Operations Services throughout Europe. Our services have been proven for nearly 20 years and through many successful projects. The services include feasibility surveys in European countries, regulatory document preparation and submissions, site identification and initiation, investigator contract negotiations, clinical trials management, monitoring, and quality assurance. Our indication focus in the past years has lied on Oncology, Neurology, Nephrology, and Pulmonology. Due to our long standing partnerships we have deep insights into the potentials of many possible study sites in these areas.

SÜD-LABORBEDARF GmbH

LABORATORY SERVICES

SLG is a German whole seller for molecular biology research consumables, located in Gauting near Munich since 1980. Our main business is high quality consumables such as gloves, liquid handling products, DNA/RNA kits and plastic ware like racks and cryo boxes. We sell by direct mail to Germany, Austria and Switzerland and through distributors in various European Union countries under our own brands SLG, SafeGrip, SL-Tip, SL-Pette and Hi Yield.



Contact:
PD Dr. Ilona Funke

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 540 41 34-0
Fax: +49 (0) 89 540 41 34-20
E-Mail: ajaeger@spherotec.com
Internet: www.spherotec.com



INTERNATIONAL CLINICAL RESEARCH

Contact:
Dr. Michael Sigmund

Landsberger Str. 23/25
D-82110 Germering
Phone: +49 (0) 89 8006500
Fax: +49 (0) 89 800650555
E-Mail: michael.sigmund@cro-sss.eu
Internet: www.cro-sss.eu



Contact:
Roman Müllner

Starnberger Str. 22
D-82131 Gauting
Phone: +49 (0) 89 850 65 27
Fax: +49 (0) 89 850 76 46
E-Mail: info@suedlabor.de
Internet: www.suedlabor.de

SuppreMol

Contact:
Nadja Kiehl

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 30905068-0
Fax: +49 (0) 89 30905068-68
E-Mail: info@suppremol.com
Internet: www.suppremol.com

synlab

Contact:
Dr. rer. nat. Christian Hilgarth

Bayerstr. 53
D-80335 München
Phone: +49 (0) 89 54308-0
E-Mail: muenchen.zentrum@synlab.com
Internet: www.futurebiolab.de

SuppreMol GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Autoimmune Diseases, Rheumatoid Arthritis, Antibody, Drug Development, Peptide/Protein

SuppreMol is a clinical stage biotech company developing first-in-class biopharmaceutical drugs based on a new therapeutic principle. Development candidates comprise therapeutic proteins and antibodies with the potential to cure autoimmune diseases instead of only treating symptoms.

SuppreMol is developing its lead product SM101 in proof-of-concept studies in Primary Immune Thrombocytopenia (ITP), an orphan disease, as well as Systemic Lupus Erythematosus (SLE). The company is further evaluating more common and mainstream diseases such as Rheumatoid Arthritis, Multiple Sclerosis (MS), and Chronic Obstructive Pulmonary Disease (COPD). SuppreMol is a spin-off from the laboratories of the Nobel Laureate Prof. Robert Huber of the Max Planck Institute of Biochemistry in Martinsried, Germany.

synlab Labor München Zentrum synlab Medizinisches Versorgungszentrum

BIOTECH ANALYTICS & DIAGNOSTICS

synlab Holding GmbH was founded in 2010 as a merger of synlab GmbH (Augsburg), Futurelab GmbH (Vienna, Austria) and Fleminglabs Srl (Brescia, Italy). Objects of the company: Laboratory diagnostics for human and veterinary medicine, environmental analysis services. Furthermore, medical supplies trade, consultancy services, plasma donation centres and clinical trials. Turnover 2011: € 570,8 million. Number of analyses in 2011: Approx. 300 million. Number of employees: Approx. 6.800. Number of sites, incl. blood collection points: 300 in 20 countries. Our Customer structure: Doctor's surgeries, patients, clinics, university hospitals, retirement and nursing homes, veterinary practices, business enterprises, communities and authorities, pharmaceutical companies.

Syntacoll GmbH

PHARMA & CHEMICAL INDUSTRY

Syntacoll is the manufacturing division of Innocoll, Inc. and produces clinical supply or commercial product to its marketing partners and to Innocoll's two other divisions, Innocoll Technologies and Innocoll Pharmaceuticals. Using proprietary manufacturing processes, Syntacoll converts raw collagen material and incorporates medicinal compounds yielding finished pharmaceutical product in the form of a sponge or membrane. This system forms the basis of Innocoll's lead collagen-based technology, CollaRx. The sponge or membrane product format is a unique way to locally deliver a wide variety of medicinal compounds and is fully biodegradable and resorbable. The sponge and the membrane formats can be implanted at the time of surgery or applied topically to a chronic, acute or traumatic wound. Delivering drug locally to the site of action has a number of benefits, including the safe delivery of higher doses than could be achieved through systemic routes and avoidance of systemic side effects.

Temmler Werke GmbH

PHARMA & CHEMICAL INDUSTRY

The Temmler Group, now a member of the Aenova group, is one of the largest providers of contract services in the pharmaceutical environment. Temmler has a wide experience in formulation development of finished solid, semi-solid and liquid dosage forms, in manufacture, packaging, blinding, distribution and return handling of clinical trial supplies, in the optimization of established manufacturing processes as well as in the contract manufacture of medicinal products with marketing authorization, supplemented by Quality Control and Analytical services. Temmler offers services from stand-alone processes according to customer specifications, to strategic services comprising the entire supply chain.

TILL Photonics GmbH – an FEI Company

BIOTECH DEVICES & REAGENTS

Keywords: Automation, Microscopy, Devices

TILL Photonics GmbH, founded in 1993 and acquired in 2011 by FEI (Hillsboro, USA), is a global microscopy solutions provider that develops and markets live cell fluorescence microscopes and routine, applied science and diagnostics products. TILL produces extremely flexible, modular microscopy systems that are complete turnkey solutions for imaging and photometry applications. These systems are based on patented technology for confocal and conventional fluorescence microscopy and were originally developed in collaboration with the Bioluminescence Zentrum at the LMU in Munich.

Syntacoll

Contact:
Rita Wittmann

Donaustr. 24
D-93342 Saal/Donau
Phone: +49 (0) 9441 68600
Fax: +49 (0) 9441 686030
E-Mail: info@syntacoll.de
Internet: www.innocoll.de



TEMMLER

Contact:
Dr. Claudio Lorck

Weihenstephaner Str. 28
D-81673 München
Phone: +49 (0) 89 427299-01
Fax: +49 (0) 89 427299-1000
E-Mail: info@temmler.eu
Internet: www.temmler.de



Contact:
Erika Weber

Lochhamer Schlag 21
D-82166 Gräfelfing
Phone: +49 (0) 89 89 56 62-0
Fax: +49 (0) 89 89 56 62-101
E-Mail: TILL-info@fei.com
Internet: www.till-photonics.com



Contact:

Dr. Elfriede Müller

Fraunhoferstr. 18 a
D-82152 Martinsried
Phone: +49 (0) 89 856512-83
Fax: +49 (0) 89 856512-86
E-Mail: info@toplab.de
Internet: www.toplab.de

TRANSCATHETER TECHNOLOGIES

Contact:

Dr. Wolfgang Goetz

Josef-Engert-Str. 13
D-93053 Regensburg
Phone: +49 (0) 170 63099-20
Fax: +49 (0) 941 63099-897
E-Mail: wolfgang.goetz@transcatheter-technologies.com
Internet: www.transcatheter-technologies.com



Contact:

Brigitte Stempfer

Frankfurter Ring 193a
D-80807 München
Phone: +49 (0) 89 324 266-0
Fax: +49 (0) 89 324 266-199
E-Mail: mail@trionpharma.de
Internet: www.trionpharma.com

TopLab GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: [Proteomics](#)

TOPLAB GmbH is a leading ISO 9001 certified service provider with high end research facilities for proteomics, protein analytics, target and biomarker discovery and validation. The company has outstanding expertise in proteome analysis, protein identification and characterisation with more than 15 years experience. A portfolio of proprietary technologies has been developed and/or licensed that is able to significantly enhance the rate of discovery of potential biomarkers and novel therapeutic targets. The vision of TOPLAB is to support our clients from pharma, biotech and academia with highest quality standards, modern technologies and an experienced and highly motivated team, to achieve confident results in compliance with the timelines of our customers with calculable costs.

Transcatheter Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Cardiovascular Diseases](#), [Devices](#)

TRANSCATHETER TECHNOLOGIES develops medical devices aimed at reducing the trauma of open-heart valve surgeries. Its re-positionable transcatheter aortic valve system TRINITY is at the forefront of next generation valve implantation technology. The new technology makes it possible to implant aortic valve prostheses without the need for traumatic open-heart surgery. Key features of TRINITY allow the physician to reposition the valve during implantation. ZERO PRESSURE CRIMPING™ technology protects the fragile biological leaflets when the stent is folded and expanded. This will increase the safety and durability of the valve prosthesis and will allow for implantation in younger patients.

TRION Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Immune Therapy](#), [Antibody](#), [Drug Development](#)

TRION Pharma GmbH is a privately held biopharmaceutical company that has established a novel approach to cancer immunotherapy. The Company's unique family of trifunctional therapeutic antibodies, called Triomab®, simultaneously activates multiple immune defense mechanisms against cancer. Removab® (catumaxomab), the most advanced candidate of the Triomab® family, received EU market approval for the intraperitoneal treatment of malignant ascites. Removab® is not only the first drug indicated for the treatment of malignant ascites, but also the first approved bispecific, trifunctional antibody worldwide. TRION employs about 90 people in Munich for development and cGMP-manufacturing of its antibody products.

TRION Research GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antibody Production Service, Immune Therapy, Drug Development

TRION Research GmbH, founded in 1998, is a Biotech research company and a strategic partner of TRION Pharma GmbH focusing on the generation of novel Triomab[®] antibody candidates and the support of non-clinical and clinical development of Triomab[®] antibodies. The company offers Immunomonitoring Service, special antibody conjugation support, additional analytical service in tumor biology and further analytical support for reagent control to investigators, study sponsors and CROs. TRION Research is ISO 9001:2008 certified. The core competences of the company are:

- Immunomonitoring and logistical support for clinical and non-clinical studies
- Supply of purified antibodies (labeled and unlabeled)
- Development of immunological assays

U3 Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Antibody, Drug Development

U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in targeted cancer drug development. Established in July 2001, the company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Professor Axel Ullrich. Since May 2008 U3 Pharma belongs to DAIICHI Sankyo Co. Ltd., one of the top 20 leading pharmaceutical companies worldwide and no. 3 in Japan. Being part of this global environment, U3 Pharma is striving to provide patients around the world with innovative antibody-based therapeutics.

UniEquip Laborgerätebau & Vertrieb GmbH

LABORATORY SERVICES

Keywords: Devices

UniEquip provides production and distribution of biotech instruments, e.g. AutoGen (fully automated nucleic acid extraction), highly advanced gel documentation systems, nucleic acid purification kits, ThermoCycler and most typical laboratory equipment for molecular biology.



Contact:
Brigitte Stempfer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700766-0
Fax: +49 (0) 89 700766-11
E-Mail: mail@trionresearch.de
Internet: www.trionresearch.com



Contact:
Michaela Stein

Fraunhoferstr. 22
D-82152 Martinsried
Phone: +49 (0) 89 8103-9100
Fax: +49 (0) 89 8103-9199
E-Mail: information@u3pharma.com
Internet: www.u3pharma.com



Contact:
A. N. Kraupa

Fraunhoferstr. 11
D-82152 Martinsried
Phone: +49 (0) 89 8575200
Fax: +49 (0) 89 8561304
E-Mail: info@uniequip.de
Internet: www.uniequip.com



Contact:
Dr. Reinhard Zeidler

Marchioninstr. 25
D-81377 München
Phone: +49 (0) 89 709 92 96
Fax: +49 (0) 89 709 92 25
E-Mail: info@vaecgene.de
Internet: www.vaecgene.de



Contact:
Christian Wandersee

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 359099-0
Fax: +49 (0) 931 359099-12
E-Mail: office@vasopharm.com
Internet: www.vasopharm.com



Contact:
Barbara Roderus

Emmy-Noether-Str. 2
D-80992 München
Phone: +49 (0) 89 15882-0
Fax: +49 (0) 89 15882-100
E-Mail: info@vermicon.com
Internet: www.vermicon.com

Vaecgene Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Proteomics, Drug Development, Immune Therapy, Infectious Diseases, Oncology

Vaecgene focuses on the research and development of novel therapeutics and in vitro diagnostics. Core competence and proprietary technology are the development of viral vectors that helped Vaecgene to establish a broad portfolio including individual drugs for immunological treatment of tumors and infectious diseases. Recently, Vaecgene has developed a new intelligent technology, AMIDA, for functional proteomics for fast and efficient identification and validation of tumor markers for early detection of cancer. In addition, the company offers services related to Epstein-Barr Virus.

The company has also extensive experience in monitoring and quantitating the immune competence in patients and non-human primates.

vasopharm GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits steering the bioavailability of biological NO, covering the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm's drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure after a traumatic brain injury. www.vasopharm.com

vermicon AG

BIOTECH AGRO, FOOD, ENVIRONMENT

vermicon AG offers solutions for microbiology. The company develops and markets products and services for the detection and analysis of microorganisms. Additionally the company offers microbiological consulting. Its approach is new and non-conventional. Our portfolio comprises: The products – our detection systems for industrial and private customers. The services – extensive analyses for microbiology. Microbiological consulting – the unique link between microbiology and consulting. The power of the technology portfolio combined with a strong and innovative team consisting of microbiologists and chemists allows us to explore completely new and exciting ways.

vertis Biotechnologie AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: PCR, NGS, Informatics, Genomics

VERTIS was established in 2000 as a spin off from Technical University Munich-Weihenstephan, Germany. The company offers molecular biology services in the field of functional genomics with focus on Next Generation Sequencing (NGS) especially on transcriptome sequencing (RNA-seq). The company offers a complete product line, ranging from project consulting, nucleic acid isolation, sample preparation and DNA sequencing to bioinformatic sequence analysis and data mining. The strength of the VERTIS is customer-oriented flexibility, which is based on an innovative technology platform, the company has developed in its 13-year history. VERTIS is a pioneer in the analysis of small non coding RNAs (sncRNA) and of bacterial transcriptomes.

verum.de GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Dermatology, Diabetics, Oncology, Respiratory Diseases

Experts and experience in clinical trials. Pooled for success: Verum has been the first Western-Standard CRO specializing in CEE countries, operations starting in 1992. Our core business and key competence is Full Clinical Service for Phase II-IV in CEE countries. Our team consists of about 100 experts that share our experience of more than 120 trials with some 35.000 patients in indications like cardiovascular, neurology, psychiatry, pain, CNS-diseases and oncology. With offices from Eastern Europe to the US we are pooled for the success of our trials.

Viramed Biotech AG

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, ELISA/EIA, Infectious Diseases

Based on 20 successful years on the German IVD-Market, Viramed Biotech AG produces and markets IVD-Products, based on its proprietary research and development. The company focuses on Westernblot-, Stripe- and Elisa-test kits for serological screening and confirmation of infectious and autoimmune diseases. The major products are Westernblot tests for Borrelia sp., Yersinia, Helicobacter p., Epstein-Barr-Virus, Bordetella pertussis, ENA and autoimmune liver diseases. New analytics based on purified and recombinant antigens are under development. The development of antigens and test kits for specific analytics are offered as service. The company aims to intensify export of existing products worldwide and appreciates further distribution contacts.



Contact:
PD Dr. Fritz Thümmeler

Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 18516-11
Fax: +49 (0) 8161 18516-12
E-Mail: info@vertis-biotech.com
Internet: www.vertis-biotech.com



Contact:
Christian Sacher

Sembdnerstr. 5
D-82110 Germering
Phone: +49 (0) 89 800777-60
Fax: +49 (0) 89 800777-88
E-Mail: verum@verum.de
Internet: www.verum.de



Contact:
Dr. Ludwig Furtmayr

Behringstr. 11
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 899336
Fax: +49 (0) 89 8599949
E-Mail: viramed@viramed.de
Internet: www.viramed.de



Contact:
Karl Appelmann

Henkestr. 91
D-91052 Erlangen
Phone: +49 (0) 9131 974434-0
Fax: +49 (0) 9131 974434-43
E-Mail: info@virologik.com
Internet: www.virologik.de



Contact:
Dr. Melanie Keller

Grillparzerstr. 25
D-81675 München
Phone: + 49 (0) 89 552797-590
Fax: + 49 (0) 89 552797-599
E-Mail: info@vivopharm.eu
Internet: www.vivoPharm.eu

ViroLogik GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: [Drug Development](#), [Infectious Diseases](#)

ViroLogik develops innovative drugs for treatment of viral diseases with a focus on Hepatitis C, HIV and Influenza. ViroLogik devised a novel strategy to overcome the formation of drug-resistance. The approach aims at the inhibition of highly conserved host cell factors mandatory for viral replication. This is in contrast to many current drugs that target fast changing viral proteins and, hence, are prone to formation of drug resistance. ViroLogik obtained a licence for a highly promising drug candidate and owns a broad panel of patents and patent applications. Comprehensive partnerships with leading research institutions, hospitals and pharmaceutical companies secure access to valuable expertise, networks and resources.

vivoPharm Europe Ltd

CRO

Keywords: [Toxicology](#), [Pharmacology](#), [Medical Writing](#), [Drug Development](#), [Oncology](#), [Metabolic Diseases](#), [Bone/Joint Diseases](#)

vivoPharm is a contract research organization that offers integrated preclinical services in various disease areas (with focus on cancer) to the biotechnology and pharmaceutical industries. We specialize in planning and conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug Applications (IND) filing. The company's state-of-the-art animal facilities, laboratories and its corporate headquarters are located in Melbourne, Australia and Hershey, PA, USA. Its European office is based in Munich, Germany. vivoPharm operations follow strict quality control methods and meet the highest industrial standards, acknowledged by our customers worldwide. Our highly motivated and qualified team guarantees short response times, consistency of service, regular updates and transparency. vivoPharm operates in AAALAC accredited and GLP compliant audited facilities.

Wacker Chemie AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Antibody Production Service, Peptide/Protein, CRO/CMO, Nutraceuticals

WACKER is a globally active chemical company headquartered in Munich, Germany. With a wide range of state-of-the-art specialty products, WACKER is a leader in numerous industrial sectors. Its products are required in countless high-growth end-user sectors such as photovoltaics, electronics, pharmaceuticals and household/personal care products. Within its bio division, WACKER uses advanced biotech processes to offer innovative and tailored solutions and biotech products for the pharma and the food & nutrition industry. Its products include pharmaceutical proteins, cyclodextrins and fermentation-grade cysteine. The division focuses on developing customized solutions for growth sectors such as food additives and pharmaceutical actives.

WILEX AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Small Molecules, Antibody, Drug Development

WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the company develops diagnostic and therapeutic product candidates for the specific detection and targeted treatment of various types of cancer. In the field of therapeutics, WILEX develops small molecules (MESUPRON® two Phase IIa trials completed, WX-554 in Phase Ib/II and WX-037 in preclinical development). In the field of diagnostics, REDECTANE® is an antibody-based imaging in vivo diagnostic agent that is currently in a Phase III programme.

The company also has a portfolio of research use only tests and in vitro diagnostic agents that are marketed under the brand Oncogene Science via its US subsidiary WILEX Inc. in Cambridge, MA. WILEX's subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and a highly promising antibody drug conjugate (ADC) technology platform. The business model of WILEX comprises research and product development as well as the commercialisation of its activities. WILEX's customers and partners include leading international pharmaceutical companies.

WACKER

Contact:
Rachela Mohr

Hanns-Seidel-Platz 4
D-81737 München
Phone: +49 (0) 89 6279-0
Fax: +49 (0) 89 6279-1770
E-Mail: info@wacker.com
Internet: www.wacker.com

WILEX

Focused Cancer Therapies


Contact:
Katja Arnold

Grillparzerstr. 10
D-81675 München
Phone: +49 (0) 89 413138-0
Fax: +49 (0) 89 413138-99
E-Mail: investors@wilex.com
Internet: www.wilex.com



Contact:
Carlos Urquizar

Karlstr. 55
D-80333 München
Phone: +49 (0) 89 4524466-0
Fax: +49 (0) 89 4254466-50
E-Mail: kilian.schramm@wimasis.com
Internet: www.wimasis.com



Contact:
Nicole Czesak

Deuschherrnstr. 15-19
D-90429 Nürnberg
Phone: +49 (0) 911 92680 0
Fax: +49 (0) 911 92680 8839
E-Mail: wn@winicker-norimed.com
Internet: www.winicker-norimed.com



Contact:
Prof. Dr. Arne Skerra

Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161 53730-90
Fax: +49 (0) 8161 53730-99
E-Mail: info@xl-protein.com
Internet: www.xl-protein.com

Wimasis GmbH

BIOTECH BIOINFORMATICS

Keywords: Inflammation, Dermatology, Cardiovascular Diseases, Microscopy, Automation, Devices

Wimasis is an image analysis service in the field of life science, preclinical and clinical research. Its focus lies in the automation of image analysis tasks via an intuitive, web-based interface, that allows access to large scale computing power. With multiple fully automated solutions in the life sciences (Scratch, Tube Formation, Chemotaxis Assays, etc.), Wimasis has grown a worldwide userbase from Australia to Zypress. Besides the ongoing development projects in the field of cell-based assays, many custom solutions are continuously being developed for in vitro and in vivo analysis. If you are looking at cells, tissue or data generated from clinical imaging modalities, Wimasis can help you solve the automation task with cost efficient tools.

Winicker Norimed GmbH Medizinische Forschung

CRO

Winicker Norimed GmbH, located in Nuremberg, is an independent, owner-operated contract research organization. Our experienced, interdisciplinary team of approximately 100 employees manages your projects from the planning through the field phase to the analysis and the clinical study report or publication. We deliver quality services according to applicable laws and international guidelines based on either our own or our clients' standard operating procedures. In cooperation with hospitals and primary care physicians, we manage phase II-IV clinical trials with pharmaceuticals, studies with medical devices as well as non-interventional and epidemiological studies.

XL-protein GmbH

BIOTECH

Keywords: Drug Development, Pharmacokinetics, Peptide/Protein

XL-protein is a biopharmaceutical company utilizing its proprietary 'PASylation' technology to develop second generation biopharmaceuticals with prolonged plasma half-life. PASylation of therapeutic proteins allows less frequent and lower dosing combined with better tolerability, also opening perspectives for follow-on products of approved biopharmaceuticals. PASylation – the genetic fusion with conformationally disordered polypeptide sequences composed of the amino acids Pro, Ala, and/or Ser - provides a superior way to attach a solvated random chain with large hydrodynamic volume to a biologically active protein. Thus, its typically rapid clearance via kidney filtration can be retarded by one to two orders of magnitude while the PAS moiety is biochemically inert and easily degradable.

X-Pert Med GmbH

CRO

X-pert Med GmbH is a family owned and operated CRO/SMO with a focus in pain, musculoskeletal medicine and dermatology. The company is managing clinical trials and development programs like a CRO with a focus on services that require an M.D. since 5 of the 20 employees are M.D's (e.g. medical monitoring, pharmacovigilance). In addition, we serve as investigators for both sponsor and investigator sponsored clinical trials. This helps us to translate experiences from daily care of patients into clinical trials protocols or development programs. We have access to validated clinical surrogate models to test concepts in the early stages of clinical development, e.g. UVB induced pain and inflammation, muscle pain induced by eccentric contraction, psoriasis plaque test, UVB irritation/sensitization.

XVir® Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Xvir Therapeutics GmbH was founded in 2004 and is focusing on the clinical development of novel cancer therapies for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. Such cancer therapies are based on the use of oncolytic adenoviruses restoring drug sensitivity and radiation-sensitivity, respectively, of the tumors. Experimental evidence for the efficacy of Xvir's therapeutic approach has been provided in several animal studies. Xvir's therapeutic approach is covered by proprietary patents and patent applications, respectively.

Zentiva Inhalationsprodukte GmbH

PHARMA & CHEMICAL INDUSTRY

Zentiva, the generics business for the Sanofi group, is the third largest and fast growing generics company in Europe. With origins dating back to the 15th century, Zentiva is a valued generics partner. Today, we are at the forefront of developing modern, high-quality and affordable medicines. We currently operate in 50 markets, targeting a population of more than 1 billion people. Zentiva holds leading positions in several pharmaceutical markets, such as the Czech Republic, Romania and Turkey and is successfully expanding its business in other international markets. In Bavaria, Zentiva Inhalationsprodukte GmbH is located in Munich and runs a production plant in Höchststadt/Danube.

X-Pert Med IMR Partner GmbH

Contact:

Dipl. Kfr. Heidi Adelman-Borbe

Lärchenstr. 3-3a

D-82166 Gräfelfing

Phone: +49 (0) 89 89665425

Fax: +49 (0) 89 82084607

E-Mail: info@x-pert-med.de

Internet: www.x-pert-med.de



Contact:

Dr. Per Sonne Holm

Nymphenburger Str. 1

D-80335 München

Phone: +49 (0) 89 99317446

Fax: +49 (0) 89 51556413

E-Mail: info@xvir.com

Internet: www.xvir.com

Zentiva

Contact:

Staffelseestr. 4

D-81477 München

Phone: +49 (0) 89 7874760

Internet: www.zentiva.de

AMBULATORY HEALTHCARE CENTER MARTINSRIED
Dr. Klein, Dr. Rost and Colleagues



Contact:
Ursula Mader

Lochhamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 89 895578-0
Fax: +49 (0) 89 895578-780
E-Mail: info@medizinische-genetik.de
Internet: www.medicinische-genetik.de

Zentrum für Humangenetik und Laboratoriumsmedizin Dr. Klein, Dr. Rost und Kollegen

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Pharmacogenetics, PCR, Genomics, Chip/Array Technology, ELISA/EIA, NGS, Clinical Diagnostics

The Ambulatory Healthcare Center in Martinsried was founded in 1998 and is accredited according to DIN EN ISO/IEC 17025 and ISO 15189. The facility is specialized in advanced laboratory testing in genetics, clinical chemistry and immunology – continuously developing new tests and implementing state-of-the-art technologies. The institution offers clinical consultations with a focus on pediatric genetics, infertility and inherited diseases, applying proven as well as latest technologies such as PID, NIPT, Next Generation and Sanger Sequencing, Array technologies, Blotting, FACS, FISH, HPLC, pyrosequencing, real-time PCR and tandem mass spectrometry.

Professionelle Lösungen für kreative Ideen



Creative Consulting



Corporate Design



Premium Websites



Web Applications



 **aimcom**
fit for communications

Werbe- & Internetagentur · Landshuter Allee 61 · 80637 München
Fon: +49 (0)89 18 93 38 - 60 · info@aimcom.de · www.aimcom.de

Biotech Incubators in Bavaria





Karrierperspektiven für Naturwissenschaftler und Ingenieure entdecken!

- Tagesaktuelle Stellenangebote
- Kostenlose Hinterlegung Ihres Lebenslaufs
- Fachspezifische Karrieretipps



We
focus
on your
career.





FULL SERVICE
Contract Research Organization
for global healthcare

NUVISAN Pharma Services

We have the experience to support new Products from conception to filing. A comprehensive management team maintains thorough cGMP documentation and provides clients the information needed for regulatory filings.

NUVISAN Pharma Services provides research-driven biotech companies with all the resources of a pharmaceutical product development company to ensure a rapid-evaluation of prototype formulations, bulk drug substances, and final drug products. Experienced scientists and state of the art instrumentation give our clients the full range of biochemical, cell biology and immunological procedures to evaluate their products.

For more information, contact our technical experts or visit our website.

ALL SERVICES UNDER ONE ROOF

LAB SERVICES

- **Biopharmaceuticals**
- Bioanalytics
- Clinical Trial Supplies
- Formulation Development
- Pharmaceutical Analytics

EARLY CLINICAL DEVELOPMENT

- Phase I unit
- Biostatistics
- Regulatory Affairs

CLINICAL DRUG DEVELOPMENT

- Oncology Centre of Excellence
- Clinical Operations
- Medical Affairs
- CDM & eTrial
- Training

NUVISAN GmbH

Wegenerstraße 13
89231 Neu-Ulm
Germany

Dr. Bernhard Schmid
Vice President
Bioanalytics
& Biopharmaceutics

Phone: +49 731 9840 242
Fax: +49 731 9840 124

bernhard.schmid@nuvisan.com

Our Services in Biopharmaceuticals

- Enzyme Immunoassay
- Chemiluminescence, ECL, Fluorescence
- Singleplex / Multiplex Analysis
- Cell-Based Assays
- Immune Cell Preparations and Stimulations
- Cytokine Release Assessment / other functional Readouts
- Flow Cytometry
- Immunogenicity Analysis for Biologicals
- PCR
- Immune Monitoring of Clinical Trials



LAB RESULTS YOU CAN TRUST

CUSTOMIZED CENTRAL LAB SERVICES WITH GLOBAL REACH FOR OUR SPONSORS' SATISFACTION

GLOBAL STRENGTHS

- one single global database
- identical lab reports & flagging worldwide
- global quality assurance / global SOPs
- local support via dedicated project teams

EFFICIENT PERFORMANCE

- 11 laboratory locations on all continents
- reliable and fast sample transport
- economies-of-scale: over 50,000 visits / day
- data combinability through test correlations

RANGE OF SERVICES – NO ONE LIKES LIMITS

- bio-analytical services
- visit-kits: automatic re-supplies
- assay development
- small, regional studies; Phase I-II
- extended sample storage
- international trials; Phases II-IV
- worldwide shipping
- global QA system: CAP, ISO15189

INTERLAB

central lab services – worldwide

Head Office: Bayerstr. 53, 80335 Munich, Germany
Phone +49 89 7413930, info@interlab.de, www.interlab.de

